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ABSTRACT 
The human body is colonized by a vast number of microorganisms collectively 
defined as the microbiota. In the gut, the microbiota has important roles in health 
and disease, and can serve as a host of antibiotic resistance genes. Disturbances in 
the ecological balance, e.g. by antibiotics, can affect the diversity and dynamics of the 
microbiota. The extent of the disturbance induced by antibiotics is influenced by, 
among other factors, the class of antibiotic, the dose, and administration route. One 
of the most common consequences of excessive antibiotic use is the emergence of 
antibiotic resistant bacteria and the dissemination of the corresponding resistance 
genes to other microbial inhabitants of the gut community, in addition to affecting 
the colonization resistance and promoting the overgrowth of pathogens. These 
effects are particularly relevant for Intensive Care Unit (ICU) patients, which are 
frequently exposed to a high risk of hospital-acquired infections associated with 
antibiotic resistant bacteria.  
Due to the important roles that members of the gut microbiota play in the host, 
including their role as potential hubs for the dissemination of antibiotic resistance, 
recent research has focused on determining the composition and function of gut 
microorganisms and the antibiotic resistance genes associated with them.  
The objectives of the research described in this thesis were to study the diversity and 
dynamics of the gut microbiota and resistome in ICU patients receiving antibiotic 
prophylactic therapy, and to assess the colonization dynamics with antibiotic 
resistant bacteria focusing on the commensal microbiota as a reservoir of antibiotic 
resistance genes by using culture dependent and independent techniques. 
Furthermore, the genetic background involved in the subsistence phenotype was 
investigated to disentangle the links between resistance and subsistence.  
Bacteria harbor antibiotic resistance genes that participate in a range of processes 
such as resisting the toxic effects of antibiotics, but could also aid in the utilization 
of antibiotics as sole carbon source, referred to as antibiotic subsistence phenotype. 
In chapter 2, the potential of gut bacteria from healthy human volunteers and zoo 
animals to subsist on antibiotics was investigated.  
Various gut isolates of Escherichia coli and Cellulosimicrobium spp. displayed the 
subsistence phenotype, mainly with aminoglycosides. Although no antibiotic 
degradation could be detected, the number of colony forming units increased during 
growth in medium with only the antibiotic as a carbon source. By using different 
approaches to study the aminoglycoside subsistence phenotype, we observed that 
laboratory strains carrying the aminoglycoside 3’phosphotransferase II gene also 
displayed the subsistence phenotype on aminoglycosides and that glycosyl-
hydrolases seem to be involved in the subsistence phenotype. As the zoo animals for 
which the subsistence phenotype was investigated also included a number of non-
human primates, the applicability of Human Intestinal Tract Chip (HITChip) to 
study the gut microbiota composition of these animals was assessed, including a 
comparison with healthy human volunteers (Chapter 3). It was concluded that the 
HITChip can be successfully applied to the gut microbiota of closely related 
hominids, and the microbiota dynamics can therefore be quickly assessed by the 
HITChip.  
In Chapter 4, a combination of 16S rRNA phylogenetic profiling using the HITChip 
and metagenomics sequencing was implemented on samples from a single ICU 
hospitalized patient that received antibiotic prophylactic therapy (Selective Digestive 
Decontamination - SDD). The different approaches showed a highly dynamic 
microbiota composition over time and the prevalence of aminoglycoside resistance 
genes harbored by a member of the commensal anaerobic microbiota, highlighting 
the role of the commensal microbiota as a reservoir of antibiotic resistance genes. As 
an extension of this study (Chapter 5), 11 ICU patients receiving SDD were followed 
using 10 healthy individuals as a control group to compare the diversity and 
dynamics of the gut microbiota and resistome by HITChip and nanolitre-scale 
quantitative PCRs, respectively. The microbial diversity of the healthy individuals 
was higher compared to ICU patients, and it was less dynamic compared to ICU 
patients under antibiotic treatment. Likewise, the levels of antibiotic resistance 
genes increased in ICU patients compared to healthy individuals, indicating that 
during ICU hospitalization and the SDD, gut microbiota diversity and dynamics are 
profoundly affected, including the selection of antibiotic resistance in anaerobic 
commensal bacteria.  
This was further expanded in an extensive study focusing on colonization dynamics 
with antibiotic resistant bacteria as described in Chapter 6. This was performed in 
the same group of ICU-hospitalized patients receiving SDD therapy and showed that 
by using a range of culture media and selective conditions a variety of taxonomic 
groups could be isolated, including aerobic and anaerobic antibiotic resistant 
bacteria. The overall composition of the faecal microbiota detected by HITChip 
indicated mainly a decrease of Enterobacteriaceae and an increase of the 
enterococcal population. Since critically ill patients are susceptible to hospital-
acquired infections and the control of the emergence of antibiotic resistance is 
crucial to improve therapeutic outcomes, an extended analysis of the Enterococcus 
colonization dynamics in this group of patients by cultivation and phenotypic and 
genotypic characterization of the isolates provided new information about carriage 
of antibiotic resistance and virulence factor encoding genes (Chapter 7). It also 
highlighted the opportunity for the exchange of resistance and virulence genes, 
which could increase the risk of acquiring nosocomial infections. 
Next, chapter 8 described the implementation of high-throughput cultivation-based 
screening using the Microdish platform combined with high-throughput sequencing 
(MiSeq) using faecal samples from ICU patients receiving SDD. This allowed for the 
recovery of previously uncultivable bacteria, including a pure culture of a close 
relative of Sellimonas intestinalis BR72T that was isolated from media containing 
tobramycin, cefotaxime and polymyxin E. This strain could therefore represent a 
potential antibiotic resistance reservoir.  
In conclusion, this thesis provides broad insight into the diversity and dynamics of 
the gut microbiota and resistome in ICU hospitalized patients receiving SDD therapy 
as well as the dynamics of colonization with antibiotic resistant bacteria. Especially 
our extensive study of the colonization dynamics of Enterococcus spp. during ICU 
stay reinforced the notion that SDD therapy does not cover this group of bacteria and 
highlights the importance of a critical control of the emergence of antibiotic 
resistance in enterococci and their spread and dissemination as known potential 
pathogens.  
Furthermore, the extensive use of antibiotics could select for an increase in the rate 
of antibiotic resistance against aminoglycosides and beta-lactams, indicating that a 
control in the use of broad spectrum antibiotics needs to be considered. In addition, 
this thesis provides evidence regarding the possible genetic background involved in 
the subsistence phenotype, however, future studies on metabolic pathways could 
provide novel insight into the underlying mechanisms. 
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INTRODUCTION 
Infectious diseases represent the second most important cause of death worldwide 
(WHO, 2014). It has been estimated that 5-10% of patients develop an infection 
during hospital stay (Fauci, 2005). One of the most powerful tools for the treatment 
of infectious diseases is the use of antibiotics. However, infectious diseases caused 
by bacteria are increasingly difficult to control due to the evolution of antibiotic 
resistance. Furthermore, complex microbial communities residing in the gut play an 
important role in the selection, enrichment and spread of antibiotic resistance and 
represent an ideal reservoir for the transfer of antibiotic resistance genes to potential 
pathogens. 
 
Antibiotic use and the emergence of antibiotic resistance  
One of the major breakthroughs in the early 20th century has certainly been the 
discovery of antibiotics (Stokes and Gillings, 2011). Starting with penicillin found by 
Alexander Fleming in 1928 (Van Hoek et al., 2011), the subsequent discoveries of 
new antibiotics changed the perspective in the therapy of infectious diseases 
(Wenzel, 2004). Indeed, after the introduction of antibiotics in the pharmaceutical 
industry in the 1950s, antibiotics have been used for the control of infections and the 
reduction of the associated morbidity and mortality (Davies and Davies, 2010). At 
the same time, the evolution of antibiotic resistance was considered improbable due 
to the assumption that the frequency of mutations leading to resistance in bacteria 
was minimal (Davies, 1994). Later on this turned out to be a wrong assumption as it 
was discovered that antibiotic resistance emerged before the first antibiotic, 
penicillin, was even characterized (Abraham and Chain, 1940). Antibiotics have been 
defined as natural, semi-synthetic or synthetic compounds that can either inhibit 
bacterial growth (bacteriostatic) or kill (bactericidal) bacteria.  
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Depending on their activity, they are used against a wide range of disease-causing 
bacteria, including Gram-positive and Gram-negative strains (broad-spectrum 
antibiotics) or against a specific group of bacteria (narrow-spectrum antibiotics) 
(Demain and Sanchez, 2009).  
Nowadays, different classes of antibiotics are known and can be classified based on 
their mechanism of action (Fig. 1). In general, antibiotics interfere with important 
cellular processes and can, for instance, inhibit the bacterial cell wall synthesis (β-
lactams and glycopeptides), inhibit the protein synthesis (aminoglycosides, 
macrolides, tetracycline and chloramphenicol), interfere with the synthesis of DNA 
and RNA (quinolones or rifampin) or modify the energy metabolism of the microbial 
cell, i.e. folate synthesis (sulfonamides and trimethoprim) (Neu, 1992).  
 
 
Figure 1. Mechanisms of action of antibiotics. The four main targets of antibiotics include the 
synthesis of cell wall and cell membrane, protein synthesis (30S and 50S ribosomal subunits), nucleic acid 
synthesis and folate synthesis. Adapted from Johnson (2011). 
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Over the years, the extended use of antibiotics, estimated to be 100-200 x106 kg/year 
worldwide (Wise, 2002; Anderson and Hughes, 2010), has led to an enormous 
increase of antibiotic resistance among pathogenic bacteria (Nikaido, 2009). In fact, 
large amounts of antibiotics are used not only for clinical purposes, but also in animal 
production as therapeutic agents as well as growth-promoters, resulting in a selective 
pressure for the emergence, enrichment and spread of antibiotic resistant 
pathogenic bacteria (Anderson and Hughes, 2012).  
Analogous to the mechanism of actions, different mechanisms allow bacteria to 
become resistant to antibiotics. These mechanisms include a decrease in the 
permeability of the bacterial cell wall, enzymatic modification of antibiotics, 
degradation of antibiotics, modification of the target, overproduction of the target 
enzyme or the presence of efflux pumps in the bacterial cell (Fig. 2) (Alekshun and 
Levy, 2007).  
 
Figure 2. Mechanisms and target sites of defensive mechanisms used by bacteria to prevent 
detrimental effects caused by antibiotics. Adapted from Hawkey (1998).  
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Antibiotic resistance (AR) can be achieved by chromosomal DNA mutations 
(Martinez and Baquero, 2000) and/or by acquisition of new genetic material (mobile 
elements) from other bacteria through Lateral Gene Transfer (LGT), the latter of 
which is facilitated through three main pathways, including transformation, 
transduction and conjugation (Summers, 2006). In general, LGT requires two 
principle processes to occur: a) the physical movement of DNA from a donor to the 
recipient organism and b) the incorporation into the receiving cell and/or genome to 
allow stable inheritance (Stokes and Gillings, 2011). Such DNA acquisition can occur 
between different bacterial species and between hosts present in different 
environments (Fig. 3).  
Many of the AR genes encountered in the environment are encoded on transferable 
mobile genetic elements that are highly homologous between pathogens and 
commensal bacteria, where commensal bacteria represent the majority of the 
microbial community present in the host and natural environments. It has been 
indicated that commensal bacteria could play an important role in the evolution and 
dissemination of genetic elements such as AR genes in the microbial communities 
inhabiting different ecosystems (Wang, 2009). 
A range of factors can influence the acquisition of mobile elements containing AR 
genes such as selective pressures in the environment, non-specific and specific host 
factors and properties of the mobile genetic elements such as the production of anti-
restriction proteins (van Hoek et al., 2011). Convincing evidence for the transfer of 
AR genes between Gram-positive and Gram-negative commensal bacteria and 
between aerobic and anaerobic bacteria has been reported (Courvalin, 1994; Salyer 
et al., 2004 and Ojo et al., 2006). 
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Figure 3. Schematic representation of the transmission of AR genes and resistant bacteria between 
community, hospital, wastewater plants, farms, agriculture and industry. Adapted from Davies and 
Davies (2010) 
 
AR genes: the ecological context  
Since the majority of antibiotics used for the treatment of infections have originated 
from natural environments, AR genes acquired by pathogens could similarly 
originate from the same sources (Martinez, 2008; Bhullar et al., 2012). Natural 
habitats, such as soil, for example, represent a common reservoir of resistance genes 
(Dantas et al., 2008). In hospital environments, the high concentrations of 
antibiotics used for clinical propose can select for resistant mutants which can serve 
as a reservoir of resistance genes. The selection of resistant mutants was thought to 
occur at concentrations between the minimal inhibitory concentration (MIC) of the 
susceptible wild type strain and the MIC of the resistant bacteria, and concentrations 
below the MIC of the susceptible strain should not inhibit the growth of the bacteria 
and hence not be selective.  
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However, a recent study has shown that the low antibiotic concentrations present in 
natural environments might actually contribute significantly to the emergence and 
maintenance of resistance (Gullberg et al., 2011). It has been suggested that 
antibiotic-producing microorganisms could have provided the initial pool of genes 
from which the present antibiotic resistance genes derived (Benveniste and Davies, 
1973). In fact, at the low concentrations encountered in natural environments 
antibiotics induce responses in their target microorganism, but like other 
compounds, become toxic at higher concentrations, the so-called hermetic effect 
(Martinez et al., 2009).  
Recent work has shown that a large and diverse group of bacteria from soil, seawater 
and the gut microbiota from humans and farm animals was not only able to resist 
the toxic effects of antibiotics, but also they could utilize antibiotics as a sole carbon 
source, a phenotype commonly referred to as antibiotic subsistence (Dopazo et al., 
1988; Dantas et al., 2008; Barnhill et al., 2011; Xin et al., 2012). Controversially, 
Walsh et al. (2013) showed that soil bacteria could not utilize antibiotics as a carbon 
source since no degradation of antibiotics occurred. The fact that multidrug 
resistance elements participate in other processes such as detoxification of metabolic 
intermediates, signal trafficking and virulence, could perhaps explain why genes 
could not only play a role in resistance but also evolved into other functions.  
Nonetheless, the genes involved in the antibiotic subsistence phenotype have not 
been identified and therefore, the relationship between resistance and subsistence 
remains unclear (Dantas & Sommer, 2012). Previous studies indicated that, for 
example, humans are continuously exposed to AR genes present in bacteria 
associated with retailed food (Wang et al., 2006).  
Recently, Kluytmans and colleagues showed that extended-spectrum β-lactamase-
producing Escherichia coli isolates from chicken meat and human faecal samples 
shared similar genetic mobile elements, virulence genes and genomic backbone 
(Kluytmans et al., 2013).  
Chapter 1 
 
8 
 
Furthermore, an association has been established between the AR genes present in 
commensal bacteria from food animals, lagoon water, farm manures and exposure 
to growth-promoting antibiotics (Allen et al., 2010). In contrast, the relationship 
between the AR genes present in commensal bacteria from healthy humans and wild 
animals without recent antibiotic exposure is still unclear. Nonetheless, Kuiken and 
collaborators indicated that more than 70% of emerging infections originate from 
animals, especially wild animals (Kuiken et al., 2005). Wild animals held in captivity 
in zoos could therefore serve as a reservoir for zoonotic pathogens and transfer their 
pathogens and resistance genes to humans through direct contact (handing and 
feeding activities) (Wang et al., 2012); Bender and Shulman supported this claim, 
and reported that a human infectious disease outbreak in the period of 1990 to 2000 
was associated with animal contact (Bender and Shulman., 2004).  
Besides animal handling, the contamination of water and food with multidrug-
resistant bacteria is one of the main sources of the spread of antibiotic resistance in 
humans and animals. Recent studies reported the presence of multidrug-resistant 
bacteria present in food and water systems, highlighting the potential risk for the 
human health after consumption, being the gut microbiota the most substantial 
reservoir of antibiotic resistance (Karumathil et al., 2016; Stange et al., 2016). 
 
Gut microbiota: Composition and functions  
The human body coexists with a vast number of microbes, including bacteria, 
archaea, viruses and unicellular eukaryotes, commonly referred to as the microbiota 
(Neish, 2009). Among all external body surfaces, the gut harbours over 70% of the 
total microbes (Ley et al., 2006). The majority of the gut microbiota is dominated by 
anaerobes, followed by facultative anaerobes and aerobes, having as predominant 
phyla Bacteroidetes and Firmicutes, whereas Proteobacteria, Actinobacteria, 
Cyanobacteria, Fusobacteria and Verrucomicrobia represent only a minor 
proportion of the total microbial load (Eckburg et al., 2005).  
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The number of microbial cells and their composition varies greatly along the gut, 
starting from 101 to 103 bacteria per gram in the stomach due to the short retention 
time of gastric content and acid pH, increasing to 104 to 108 per gram in the small 
intestine and ending in the large intestine. Here the rate of peristaltic movements 
decreases, facilitating the development of a complex and dense microbial community 
with 1011 to 1012 bacterial cells per gram of content (Sekirov et al., 2010).  
Starting from the moment of birth, the human gut microbiota becomes more diverse 
rapidly until reaching a relatively stable state during childhood. At old age the 
diversity decreases again (Claesson et al., 2011; Scholtens et al., 2012). Although it 
has been established that the human gut microbiota composition is unique per 
individual, a classification into a limited number of major constellations has been 
proposed, the so-called enterotypes. Each enterotype is defined by correlation 
networks and named according to microorganisms at central nodes within these 
networks, namely Bacteroides (enterotype 1), Prevotella (enterotype 2) and 
Ruminococcus (enterotype 3) (Arumugam et al., 2011). Interestingly, Wu and 
colleagues showed that long-term dietary changes could contribute to shifts between 
different enterotypes (Wu et al., 2011). A recent study based on phylogenetic analysis 
of the gut microbiota of a thousand western adults, indicated the presence of 
different groups of bimodally distributed bacteria that are in most cases either 
abundant or almost absent, and which could represent “tipping elements” of the gut 
microbiota that are indicators and/or drivers of the transition between alternative 
stable states of gut microbiota composition (Lahti et al., 2014). 
It has been well documented that the human gut microbiota plays an important role 
in a broad range of metabolic, nutritional, physiological and immunological 
processes within the host, and as such contributes to gut and systemic homeostasis 
(O’Hara and Shanahan, 2006). One important metabolic activity of the gut 
microbiota is the breakdown of dietary components that are not digested by the 
host’s own secreted enzymes, converting them through fermentation to short-chain 
fatty acids (SCFA) such as acetate, propionate and butyrate.  
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Particular interest has been attributed to butyrate as the main energy source for 
colonocytes (Hamer et al., 2008). Changes in gut microbial composition have been 
found to correlate with inflammatory and metabolic disorders (O’Toole and 
Claesson, 2010) such as inflammatory bowel diseases (Frank et al., 2007), irritable 
bowel syndrome (Jeffery et al., 2012), obesity (Ley et al., 2006), cancer (Lupton, 
2004) and diabetes (Larsen et al., 2010).  
Different internal and external factors can affect the composition and disrupt the 
ecological balance of the gut microbiota, including, for example, age, genetics and 
host immune response (internal factors), and geographic location, diet and 
administration of modulators of the gut microbiota such as prebiotics, probiotics and 
antibiotics (external factors). 
The gut microbiota of other mammals resembles that of humans; however, more or 
less pronounced differences are observed between animals that differ, e.g. in terms 
of genetic background, anatomy and morphology of the gut, and dietary habits (Ley 
et al., 2008). In fact, similar to what has been described for humans, also the gut 
microbiota in other mammals is affected by a range of different external or internal 
factors (Yildirim et al., 2010, Moeller and Ochman, 2013). Recently, Moeller and 
colleagues, described the cospeciation of microbiota with hominids, further 
emphasizing the functional role of the microbiota for the specific needs of the host 
(Moeller et al., 2016). 
 
Interplay between gut microbiota and antibiotics  
The gut microbiota of healthy adults remains generally stable over time (Martinez et 
al., 2013). During antibiotic treatment, however, a disturbance in microbiota 
composition is established, the number of commensal bacteria is reduced and the 
colonization resistance barrier is broken, which can lead to an overgrowth of and 
colonization with potentially pathogenic bacteria (Schjørring and Krogfelt, 2011) 
(Fig. 4). 
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Figure 4. Schematic representation of the disrupted balance of the gut microbial 
community induced by antibiotics. The antibiotic selective pressure induces a disbalance in the 
commensal microbiota that normally provides colonization resistance (1). The resulting reduction in the 
commensal microbiota (2) is followed by overgrowth of and colonization with antibiotic resistant 
pathogenic bacteria (3, 4). Adapted from Kamada et al., 2013. 
 
One of the most important factors that influence the extent to which a given 
antibiotic will change and decimate the microbiota is the degree to which it is 
absorbed in the gut and thus its effective local concentration that directly acts on the 
microbiota, as well as the duration of the exposure. Due to the fact that different 
antibiotics induce specific effects on the gut microbiota, as reported previously 
(Young and Schmidt, 2004; Robinson and Young, 2010), a selective pressure of the 
antibiotic is maintained in this microbial environment, which contributes to the 
increase of antibiotic resistant bacteria.  
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Furthermore, previous studies showed that co-selection of AR determinants by other 
antimicrobial compounds such as antiseptics and heavy metals can further 
contribute to the occurrence of antibiotic resistance without antibiotic selective 
pressure (Baker-Austin et al., 2006). The complexity and dynamics of the gut 
microbiota further increases the feasibility for the exchange of AR genes between 
commensals and pathogens (Kazimierczak and Scott, 2007). The hypothesis “Could 
the microflora of the human colon, normally considered innocuous or beneficial, be 
playing a more sinister role in human health as a reservoir for antibiotic resistance 
genes?” established by Salyers and collaborators is nowadays well accepted (Salyers 
et al., 2004). A growing number of publications indicated that gut commensal 
bacteria, including aerobes and anaerobes, act as a donor of AR genes to bacteria 
that are transitory in the gut microbiota. The principal adverse effect is the increase 
of nosocomial pathogens resistant to antibiotics, which reduces the efficacy of 
antibiotic treatment, and thereby increases morbidity and mortality and the cost of 
hospitalization. 
 
Antibiotic therapy: Control of gut colonization and overgrowth of 
nosocomial pathogens  
Hospital-acquired infections represent a major cause of mortality and increase of 
health care cost around the world. In intensive care units (ICUs), critically ill patients 
are at continuous risk of acquired infections due to their vulnerable conditions 
(Vincent, 2003). One of the main concerns in this category of patients is that they 
are susceptible to colonization with antibiotic resistant bacteria due to the exposure 
to invasive procedures and antibiotic administration, which could increase the 
incidence of infection, reduce the efficacy of antibiotics and increase AR selection 
(van Duijn et al., 2011). During invasive procedures, the skin and mucosa are 
disrupted allowing the translocation of bacteria into the bloodstream, causing 
bacteraemia or candidaemia, or into the oro-pharyngeal and nasal cavities causing 
ventilator associated pneumonia (VAP) (Thom et al., 2010 and Carlet, 2012).  
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Not only colonization with antibiotic resistant bacteria, but also overgrowth of 
bacteria, defined as the presence of potential pathogens at high concentration (> 105 
colony forming units/ml) could facilitate the bacterial translocation (Pierro et al., 
1998). 
One of the most common factors associated with the risk of infections in ICU patients 
is the duration of ICU stay. An international study that focused on the prevalence 
and outcomes of infection in 1265 participating ICUs (14,414 patients in total) from 
75 countries, showed that 51% of the patients were considered infected and 71% of 
them received antibiotics. The main origin of infections was respiratory and more 
than 50% of the isolates were Gram-negative bacteria followed by Gram-positive 
bacteria and a minor percentage of fungi. Likewise, the authors reported that a 
higher rate of infection was associated with prolonged stays in ICU (Vincent et al., 
2009).  
It has been shown that broad spectrum antibiotic therapy affects the target bacteria 
as well as the entire microbial community (Jernberg et al., 2010), increasing the pool 
of antibiotic resistant bacteria present in the gut. AR rates in European ICUs were 
recently studied, indicating that Gram-negative bacteria (e.g. Escherichia coli and 
Klebsiella pneumoniae) play the main role in the emergence and spread of 
infections, facilitating the exchange of resistance genes, while methicillin-resistant 
Staphylococcus aureus (MRSA) remained stable (van Duijn et al., 2011). 
Different measures have been established for the control of infections in ICUs such 
as standard care, strict hand hygiene to decrease the cross-transmission and the 
implementation of prophylactic antibiotic therapy (D’Amico et al., 1998; Liberati et 
al., 2009). Two prophylactic antibiotic therapies, Selective Oropharyngeal 
Decontamination (SOD) and Selective Digestive Decontamination (SDD), have been 
used to prevent the colonization by Gram-negative bacteria, Staphylococcus aureus 
and yeast without disrupting the anaerobic microbiota, through the application of 
non-absorbable antimicrobial agents into the oropharynx and gastrointestinal tract.  
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Different combinations of antimicrobial agents have been used. The most frequent 
combination used in the SDD protocol includes the narrow spectrum antibiotic 
polymyxin E, the broad spectrum aminoglycoside tobramycin and the antifungal 
drug amphotericin B in the oropharynx (paste) and the gastrointestinal tract 
(suspension) applied four times daily, and a short course (first 3-4 days of ICU 
admission) of a broad spectrum systemic antibiotic, usually a third generation 
cephalosporin (cefotaxime or ceftriaxone). The SOD protocol includes only the 
application of the same topical antibiotic through the oropharynx, and is considered 
as an alternative therapy to prevent VAP (Melsen et al., 2012).  
SDD was introduced in 1984 as a method to reduce the rate of nosocomial infections 
in trauma patients (Stoutenbeek et al., 1984). During the following years, several 
studies were conducted (http://www.clinicaltrials.gov, Bonten et al., 2000), and the 
main conclusions were that SDD reduces the occurrence of VAP and that low levels 
of antibiotic resistance remain. The lack of evidence of patient outcome, however, 
and the unknown role in the development of AR led to a European consensus 
conference (European consensus conference, 1992), which recommended to not 
apply SDD in ICU patients until enough proof of the beneficial effect of the therapy 
has been established.  
In 2001, van Nieuwenhoven and collaborators showed that during studies, special 
attention needs to be given to the design and methodology used, since an inadequate 
approach could introduce bias and overestimate the effects of the SDD treatment 
(van Niewenhoven et al., 2001).  
In the Netherlands, several additional studies were performed and showed that 
indeed the application of prophylactic antibiotic therapy decreased the incidence of 
VAP, with a low level of antibioticresistance remaining, and that the rate of mortality 
decreased compared with standard care (de Jonge et al., 2003 and de Smet et al., 
2009). Later on, Melsen and colleagues showed that SDD therapy reduces the 
mortality in surgical and non-surgical patients, while SOD therapy showed a similar 
effect only in non-surgical patients (Melsen et al., 2012).  
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While it is well established that SDD reduces the incidence of VAP, fewer studies 
were performed in order to study the effect of SOD in a short course application on 
the development of VAP. To this end, Schnabel and colleagues, reported a significant 
reduction of VAP during SOD/SDD therapy compared with the control group 
(Schnabel et al., 2015). Based on these results and considering that only 30% of ICUs 
in the Netherlands implemented SDD-SOD therapy (Barends et al., 2008), an 
evaluation of the trends of antibiotic resistant Gram-negative bacteria was needed, 
especially because the effect of both therapies on AR was still unclear. A study 
performed in 38 ICUs (17 used continuously SDD/SOD, 8 introduced SDD/SOD and 
13 did not use SDD/SOD) during 2008-2012 indicated that a significant reduction 
in antibiotic resistant Gram-negative bacteria was associated with continuous or 
recent use of SDD/SOD as compared with no use (Houben et al., 2013). Similarly, 
an evaluation on the trends of antibiotic resistant Gram-positive bacteria was 
performed in 42 Dutch ICUs from 2008-2013, indicating that a continuous use of 
SDD/SOD therapy was not associated with an increase of isolates of Gram-positive 
cocci. Although the introduction of SDD/SOD was associated with an increase in rate 
of isolation, it was not associated with antibiotic resistance (van der Brij et al., 2016). 
A more recent survey performed in ICUs registered in the European Registry for 
Intensive Care (ERIC) showed that only 17% of them used SDD as a prophylactic 
therapy, and mainly ICUs in the Netherlands (13/23) and Germany (6/15) (Miranda 
et al., 2015).  
Furthermore, a number of studies was performed in order to determine the effect of 
SDD and SOD therapy on antibiotic resistance, all of them focussing on the target 
group for the therapy without considering the commensal microbiota.  
Oostdijk and collaborators showed that both therapies contributed equally to low AR 
prevalence in Gram-negative bacteria in rectal and respiratory samples, however, an 
increase of ceftazidime resistant Gram-negative bacteria was observed after SDD 
therapy discontinuation (Oostdijk et al., 2010).  
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In another study performed in 13 ICUs in the Netherlands, the rate of acquisition of 
respiratory tract colonization with Gram-negative antibiotic resistant bacteria was 
higher during SOD therapy compared to SDD (de Smet et al., 2011). A recent meta-
analysis of randomized control trials indicated that SOD therapy has similar effects 
as SDD in reducing mortality, in spite of the fact that SOD has been associated with 
a higher incidence of ICU-acquired bacteremia and antibiotic-resistant Gram-
negative bacteria, while SDD increased the risk of antibiotic resistance 
(cephalosporins). Based on this outcome, the authors recommend the use of SOD as 
prophylactic antibiotic regimen in patients in the ICU (Zhao et al., 2015).  
These results raised questions with respect to the contribution of SOD and SDD on 
colonization with antibiotic resistant Gram-positive bacteria. In a trial performed in 
a non-endemic area, de Smet and co-authors (2009) reported low levels of MRSA 
and Vancomycin Resistant Enterococcus (VRE) during SOD therapy compared with 
the control group (no antibiotics). It is important to consider that the antibiotics 
included in SOD and SDD therapies do not target most Gram-positive bacteria. 
Therefore, increased rates of colonization and infection by the two main players of 
nosocomial infections, namely MRSA and VRE, can be expected. In Europe, Austria 
and Belgium studies have reported an increase of MRSA in SDD treated patients 
(Verwaest et al., 1997; Lingnau et al., 1998).  
On the other hand, Enterococcus species, mainly Enterococcus faecium and E. 
faecalis, represent the third most common cause of bacteraemia, frequently 
associated with a high rate of antibiotic resistance. Usage of SDD therapy in 
combination with topical and enteral vancomycin has been effective to eradicate 
VRE where VRE is not endemic, however, Dahms and collaborators reported an 
increase of VRE colonization in ICU patients when SDD therapy was applied in 
combination with vancomycin or ceftazidime and vancomycin (Dahms et al., 2000). 
Most recently, Benus and collaborators showed that during SDD therapy, an increase 
of enterococci was observed when compared to SOD or standard care (Benus et al., 
2010).  
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Interestingly, the presence and spread of high risk clonal complexes, especially the 
ones with the capacity to adapt to hospital environments, carrying antibiotic 
resistance and virulence genes, represent a growing problem around the world. In 
2015, a spread of E. faecalis clonal complex (CC2) present in ICU patients receiving 
SDD therapy was reported in Spain (Muruzabal-Lecumberri et al., 2015).  
SDD and SOD therapies do not only have a short-term effect on the microbiota 
composition but also long term effects. It cannot be excluded that during SDD 
therapy, the concentration of antibiotics in faeces reach a high level due to the direct 
administration of antibiotics through a gastric tube providing a protective effect 
against overgrowth, but when the therapy is terminated, a recolonization occurs.  
A recent emergence of polymyxin E (Colistin) resistance in Enterobacteriaceae has 
been reported after the introduction of SDD therapy (Halaby et al., 2013 and Lubbert 
et al., 2013). Similarly, Sanchez-Ramirez and collaborators reported that after three 
years of SDD application, a reduction in infections with antibiotic resistant bacteria, 
decrease in nosocomial infections and antibiotic consumption was observed 
compared with the control group; however, colonization by tobramycin and colistin 
resistant bacteria was observed during the study period (Sanchez-Ramirez et al., 
2015). In contrast, in the Netherlands, Wittekamp and collaborators showed that 
long-term use of SOD and SDD therapy was not associated with an increase of 
colistin and tobramycin-resistant Gram-negative bacteria (Wittekamp et al., 2015). 
So far, questions remain with respect to the direct health effects of SDD and SOD 
therapies during and after the ecological perturbations induced in terms of reduction 
of hospital-acquired infections and potential development of antibiotic resistance 
being the main goal from the public health perspective, but also in terms of microbial 
composition and functions.  
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Tools for studying the gut microbiota and resistome  
The compositional and genetic complexity of the gut microbial ecosystem have 
increased the interest to understand its role and functions by using state of the art 
microbiological tools. For many years, the techniques used to study microbial 
diversity have been divided in culture dependent and independent methods. Both 
types of approaches contributed to a better understanding of the microbial 
composition and ecological perturbations induced for example by antibiotic 
administration.  
By using culture dependent methods, microbiologists have been able to study only a 
small fraction of the complex community present in the gut, and it has been 
previously estimated that only 10% of the gut microbiota can be cultivated under 
standard conditions (Eckburg et al., 2005). As a consequence, the diversity of the 
microbiota has been grossly underestimated based on cultivation-derived data. 
Generally, microbiologists use selective and non-selective media to culture specific 
functional groups of microorganisms or rather as many different microorganisms as 
possible, respectively. It has been noted, however, that many of the bacteria thriving 
in the gut environment may require special nutrients or other metabolic products 
that can be provided by other members of the gut microbiota, and thus can be 
classified as obligate syntrophs (Macfarlane and Gibson, 1994; Macfarlane et al., 
1994).  
In addition, sampling methods, transportation, storage and cultivation technique 
used can lead to differences with respect to results reported by different studies 
(Macfarlane and Macfarlane, 2004, Tedjo et al., 2015).  
In the last years, a growing interest in innovative culture methods has been 
established, for example by using diffusion chambers to stimulate the growth of 
previously uncultured bacteria or by using rumen fluid or extract of fresh faecal 
material to better simulate the environmental conditions present in the gut 
(Kaeberlein et al., 2002).  
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Browne et al. (2016) recently showed more than 10% of the gut bacteria are 
culturable by using a single growth medium to isolate spore-forming bacteria.  
One of the advances in culturing techniques include the implementation of the 
micro-petri dish. Porous aluminium oxide (PAO) or PAO Chips, were introduced in 
2005 (Ingham et al., 2005) as a microbial culture support while agar functioned as 
a matrix supplying nutrients to the bacterial cells. It has been used in microbiology 
for different purposes, including cell counting and identification, growth and micro-
colony imaging of microorganisms, and as a high throughput screening tool (Ingham 
et al., 2007; Ingham et al., 2012). Several studies have used cultivation techniques 
in order to detect the growth of common pathogens e.g. during SDD or SOD therapy. 
In contrast, strictly anaerobic bacteria, which represent the majority of the gut 
microbiota and comprise an important reservoir of antibiotic resistance in the gut 
(Shoemaker et al., 2001; Sommer et al., 2009), have not been extensively explored 
by cultivation methods because their cultivation is time consuming and laborious 
and requires special equipment (Macfarlane, 1994).  
Since culture dependent methods underestimate the microbial diversity present in 
the gut, molecular biological techniques (culture independent methods) have been 
introduced, allowing microbiologists to characterize more comprehensively the 
complex ecosystem present in the gut. By using the bacterial 16S ribosomal RNA 
(rRNA) gene as a genetic marker, an analysis of the phylogenetic groups present in 
the gut community can be established. In the 1990s, Polymerase chain reaction 
(PCR) was introduced to detect bacteria in complex communities by using specific 
primers. As one of the first examples, Matsuki et al. (1999) showed that a qualitative 
detection of bifidobacterial species present in faecal samples from healthy adults and 
breast-fed infants could be accomplished by 16S rRNA-gene-targeted species-
specific PCR.  
It has been noted that also cultivation-independent approaches are not without 
limitations, including, e.g., differences in the efficiency of extraction of DNA and 
RNA from different bacteria, which is related to difference in the susceptibility to 
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chemical enzymatic and/or mechanical lysis for some bacterial groups (Zoetendal et 
al., 2001). Advances in molecular analysis include the quantitative analysis of 
microbial communities by Real-Time PCR by using genus- or species-specific 
primers to quantify specific groups of bacteria. Early examples include the analysis 
of microorganisms associated with the mucosa in the gastrointestinal tract 
(Huijsdens et al., 2002), and the comparison of patients treated or not treated with 
antibiotics (Bartosch et al., 2004).  
Moreover, 16S rRNA gene clone libraries have been used for phylogenetic analysis of 
the intestinal microbiota (Suau et al., 1999), however, this technique is time 
consuming and does not allow to comprehensively characterize complex microbial 
communities such as those residing in the gut at realistic costs. Therefore, other 
techniques based on molecular fingerprinting such as Denaturing Gradient Gel 
Electrophoresis (DGGE) and Terminal Restriction Fragments Length Polymorphism 
(T-RFLP) have been used in the past for rapid comparative analysis of microbial 
communities, for example to monitor the microbiota present in different regions in 
the gut (Zoetendal et al., 2002) and to analyze the disruption of the microbiota 
during antibiotic treatment (Donskey et al., 2003). More recently, the advent of a 
growing list of next generation sequencing technologies, including but not limited to 
pyrosequencing and Illumina sequencing, dramatically increased the possibilities to 
analyse large numbers of samples in the same sequencing run using sample-specific 
bar-coded primers. Early examples include the comparison of gut microbiota present 
in obese and lean twin pairs (Turnbaugh et al., 2009) and the evaluation of the effect 
of a short course ciprofloxacin treatment in three healthy adults (Dethlefsen et al., 
2008). In addition to next generation technology sequencing based approaches, also 
DNA microarrays represent powerful tools designed for high-throughput screening 
of the gut microbiota. By using the Agilent platform, Palmer and collaborators 
designed for the first time a DNA microarray containing probes targeting 359 
microbial species and 316 novel Operational Taxonomic Units (OTUs) (Palmer et al., 
2006; Palmer et al., 2007).  
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More recently, Rajilic-Stojanovic and colleagues designed the Human Intestinal 
Tract Chip (HITChip) that contains 4800 oligonucleotides probes based on two 
hypervariable regions of the SSU rRNA gene of microorganisms detected in the 
human gastrointestinal microbiota (Rajilic-Stojanovic et al., 2009). The HITChip 
has been extensively used to determine the diversity and dynamics of the gut 
microbiota in a broad range of different subject groups. A comparison between 
phylogenetic microarray (HITChip) and pyrosequencing-derived data was 
established for four faecal samples of elderly individuals, showing good correlation 
of both methods especially at higher taxonomic ranks (Claesson et al., 2009).  
Fluorescent In Situ Hybridization (FISH) is a useful technique when specific 
bacterial phylogenetic groups are targeted and allows to monitor the spatial 
organization of bacteria in the community. Nevertheless, some limitations have been 
encountered such as design of probes and the ability of the probes to reach the target 
side. Similar to FISH, for qPCR, target-specific primers are needed, and generally, 
both techniques are applied in combination with other more generic approaches to 
support the results (Kerckhoffs et al., 2009). Recently, a high-throughput qPCR chip 
has been designed to study gut microbial diversity in combination with next 
generation sequencing (Hermann-Bank et al., 2013). The majority of the molecular 
methods described above require the use of more or less specific primers or probes 
targeting a microbial group of interest.  
In contrast, by using metagenomics, the repertoire of bacteria that can be studied is 
extended. Furthermore, metagenomics allows not only to identify the bacterial 
species but also their functional role in the microbial community. The introduction 
of metagenomics methods has turned on a new page for characterizing uncultivable 
organisms present in different environments (Martinez, 2008; Aminov, 2009). 
Functional metagenomics screening has also been used to study the function of 
several of the encoded genes, especially the flow of resistance genes and unknown 
genes that cannot be detected by PCR (Riesenfeld et al., 2004; Sommer et al., 2009). 
Targeted (PCR-based), functional and sequence-based metagenomics methods have 
been applied to study the resistome (Penders et al., 2013).  
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The implementation of culture dependent and independent techniques including 
metagenomics and high-throughput sequencing have been increasing our 
knowledge in the study of the gut microbiome and resistome. Recently, Dubourg et 
al. (2014) implemented the integrated application of culture dependent and 
independent techniques to determine the impact of antibiotics on the gut microbiota 
in patients treated with broad-spectrum antibiotics. Similarly, Rettedal and 
collaborators (2014) showed that the combination of novel cultivation methods with 
high-throughput sequencing can allow scientists to identify and phenotypically 
characterize previously uncultivated species.  
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Research aim and thesis outline 
In line with the above, the aim of the research described in this thesis was to increase 
our knowledge regarding the gut microbiota and associated resistome by using 
culture dependent and independent techniques, focusing on the diversity and 
dynamics of the gut microbiota induced by antibiotic treatment. 
Chapter 1 provides an overview of the introduction of antibiotics as a powerful tool 
to fight nosocomial infections and the subsequent development of resistance, 
considering the emergence of antibiotic resistant genes from an ecological point of 
view. Furthermore, information is given on our current knowledge regarding the role 
of the gut microbiota as a reservoir of antibiotic resistance genes and the ecological 
implications of antibiotic administration in critical ill patients, including the 
different tools developed for the study of the gut microbiota and resistome. 
It has been previously shown that antibiotics can not only act as a toxic compound, 
but also can be used as a single source of carbon by bacteria, which is referred to as 
the “Subsistence phenotype”. Chapter 2 describes different strategies that were 
implemented to study the subsistence phenotype in microorganisms present in 
faecal samples from humans as well as zoo animals. 
The animals included in this initial study of subsistence also included a number of 
non-human primates. Therefore, in order to allow for deep and comprehensive 
analysis of the composition of gut microbiota in these animals, experiments were 
performed as reported in Chapter 3 that investigated to what extent the Human 
Intestinal Tract Chip (HITChip) could also be applied for the characterization of gut 
microbiota composition in non-human primates.  
In the gut microbiota, commensal bacteria play an important role in homeostasis 
with respect to a broad range of metabolic, nutritional, physiological and 
immunological processes, but can also act as a reservoir of antibiotic resistance 
genes.  
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The majority of the commensal bacteria is represented by anaerobes, however, few 
studies have been performed in this group of microorganisms due to the laborious 
and difficulties to cultivate them. In Chapter 4, culture independent techniques 
such as HITChip phylogenetic microarray, metagenomics-shotgun sequencing and 
functional metagenomics were applied to study the gut microbiota and resistome in 
a single ICU patient receiving prophylactic antibiotic therapy.  
The analysis was further expanded in Chapter 5 by studing the dynamics of the 
microbiota and resistome in eleven ICU patients receving prophylactic antibiotic 
therapy using HITChip phylogenetic microarray and nanolitre-scale quantitative 
PCRs, targeting a broad range of antibiotic and disinfectant resistance genes. 
Using cultivation techniques, complementary information regarding the ecological 
consequences of antibiotic administration in critically ill patients can be established. 
In Chapter 6 a range of cultivable aerobic and anaerobic bacteria was isolated and 
further characterized from eleven ICU patients receiving prophylactic antibiotic 
therapy, by using several complementary culture media, and the cultivable fraction 
was compared with the overall composition of the microbiota present in the samples 
as measured by using the HITChip. 
Chapter 7 provides a more detailed acount of the dynamics of Enterococcus species 
colonization in ICU patients receiving prophylactic antibiotic therapies, including 
the identification of clonal complexes. Furthermore, carriage of antibiotic resistance 
and virulence factor encoding genes was determined, highlighting the opportunity 
for the exchange of resistance and virulence genes, which could increase the risk of 
aquiring nosocomial infections. 
Chapter 8 describes the implementation of high-throughput cultivation-based 
screening using the PAO-based Microdish platform combined with high-throughput 
sequencing (MiSeq), which allowed the recovery previously uncultivable bacteria 
present in the gut of critical ill patients receiving antibiotic treatment. 
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Chapter 9 provides a general discussion of the results obtained from the studies 
described in this thesis, with emphasis on the different approaches implemented to 
study the microbiome and resistome.  
Furthermore, this chapter provides an outlook and unanswered questions that 
should be included in the design of future studies. 
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 Abstract 
Recent studies indicate that next to antibiotic resistance, bacteria are able to subsist 
on antibiotics as a carbon source. Here we evaluated the potential of gut bacteria 
from healthy human volunteers and zoo animals to subsist on antibiotics. Nine gut 
isolates of Escherichia coli and Cellulosimicrobium spp. displayed increases in 
colony forming units (CFU) during incubations in minimal medium with only 
antibiotics added, i.e. the antibiotic subsistence phenotype. Furthermore, laboratory 
strains of E. coli and Pseudomonas putida equipped with the aminoglycoside 
3’phosphotransferase II gene also displayed the subsistence phenotype on 
aminoglycosides. In order to address which endogenous genes could be involved in 
these subsistence phenotypes, the broad-range glycosyl-hydrolase inhibiting 
iminosugar deoxynojirimycin (DNJ) was used. Addition of DNJ to minimal medium 
containing glucose showed initial growth retardation of resistant E. coli, which was 
rapidly recovered to normal growth. In contrast, addition of DNJ to minimal 
medium containing kanamycin arrested resistant E. coli growth, suggesting that 
glycosyl-hydrolases were involved in the subsistence phenotype. However, antibiotic 
degradation experiments showed no reduction in kanamycin, even though the 
number of CFU increased. Although antibiotic subsistence phenotypes are readily 
observed in bacterial species, and are even found in susceptible laboratory strains 
carrying standard resistance genes, we conclude there is a discrepancy between the 
observed antibiotic subsistence phenotype and actual antibiotic degradation. Based 
on these results we can hypothesise that aminoglycoside modifying enzymes might 
first inactivate the antibiotic (i.e. by acetylation of amino groups, modification of 
hydroxyl groups by adenylation and phosphorylation respectively), before the 
subsequent action of catabolic enzymes. Even though we do not dispute that 
antibiotics could be used as a single carbon source, our observations show that 
antibiotic subsistence should be carefully examined with precise degradation 
studies, and that its mechanistic basis remains inconclusive. 
 
Keywords: Antibiotic resistance, antibiotic subsistence, antibiotic subsistence phenotype, 
aminoglycosides, single carbon source 
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Introduction 
Antibiotic resistance is a global health problem, and resistance is prevalent in 
bacteria isolated from both human and animal sources ( van den Bogaard & 
Stobberingh, 2000; Sommer et al., 2009). Also, other natural habitats, for example 
soil, represent a common reservoir of resistance genes (Dantas et al., 2008). Recent 
metatranscriptome analyses have revealed that antibiotic resistance genes are 
expressed in a broad range of natural habitats, even in the absence of obvious 
antibiotic selection pressure (Versluis et al., 2015). Furthermore, metagenomic 
studies of ancient environments have revealed that antibiotic resistance is a natural 
phenomenon that predates the anthropogenic selective pressure of clinical antibiotic 
use (D'Costa et al., 2011).  
 
It has long been speculated that, for example in clinically relevant strains, genes 
conferring resistance to aminoglycoside antibiotics were derived from organisms 
producing aminoglycosides, suggesting that members of the Actinomycetes could 
have provided the initial pool of aminoglycoside resistance genes (Benveniste & 
Davies, 1973; Wright, 2007). Aminoglycosides are useful in the treatment of Gram-
negative aerobic bacilli, staphylococci and other Gram-positive bacterial infections 
(Yao and Moellering, 2007). The initial site of aminoglycoside action is the outer 
bacterial membrane, where the cationic antibiotic molecules create fissures in the 
outer cell membrane. These fissures result in leakage of intracellular contents, and 
enhanced antibiotic uptake. Once inside the bacterial cell, aminoglycosides inhibit 
protein synthesis by binding to the 30S ribosomal subunit (Gonzalez et al., 1998). 
Resistance to aminiglycosides is often due to enzymatic inactivation by 
acetyltransferases, nucleotidyltransferases and phosphotransferases. Other 
resistance mechanisms include loss of permeability, structural alteration of the 
ribosomal target and the presence of efflux pumps (Azucena and Mobashery, 2001).  
Streptomycin, a representative of aminoglycoside antibiotics produced naturally by 
bacteria, has been shown to participate in microbial survival pathways.  
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These pathways can be defined as the capacity of bacterial metabolism to modulate 
antibiotic resistance (Martinez and Rojo, 2011). This could indicate that 
aminoglycosides, apart from inhibiting bacterial growth, could stimulate the 
acquisition of aminoglycoside resistance genes. This can play an important role in 
the survival of microorganisms, as indicated for the acetyltransferase involved in 
aminoglycoside resistance in Providencia stuartii (Goldberg et al., 1999; Barlow and 
Hall, 2002).  
 
Recently a large and diverse group of bacteria from soil, seawater, and the gut of 
humans and farm animals were found to not merely resist the toxic effects of 
antibiotics, but also to use antibiotics including aminoglycosides as a single carbon 
source. This phenotype is commonly referred to as “antibiotic subsistence” (Dopazo 
et al., 1988; Dantas et al., 2008; Barnhill et al., 2011; Xin et al., 2012). In addition, 
the concept of bacteria subsisting on antibiotics has been referred to as “antibiotic-
resistant extremophiles” (Gabani et al., 2012) or “antibiotrophs” (Woappi et al., 
2014). These alternative terms depict the microorganisms as being able to subsist 
under harsh environmental conditions, e.g. elevated antibiotic concentrations or the 
use of antibiotics as the sole carbon source. In disagreement with the accumulating 
body of literature supporting the possibility of bacterial subsistence on antibiotics, 
Walsh et al. (2013) tested whether soil bacteria could subsist on antibiotics. As no 
degradation of antibiotics occurred, Walsh et al. (2013) concluded that soil bacteria 
could not utilise antibiotics (including streptomycin, trimethoprim, penicillin and 
carbapenicillin) as a carbon source. 
 
To date, no genes have been identified that could enable bacteria to use antibiotics 
as a single carbon source, and therefore the relationship between antibiotic 
resistance and antibiotic subsistence remains unclear (Dantas & Sommer, 2012). To 
this end, and since the gut microbiota of humans and animals has been described as 
a reservoir of antibiotic resistance, we studied the potential of gut bacteria to display 
the antibiotic subsistence phenotype using a range of antibiotics.  
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Almost all of the bacteria able to subsist on antibiotics grew on an aminoglycoside, 
and therefore we focused on aminoglycosides to address mechanistic aspects of the 
subsistence phenotype that could be readily approached using laboratory model 
organisms.  
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Materials and methods 
 
Samples and antibiotics used 
We evaluated the antibiotic subsistence phenotype of bacteria subsisting on a range 
of antibiotics: ampicillin, chloramphenicol, erythromycin, kanamycin, streptomycin 
and tetracycline (1mg/ml) (Sigma-Aldrich, Zwijndrecht, The Netherlands). Faecal 
samples from two healthy human volunteers and six species of exotic zoo animals 
(Burgers ‘Zoo - Arnhem, the Netherlands) with no previous antibiotic administration 
(6 months) were used as inocula (Table 1). Faecal samples from zoo animals were 
taken by the zookeepers following internal standard regulations. The samples were 
collected immediately after defecation into a sterile container, and then stored at 4°C 
(for 0.5-4 h) before being transferred to -80°C. 
 
 
Isolating bacteria with the subsistence phenotype 
Faecal samples (˜ 200 mg) were suspended in 5 ml of M9 minimal salts medium 
(Sigma-Aldrich) and centrifuged twice (5 min at 18,400 g) to prevent carry-over of 
dissolved carbon from the faecal material. Washed bacterial cells were then 
suspended in 5 ml of fresh M9 medium, and 50 μl inoculated into 5 ml M9 medium 
supplemented with 1 mg/ml of a single antibiotic (98-99% purity) and incubated at 
37°C for 24 h. Then, the cultures were serially transferred twice to a fresh media with 
antibiotic, followed by plating on Luria Broth agar (LB agar), to quantify the bacterial 
growth based on enumeration of colony forming units (CFU) on the LB plates were 
counted after 8, 24, 48 h of incubation at 37°C. The subsistence phenotype criteria 
were identified based on a two-fold increase of CFUs over multiple transfers. A single 
colony was selected and tested to confirm the subsistence phenotype. Glucose (1 
mg/ml) was used as a positive control, while M9 medium lacking any carbon source 
served as negative control for growth. All experiments were performed in duplicate.  
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Identification of bacterial isolates with the subsistence phenotype 
Bacteria subsisting on antibiotics were selected for DNA amplification using the 27F 
and 1492R primers. PCR was carried out with FastStart Taq DNA polymerase 
(Roche) in a reaction mixture containing 10X Fast Taq buffer + MgCl2, dNTPs 
(10mM each, Roche), 10pmol of both primers in a final volume of 49μl; finally add 
the template of DNA (1 μl). For the amplification reaction, after 5 min at 950C, 35 
identical cycles (30 s of denaturation at 950C, 40 s of annealing at 520C, 90 s of 
elongation at 720C) were followed by a final elongation step of 7 min at 720C. The 
amplified fragments were selected for partial sequence analysis of the 16S rRNA gene 
(~800bp) using the 1392R primer, and sequences were deposited in GenBank with 
accession numbers KT989026, KT989027, KT989028, KT989029, KT989030, 
KT989031, KT989032, KT989033, KT989034, KT989035 (Table 1). Furthermore, 
all isolates were tested for their antibiotic resistance phenotype by dilution agar test 
as recommended by Clinical & Laboratory Standards Institute (2014).  
 
 
Experimental controls to differentiate between aminoglycoside 
resistance and the subsistence phenotype 
In order to differentiate between antibiotic resistance and antibiotic subsistence, we 
used transformants containing a gene encoding aminoglycoside 
3’phosphotransferase II (APH (3’) II) (Berg et al., 1975), one of the most common 
aminoglycoside-modifying enzymes in prokaryotes, as a control. In detail, 
chemically competent cells of two different strains of E. coli (DH5α and TOP10) were 
transformed by heat-shock with cloning vectors pRSF-1b (Novagen, Billerica, MA, 
USA) and pCR-2.1TOPO (Invitrogen, Carlsbad, CA, USA) respectively, both 
containing an APH (3’) II gene. Also, we used Pseudomonas putida TEC1 
transformed with the cloning vector pUTmini-Tn5-Km1 (de Lorenzo et al., 1990; 
Leprince et al., 2012). Transformed and non-transformed strains were tested for 
their ability to resist and subsist on the aminoglycoside antibiotics kanamycin and 
neomycin using the protocol described above. 
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Effect of deoxynojirimycin (DNJ) on the aminoglycoside subsistence 
phenotype 
To evaluate the involvement of glycosyl hydrolases (GH) in the subsistence 
phenotype on aminoglycoside we selected deoxynojirimycin (DNJ) (Laboratory of 
Organic Chemistry, Leiden University, The Netherlands), which is one of the 
simplest natural carbohydrate mimics that can competitively inhibit specific 
glycosidic enzymes (Hughes & Rudge, 1994). We tested the capacity of E. coli (DH5α) 
transformed with pRSF-1b plasmid-encoded APH (3’) II gene, to grow on kanamycin 
or glucose (1mg/ml) as a single carbon source in the presence of DNJ (range of 
0.00001-10 mM of DNJ) and monitored growth for 24 hours. All the experiments 
were performed in triplicate and used 96-well plates. Growth was measured by 
OD=600nm for 24 h continuously during incubation at 37°C with agitation at 75 
rpm. 
 
Kanamycin degradation by Escherichia coli  
To investigate kanamycin degradation by E. coli we performed an LC-MS/MS 
analysis. The experimental control was carried out using E. coli (DH5α) with and 
without cloning vector pRSF-1b in the presence of kanamycin (99.25% Kanamycin A 
Sulfate, EvoPure™, GENTAUR Netherlands) (1mg/ml). An aliquot was taken at 0, 
4, 8, 24 h and analysed in duplicate using LC-MS/MS. In detail, the samples were 
diluted hundred times in 0,065% heptafluorbutyric acid, with an expected 
concentration of 10 mg/L. Octamethylkanamycine was added as an internal 
standard to the diluted samples at a concentration of 10 mg/L. Fifty microliter of the 
diluted sample was injected using a 2690 separations module high-performance 
liquid chromatography (HPLC) system (Waters Corporation, USA) coupled to a 
Quattro Micro tandem mass detector (Waters-Micromass, Manchester, UK). For the 
analysis samples were separated using a Symmetry C18 (150 × 3 mm, 5 μm) 
chromatographic column from Waters (Milford, PA, USA) working at 30°C and at a 
flow rate of 0.4 ml/min.  
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The mobile phase was water containing 0.065% heptafluorbutyric acid (A) mixed on 
a gradient mode with methanol containing 0.065% heptafluorbutyric acid (B), as 
follows: initiated at 100% A, from 100% to 55% A in 5 min, from 55% to 40% A in 
11.5 min, kept isocratic at 60% B for 5 min, from 60% B to 0% B in 1 min for 
equilibration of the column (initial conditions). The mass spectrometer was operated 
in electrospray positive mode, and data acquisition was in multiple reactions 
monitoring mode (MRM). Source settings were as follows: capillary voltage 2.7 kV, 
cone voltage 25 V, source temperature 120°C, desolvation temperature 400°C, cone 
nitrogen gas flow 60 L/h, desolvation gas flow 600 L/h. Argon was used as the 
collision gas at 3.2 × 10-3 mbar. Calibration was done by means of a calibration curve 
(0, 2, 5, 10 and 20 mg/L) in 0.065% heptafluorbutyric acid. Quantification of 
kanamycin in the samples was done on the calibrators by means of isotope dilution 
using octamethylkanamycin. The bacterial culture was also plated on LB agar for 
growth assessment (CFU/ml) as described above. 
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Results 
 
Gut bacteria of human and zoo animals displayed subsistence phenotype 
Nine isolates from human and animal faecal samples displayed subsistence 
phenotypes when cultivated with a single antibiotic as the sole carbon source: six on 
kanamycin, two on streptomycin and one isolate displayed the subsistence 
phenotype on both erythromycin and kanamycin (Table 1).  
 
The subsistence phenotype was measured by plating and counting CFU increases, 
with a two-fold increase of CFUs used to identify the phenotype. The isolates were 
classified by partial sequence analysis of 16S rRNA genes, and seven isolates were 
identified as E. coli and three as Cellulosimicrobium sp. The Cellulosimicrobium sp. 
are members of the family Promicromonosporaceae within the Actinobacteria, and 
were most closely related to Cellulosimicrobium cellulans and Cellulosimicrobium 
funkei (Table 1), which are all related to human pathogens (Funke et al., 1995; 
Kaper et al., 2004; Petkar et al., 2011). All nine isolates were resistant to two or more 
of the following antibiotics: ampicillin, chloramphenicol, tetracycline, erythromycin, 
streptomycin and kanamycin (Table 1).  
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Table 1. Human and zoo animal faecal isolates with subsistence phenotype on antibiotics 
 
Isolate  
(%16S rRNA gene 
identity) 
Source  
(Latin name) 
Resistant to* Subsisting 
on* 
Accession 
number 
Escherichia coli (100) Human 1 
(Homo sapiens) 
AMP, TET, E, 
KAN, STR 
STR KT989026 
Escherichia coli (100) Human 2 
(Homo sapiens) 
AMP, TET, 
KAN, STR, CL 
KAN KT989027 
Cellulosimicrobium sp. 
(99) 
Chimpanzee 
(Pan troglodytes) 
AMP, TET 
KAN, STR 
KAN KT989030 
Cellulosimicrobium sp. 
(100) 
Chimpanzee 
(Pan troglodytes) 
AMP, TET 
KAN, STR  
STR KT989029 
Escherichia coli (100) Baringo giraffe 
(Giraffe camelopardalis 
rothschildi) 
TET, KAN, 
STR 
KAN KT989033 
Escherichia coli (100) Asian elephant 
(Elephas maximus) 
AMP, TET, E, 
KAN, STR 
KAN KT989034 
Escherichia coli (100) Malayan sun bear 
(Ursus malayanus) 
KAN, STR KAN KT989035 
Escherichia coli (100) Sumatran tiger 
(Panthera tigris 
sumatrae) 
AMP, TET, E, 
KAN, STR 
KAN, E KT989032 
Cellulosimicrobium sp. 
(99) 
Warthog 
(Phacochoerus 
africanus) 
AMP, KAN, 
STR 
KAN KT989028 
 
Agent abbreviation*: AMP, Ampicillin; TET, Tetracycline; E, Erythromycin; KAN, Kanamycin; STR, 
Streptomycin; and CL, Chloramphenicol. 
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Experimental controls to differentiate aminoglycoside resistance and 
subsistence phenotype 
Since nine isolates displayed the subsistence phenotype on aminoglycosides, mainly 
kanamycin, we included an experimental control in an attempt to differentiate 
between antibiotic resistance and antibiotic subsistence. This was performed by 
equipping laboratory strains with a plasmid-encoded APH (3’) II gene. All 
transformants of E. coli and P. putida, but none of the non-transformed strains, 
displayed the subsistence phenotype on kanamycin and neomycin (Table 2). 
Growth of the strains on glucose was similar to that in the presence of 
aminoglycosides, whereas no growth was observed in M9 medium to which no 
carbon source was added (Table 2).  
 
Table 2. Growth experiments (48 h, performed in duplicate) of non-resistant and resistant E. coli and P. 
putida strains on media containing no carbon source, glucose or aminoglycosides (kanamycin, neomycin) 
in M9 minimal salts medium.  
 
 M9 M9 + Glucose 
1 mg/ml 
M9 + Kanamycin 
1 mg/ml 
M9 + Neomycin 
1 mg/ml 
Escherichia coli 
DH5α - + - - 
DH5α + pRSF-1b - + + + 
DH5α + pCR-2.1 TOPO - + + + 
TOP10 - + - - 
TOP10 + pRSF-1b - + + + 
TOP10 + pCR-2.1 TOPO - + + + 
Pseudomonas putida 
TEC1 - + - - 
TEC1 + pUTmini-Tn5-Km1 - + + + 
 
Grey highlighted boxes indicate strains showing subsisting phenotype on aminoglycosides. The + 
indicates growth, - indicates no growth. 
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Effect of deoxynojirimycin (DNJ) on the aminoglycoside subsistence 
phenotype 
In order to evaluate the involvement of GH in the subsistence phenotype on 
aminoglycoside, we tested the capacity of E. coli (DH5α) transformed with pRSF-1b 
plasmid- encoded APH (3’) II gene to grow on kanamycin or glucose as a single 
carbon source in the presence of DNJ (range of 0.00001-10 mM).  Cultivability was 
measured by plating and counting CFUs during 24 h. We found that in the presence 
of DNJ and glucose, the bacteria showed initial growth retardation which was then 
rapidly overcome (Fig. 1A). In contrast, adding DNJ to a minimal medium 
containing only kanamycin as a carbon source arrested growth completely. This 
suggested that glycosyl-hydrolases are required for the subsistence phenotype on 
kanamycin (Fig. 1B).  
 
Kanamycin degradation by Escherichia coli  
Finally, we studied kanamycin degradation by E. coli (DH5α) in the presence or 
absence of the plasmid encoded APH (3’) II gene using 1 mg/ml of high purity 
kanamycin (Evopure, 99.25%) in M9 medium. Bacterial growth was calculated using 
the plate counting method, and kanamycin was measured by LC-MS/MS. It was 
observed that the number of CFUs increased during the first 8 h, although no 
degradation of the antibiotic was observed (Table 3). 
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Table 3. Concentration of kanamycin and colony forming units (CFUs) obtained in M9 minimal media 
with kanamycin (EvoPure™-1mg/ml) with and without resistant E. coli during LC-MS/MS experiments 
over time. 
 
Samples Kanamycin concentration 
(mg/L) 
Colony forming units (CFU/ml) 
Time (Hours) 0 4 8 24 0 4 8 24 
MM + KAN 978 1021 1066 1399 - - - - 
MM + Ec + 
KAN 
923 977 1005 1306 6.6E+07 5.4E+07 5.4E+07 4.0E+07 
MM + Ec-p + 
KAN 
907 984 1008 1266 4.2E+07 6.8E+07 2.2E+08 1.1E+09 
MM, minimal media; KAN, kanamycin; Ec, Escherichia coli; Ec-p, Escherichia coli-plasmid encoding 
aminoglycoside 3’ phosphotransferase II gene. 
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A 
 
B 
Figure 1. Growth dynamics (in triplicates) of transformed E. coli in M9 medium containing glucose (1 
mg/ml) (A) and kanamycin (B) in the presence of different concentrations of DNJ (in mM). 
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Discussion  
We observed that two groups of bacteria, E. coli and Cellulosimicrobium spp., 
present in the gut microbiota of healthy human volunteers and zoo animals, 
displayed the subsistence phenotype on aminoglycosides and erythromycin as a 
single carbon source. The subsistence phenotype was defined as an increase of CFUs 
over multiple transfers compared to the inoculum incubated in the same media 
without a carbon source. In order to avoid the presence of residual carbon sources, 
we included a pre-washing step to prevent carry-over of dissolved carbon from the 
faecal material and used new sterile glass material and freshly prepared media.In 
addition, we included serial two-fold dilutions of glucose and kanamycin (1 – 0.0625 
mg/ml) and observed the subsistence phenotype at all antibiotic concentrations 
including those more similar to amounts found in natural habitats (Trieu-Cuot and 
Courvalin, 1986) (data not shown). 
 
Subsistence phenotypes were found previously in P. fluorescens isolates obtained 
from lake sediments, which were described to utilize benzylpenicillin as a carbon, 
nitrogen and energy source (Johnsen, 1977). Soil bacteria from the orders 
Pseudomonadales and Burkholderiales have also been isolated based on their 
capacity to grow on a range of antibiotics as a single carbon source (Dantas et al., 
2008). In another environment including clinical and nonclinical samples, Barnhill 
et al. (2011) observed that multi-resistant Salmonella spp. were also able to subsist 
on antibiotics, highlighting the potential prevalence of the antibiotic subsistence 
phenotype in a clinical context. Xin et al. (2012) showed that two members of the 
Enterobacteria group (e.g. Klebsiella pneumoniae and Escherichia fergusonii) 
isolated from faecal material of healthy volunteers were able to subsist and bio-
degraded chloramphenicol as a sole carbon source. However, all the strains in the 
study were chloramphenicol susceptible, which indicates that the subsistence and 
resistance mechanisms were independent in this particular case.  
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In our study, since the majority of the bacteria seemed to subsist on aminoglycosides, 
we studied laboratory strains of E. coli and P. putida with a plasmid-encoded APH 
(3’) II gene in order to differentiate aminoglycoside resistance and the subsistence 
phenotype. Our results showed that a common resistance gene facilitates the 
subsistence phenotype on aminoglycosides, and these results indicated that 
resistance and subsistence mechanism might be linked. Similar subsistence 
phenotypes were obtained with Pseudomonas putida TEC1 using the cloning vector 
pUTmini-Tn5-Km1 (de Lorenzo et al., 1990; Leprince et al., 2012), which similarly 
contains an APH (3’) II gene.  
 
Previous studies have shown that kanamycin is stable under culture conditions for 
at least a week (Ryan et al., 1970). Stability has been attributed to its structure where 
a six-aminocyclitol ring is attached to aminosugar side chains through glycosidic 
bonds. We hypothesized that an intrinsic metabolic capacity to break down and 
utilize phosphorylated aminoglycosides is present in various bacteria.  
In the genomes of E. coli and P. putida a multitude of genes predicted to encode 
glycosyl hydrolases (GH) exist (40 – 50 in E. coli and 26 in P. putida), with typically 
between 20-22 GH gene families annotated in E. coli. The encoded enzymes could 
potentially be involved in breaking the glycosidic bonds in the aminoglycosides, 
releasing an accessible carbon source. Due to the large number of GH encoding genes 
though single and combinatorial gene knockouts would not be numerically feasible. 
It is also likely that this approach may not deliver the necessary result due to 
potential functional redundancy of these enzymes. In our study we showed that a 
specific glycosyl-hydrolase inhibiting iminosugar (DNJ) abolishes the subsistence 
phenotype on aminoglycosides. This suggests that glycosyl-hydrolase activity could 
be necessary for the hydrolysis of the glycosidic bond and subsequent release of the 
aminosugars from the aminoglycoside, and hence indicates an involvement of GH in 
the antibiotic subsistence phenotype.  
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Since we found several indications of aminoglycoside subsistence phenotypes in line 
with previous observations, we applied the LC-MS/MS method to study kanamycin 
degradation. However, no degradation of kanamycin was observed in our study. Our 
findings thus align with the previous observations by Walsh et al. (2013) suggesting 
that due to the lack of antibiotic degradation, the subsistence phenotype cannot be 
linked to the use of the antibiotic as a sole carbon source. 
 
So far, no genes have been identified in the catabolic pathways of kanamycin 
(http://www.ebi.ac.uk/chebi/chebiOntology.do?chebiId=CHEBI:6104). However, 
Stancu and Grifoll (2011), showed that several groups of Gram-positive and Gram-
negative bacteria (including members of the Enterobacteriaceae family), displayed 
particular metabolic capabilities such as hydrocarbon degradation since these were 
able to grow on Poeni crude oil as a single carbon source. In addition, they show that 
Gram-negative bacteria possessed between two and four catabolic genes involved in 
degradation of saturated, monoaromatic and polyaromatic hydrocarbons. 
Interestingly, these groups of bacteria were resistant to hydrophilic antibiotics such 
as ampicillin and kanamycin, and cellular and molecular modifications were induced 
by the antibiotic. 
 
Since subsistence phenotypes on a range of antibiotics are readily observed, it is 
possible that antibiotic resistance genes frequently allow not only resistance, but also 
simultaneously facilitate antibiotic subsistence. Dantas and Sommer (2012) 
investigated the connection between subsistomes and resistomes, and indicated that 
thus far not a single gene involved in antibiotic subsistence has been identified. 
Although active aminoglycoside efflux pumps have been observed in E. coli 
(Mingeot-Leclercq et al., 1999), it is hypothesised that this mechanism is not actively 
involved in the E. coli clones subsisting on the antibiotics. This is because such 
activity would hinder accumulation of the drugs in the cytoplasm, where they are 
required for catabolism to occur.  
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Another potential subsistence mechanism that we considered was ribosomal protein 
mutations in spontaneous kanamycin resistant E. coli strains. It has been indicated 
that resistance to kanamycin and neomycin by ribosomal protein mutation is 
uncommon since this antibiotic binds to multiple sites on 30S and 50S ribosomal 
subunits, and high level resistance cannot be achieved by a single mutation (Kucers 
et al., 1997). However, aminoglycoside modifying enzymes encoded by plasmids 
including the acetyltransferases, adenyltransferases and phosphotransferases 
encoded by plasmids (Neu, 1992) may inactivate antibiotics (i.e. by acetylation of 
amino groups, adenylation and phosphorylation of hydroxyl groups), before the 
subsequent action of the catabolic enzymes. 
 
Based on our results we conclude that gut bacteria isolated were not able to degrade 
kanamycin and utilise it as a carbon source. Nevertheless, we observed that the 
presence of an aminoglycoside resistance gene supports the aminoglycoside 
subsistence phenotype, and GH seem to be required. This could indicate a possible 
link between the resistance and the subsistence phenotype. In addition, as we only 
tested one type of aminoglycoside modifying enzyme, we cannot assume that all the 
aminoglycoside modifying enzymes act in the same way. The different mechanisms 
of enzymatic modification could have different consequences. Further studies of 
kanamycin degradation linked to the evaluation of the subsistence phenotype and 
other aminoglycoside modifying enzymes may therefore provide further insight to 
the underlying subsistence mechanism.  
 
Bacteria need to adapt to the growth medium in order to be able to metabolize the 
nutrients, and during the lag phase they are not completely inactive. They grow in 
size and develop primary metabolites (such as proteins, enzymes and RNA) as well 
as coenzymes and division factors required for making new cells. These factors 
together with the mechanisms involved in antibiotic resistance could also be 
hypothesised to facilitate the antibiotic subsistence phenotype.   
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It also may well be that bacteria simply need to be resistant to the antimicrobial in 
order to be able to exploit trace levels of non-toxic breakdown products.  Future 
analyses including experimental evolution of antibiotic subsistence will help to 
further unravel the possible mechanisms involved in this phenotype. Nevertheless, 
since we were able to identify a bacterial strain that displayed the subsisting 
phenotype with both aminoglycoside (kanamycin) and macrolide (erythromycin) 
antibiotics, expansion of future studies to include resistance genes and metabolic 
pathways of macrolides as well as aminoglycosides could be of special interest. 
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 Abstract 
The human intestinal microbiota is responsible for various health-related functions, 
and its diversity can be readily mapped with the 16S ribosomal RNA targeting 
Human Intestinal Tract (HIT) Chip. Here we characterize distal gut samples from 
chimpanzees, gorillas and marmosets, and compare them with human gut samples. 
Our results indicated applicability of the HITChip platform can be extended to 
chimpanzee and gorilla faecal samples for analysis of microbiota composition and 
enterotypes, but not to the evolutionary more distant marmosets. 
Keywords: Microbiota, phylogenetic profile, enterotypes, non-human primates. 
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Introduction 
The human body is colonized by vast numbers of different microbes, most of which 
are found in the gastro-intestinal (GI) tract. These microbes have been referred to as 
the intestinal microbiota and are proposed to constitute a virtual organ with a range 
of beneficial functions (Backhed, et al., 2005, Gill, et al., 2006, Murphy, et al., 2010). 
For example, intestinal microbiota can play a role in health by interacting with the 
host at the GI mucosa, modulating the host immune response (Ashida, et al., 2012). 
The extensive study of the human microbiota composition has further resulted in the 
possible distinction of a limited number of well-balanced host-microbial symbiotic 
states, the so-called enterotypes (Arumugam, et al., 2011, Koren, et al., 2013). 
Different techniques have been developed to analyse the composition and dynamics 
of the intestinal microbiota. Most recent technical advances to study microbiota 
composition include the implementation of next generation technology (NGT) 
sequencing as well as ribosomal RNA targeted microarrays for the high throughput 
and comprehensive profiling of intestinal microbiota. Our laboratory has 
implemented the Human Intestinal Tract (HIT) Chip, (Rajilic-Stojanovic, et al., 
2009). The HITChip is a well-validated phylogenetic array produced by Agilent 
Technologies (Palo Alto, CA) for human GI tract samples, with over 4,800 tiling 
oligonucleotides targeting the V1 or the V6 region of the 16S rRNA gene from 1,132 
microbial phylotypes present in the human GI tract (Rajilic-Stojanovic, et al., 2011, 
van den Bogert, et al., 2011). The HITChip provides highly reproducible (median 
Pearson’s correlation of 0.99), broad and deep analysis of the intestinal microbiota, 
comparable to new generation technology sequencing (Claesson, et al., 2009). It can 
be used to assign enterotypes and also to distinguish low and high gene count 
subjects (Arumugam, et al., 2011, Le Chatelier, et al., 2013). In addition, we have 
implemented other microarrays including the Mouse Intestinal Tract (MIT) Chip 
and Pig Intestinal Tract (PIT) Chip to analyse the composition of the microbiota in 
frequently used animal models (Geurts, et al., 2011, Haenen, et al., 2013).  
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The interest to determine the composition of the intestinal microbiota of different 
animal species lead us to the question about the applicability of HIT Chip to 
determine the composition of evolutionarily related non-human primates. In fact, 
intestinal microbiota composition is linked to evolutionary relatedness of the 
intestine. As an example, the colonic microbiota from different animals is more 
similar than the small intestinal and large intestinal microbiota of the same animal 
(Muegge, et al., 2011). Findings also suggest that for chimpanzees and humans 
intestinal bacteria patterns evolved before their split into evolutionarily separate 
ways (Degnan, et al., 2012). Furthermore, for wild great apes the composition of 
intestinal microbial communities resembles the phylogenies of their host and 
contains species-specific signatures (Ochman, et al., 2010).  
The intestinal microbiota profiles in non-human primates give insight into co-
evolution of microbiota with phylogenetic closely related hosts and how gut types, 
environments and food habits are associated with divergence. The possibility to use 
the HITChip for non-human samples, as is presented herein, provides a cost-
efficient and fast alternative to screen GI tract microbiota composition of 
chimpanzees and gorillas as compared with NGT sequencing based techniques, 
especially when performed at comparable depth of around 200.000 sequencing 
reads per sample (Clasesson, et al., 2009, van den Bogert, et al., 2011, Hermes, et al., 
2014). This could lead to advances in microbiota-related research questions in 
primatology, in relation to evolution, health, disease, diets and environmental 
factors. Most importantly, The HITChip provides robust data that allow for relative 
quantification at different taxonomic levels with extremely high reproducibility, and 
allows for analysis of single samples with short processing times, as opposed to large 
pools of barcoded PCR products as normally employed for NGT-based approaches 
(Hermes, et al., 2014).  
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Materials and methods 
A total of 12 human faecal samples were obtained from healthy volunteers. The non-
human primates samples were collected from three chimpanzees (Pan troglodytes), 
two Western gorillas (Gorilla gorilla), which are kept at Burgers’ Zoo (Arnhem, The 
Netherlands) and five marmosets (New world monkeys - Callithrix jacchus), kept at 
animal facilities of Erasmus University (Rotterdam, The Netherlands).  
DNA isolation was done using a modified repeated beating method (Salonen, et al., 
2010). Amplification for 16S rRNA gene, in vitro transcription and labelling, and 
hybridizations were carried out as described previously (Rajilic-Stojanovic, et al., 
2009). Data analysis was performed using a microbiome R-script package 
(https://github.com/microbiome) in combination with a custom designed database 
as previously described (Jalanka-Tuovinen, et al., 2011, Lahti, et al., 2011). The 
reproducibility of obtained hybridization signals was determined by calculating the 
Pearson’s linear correlation of the logarithm of spatially normalized signals of two 
independent hybridizations. Multivariate statistics using a Principal Component 
Analysis (PCA) to analyse the positive and negative correlations between the 
bacterial populations and the different species of non-human primates compared 
with faecal samples of healthy humans were performed using CANOCO 5.0 (Ter 
Braak, et al; 2012). Enterotypes were determined based on HITChip profiles  of non-
human primate samples and the HITChip data for all MetaHIT samples (n=124) 
classified by Arumugam et al (2011). The MetaHIT samples were used as a training 
set, for which the optimal number of clusters k was three as based on the Calinski-
Harabasz (CH) index to determine the optimal number of clusters in each data set, 
and the silhouette score was calculated for each data set of clusters generated by 
partition around medoids (PAM) clustering (Arumugam, et al., 2011). The QIIME 
pipeline (http://quime.org/) was used to compare our data obtained by HITChip 
analysis with high-throughput amplicon sequencing data from another study (454 
sequencing) (J.Ritali, University of Helsinki, personal communication). 
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Results and Discussion 
HITChip profiling of chimpanzee and gorilla intestinal microbiota 
composition 
The applicability of the HITChip for chimpanzees, gorillas and marmosets was 
evaluated, and profiles were compared with those obtained from faecal samples of 
healthy human individuals. Hybridization to phylotype-specific probes and high 
reproducibility was obtained for chimpanzee and gorilla samples, as calculated by 
the Pearson’s linear correlation of the logarithm of spatially normalized signals of 
two independent hybridizations (values of 0.98-0.99). In contrast, when comparing 
overall signal intensity as a percentage of that observed for  human controls, and 
taking into account  error propagation based on average and standard deviation, the 
marmoset samples had a lower overall signal intensity (41.4 +/- 14) as compared to 
samples from  chimpanzees (85.3 +/- 21) and gorillas (59.0 +/- 22), indicating that 
only a small fraction of RNA had been hybridized. Based on these results we can 
speculate that the intestinal microbiota of chimpanzees and gorillas, but not that of  
marmoset, are sufficiently related to that of humans to warrant meaningful 
application of the HITChip. 
 
Clustering of faecal microbiota composition byhost phylogeny 
The faecal microbiota profiles from the different host species clustered separately 
using Hierarchical Cluster Analysis (Fig. 1A). The results also indicated that per host 
species, individuals have high similarity scores as calculated by Pearson’s 
correlation, which reflects the influence of host on the microbiota composition 
(humans 0.80 +/- 0.03, chimpanzees 0.92 +/- 0.01, gorillas 0.85 and, marmosets 
0.89 +/-0.06). In addition, correlations between chimpanzee and humans samples 
(0.80 +/- 0.04) and between gorilla and chimpanzee (0.88+/- 0.04) were higher as 
compared to what was observed for the respective correlations between humans and 
gorilla (0.69 +/-0.04). 
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The microbial diversity scores calculated by the Shannon Index indicated that the 
diversity in chimpanzee samples is in the range of that of healthy human faecal 
profiles. The gorilla samples had a high variability in the diversity index; and very 
low diversity scores were observed for the more distantly related marmosets (Fig. 
1A), which is in line with the low hybridization signals.  
To analyse the positive and negative correlations between members of the bacterial 
communities and the different host species; we performed multivariate statistics 
using PCA. The results indicated that humans, chimpanzees and gorillas have 
distinct faecal microbial community signatures clustering in different quadrants of 
the plot. More specifically, profiles of humans and apes were largely separated along 
PC1, which explains 50% of the variation of the compositional data, while the 
distinction between chimpanzees and gorillas could in part be explained by PC2 that 
accounts for 15% of the total variation (Fig. 1B). 
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A              
B  
Figure 1. Microbiota comparison of humans, chimpanzees, gorillas and marmosets  
(A) Diversity index (Shannon), average within host similarity and Pearson clustering of samples that were 
analysed using the HITChip. (B) PCA analyses of human, chimpanzee and gorilla samples. Percentages 
indicate the variation in microbial profiles explained by principle components PC1 and PC2. Arrows and 
bacterial names indicate association of bacterial groups with the principle components. 
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HITChip profiles of microbial communities in humans, chimpanzees 
and gorillas 
In order to examine the differences in faecal bacterial community composition 
between chimpanzees, gorillas and healthy humans in more detail, we compared the 
relative abundance of microbial taxa in the different samples at phylum and at genus 
level. The phylum-level composition in intestinal microbial communities indicated 
that for all hosts the two most prevalent phyla were Firmicutes and Bacteroidetes, 
which contributed up to 90% of bacterial abundance in all samples. The percentage 
of Firmicutes and Bacteroidetes varied in each species; 84.2% in humans, 33.3% in 
chimpanzees and 66.0% in gorillas for Firmicutes and 8.2% (humans), 62.2% 
(chimpanzees) and 21.3% (gorillas) for Bacteroidetes. For chimpanzees similar 
results were obtained previously, when the distal intestinal microbiota was studied 
of individual chimpanzees from two communities in Gombe National Park in 
Tanzania (Degnan, et al., 2012). Furthermore, gorilla samples had a high prevalence 
of  Proteobacteria (7.0%) than in chimpanzee (1.2%) and human samples (1.0%), 
whereas Actinobacteria were more prevalent in humans samples (2.7%) as 
compared to chimpanzees (0.3%) and gorillas (1.0%) derived samples.  
Significant differences of bacterial populations were observed between the different 
hosts when examining the data at higher taxonomic resolution, i.e. at genus level. A 
remarkable variation was found with respect to the relative abundance of 
Faecalibacterium prausnitzii et rel., which were especially high (16.0 ± 8.7%) in 
humans versus chimpanzee (5.0 ± 1.5%) and gorilla (1.3 ± 0.8) samples. In addition, 
Bacteroides were more abundant in humans than in chimpanzees and gorillas 
derived samples. A possible explanation for this could be the high protein fat 
Western diet habits of humans that can enrich for proteolytic Bacteroides spp. 
(David, et al.,  2014; Thomas, et al., 2011). Another notable difference that was 
observed concerned high relative abundance of Prevotella melaninogenica et rel. in 
the tested chimpanzees samples (52.5±9.8%) as compared to human (2.8±5.7%) and 
gorilla (14.7±1.9%) samples.  
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This could also be the effect of diet as increased abundance of Prevotella has been 
associated with a vegetarian diet and long-term consumption of high fibre diet 
(David, et al. 2014). With respect to gorilla samples, we observed high relative 
abundance of Sporobacter termitidis et rel. (8.8 ± 4.5%) as compared to chimpanzee 
(4.4 ±3.3%) and human (4.0 ± 2.8%) samples.  
Finally, we screened for possible enterotypes in all samples, as a previous report 
indicated that they are not exclusive to humans but also occur in chimpanzees 
(Moeller, et al., 2012). Among human samples, enterotypes 1 and 3 were found. 
Interestingly, the chimpanzee samples all fell within the Prevotella dominated 
enterotype 2, whereas the gorilla samples all fell within the Ruminococcus 
dominated enterotype 3. The enterotypes observed for the chimpanzees in this study 
are similar to those described previously by Ochman et al., 2010, even that they are 
not similar to those observed within our human set of samples, this support that 
indeed particular enterotypes can changes over the time.  
 
Comparable microbiota signatures using HITChip analyses 454 
sequencing 
In order to compare our HIT Chip data analysis with microbiota profiles obtained by 
454 pyrosequencing from the same animal species, albeit from different individuals, 
we analysed our chimpanzee and gorilla microbiota profiles together with samples 
obtained by Muegge and co-workers ( 2011) using the Qiime pipeline. This 
comparison indicated that the bacterial composition of the chimpanzees and gorillas 
from our study and that of Muegge et al. (2011) have high similarity at family level. 
Because of these two techniques have a different level of resolution and in some 
cases, some Operational Taxonomic Units (OTUs) cannot be assigned to specific 
genera, we used the higher level of taxonomic resolution to compare our results.  
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More specifically, Pearson correlations between family-level relative abundances in 
chimpanzees and gorillas reported by Muegge et al. (2011) and those observed by us 
amounted to 0.98 and 0.97, respectively, showing strong correlation of microbiota 
composition.  
This high similarity reinforces the notion that the HITChip is a viable alternative for 
the currently used high throughput sequencing techniques to screen microbiota 
composition and allows forsimultaneous comparison of the relative abundance of 
specific groups of intestinal bacteria at different levels of taxonomic resolution. 
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Conclusions 
Diverse factors including geography, diet, disease state, sex and host physiology can 
affect the composition of the intestinal microbiota. Degnan et al. (2012) found that 
the geographical distribution, sex and age are associated with the long term 
composition and diversity of the intestinal microbiota in chimpanzees from Gombe 
National Park (Tanzania), but that their microbiota remains distinct from those of 
other  great apes including other subspecies of chimpanzees (Degnan et al., 2010). 
This is in line with previous studies indicating that the host genetic background is a 
selective pressure that favours inter-individual and inter-specific divergence of 
intestinal microbiota composition (Ley, et al., 2008, Ochman, et al., 2010). 
Based on the data reported here, we conclude that apart from human GI tract 
samples, the HITChip can be used for microbiota profiling of chimpanzee and gorilla 
faecal samples. Even though there are microbiota differences between the animal 
species, the 16S rRNA targeted probes used on the HITChip array hybridize the 
majority of 16S rRNA genes of chimpanzee and gorilla microbiota. Profiling the 
distinct faecal microbial communities of the different animals using the HITChip 
provides a simple and robust alternative for high throughput sequencing. We believe 
this contributes to advances in microbiota related research questions in primatology, 
in relation to evolution, health and disease, diets and environmental factors. 
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Abstract 
Objectives. Selective digestive decontamination (SDD) is an infection prevention 
measure for critically ill patients in intensive care units (ICUs) that aims to eradicate 
opportunistic pathogens from the oropharynx and intestines, while sparing the 
anaerobic flora, by the application of non-absorbable antibiotics. Selection for 
antibiotic resistant bacteria is still a major concern for SDD. We therefore studied 
the impact of SDD on the reservoir of antibiotic resistance genes (i.e. the resistome) 
by culture-independent approaches.  
Methods. We have evaluated the impact of SDD on the gut microbiota and 
resistome in a single ICU-patient during and after ICU-stay by several metagenomic 
approaches. We also determined by quantitative PCR the relative abundance of two 
common aminoglycoside resistance genes in longitudinally collected samples of 12 
additional ICU patients who received SDD.  
Results. The patient microbiota was highly dynamic during hospital stay. The 
abundance of antibiotic resistance genes more than doubled during SDD use, mainly 
due to a 6.7-fold increase of aminoglycoside resistance genes, in particular aph(2”)-
Ib and an aadE-like gene. We show that aph(2”)-Ib is harboured by anaerobic gut 
commensals and is associated with mobile genetic elements. In longitudinal samples 
of 12 ICU-patients, the dynamics of these two genes ranged from a ~104 fold increase 
to a ~10-10 fold decrease in relative abundance during SDD.   
Conclusions. ICU hospitalization and the simultaneous application of SDD has 
large, but highly individualized, effect on the gut resistome of ICU patients. Selection 
for transferable antibiotic resistance genes in anaerobic commensal bacteria could 
impact the risk of transfer of antibiotic resistance genes to opportunistic pathogens.  
Keywords: Intensive care medicine, antibiotic resistance, metagenomics 
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Introduction 
Infections are a major threat to hospitalised patients, especially to those treated in 
Intensive Care Units (ICUs), where infections are associated with increased 
morbidity, mortality and health care costs (Cosgrove, 2006; Vincet et al., 2009). 
Selective decontamination of the digestive tract (SDD) is an infection prevention 
measure that reduces ICU-acquired respiratory tract infections and bacteraemia and 
improves survival of ICU patients (De Jonge et al., 2003; de Smet et al., 2009), 
through eradication of potential pathogenic microbes in the oropharynx and the 
digestive tract, while leaving the anaerobic microbiota undisturbed (van der Waaij 
et al., 1990). SDD involves the administration of non-absorbable antibiotics (colistin 
and tobramycin) and an antifungal (amphotericin B) in the oropharynx and 
intestinal tract during the ICU stay, in combination with intravenous administration 
of a third-generation cephalosporin (usually cefotaxime) during the first 4 days in 
ICU. Despite the reported benefits of SDD, this intervention is currently not widely 
used, primarily because of concerns that it may select for antibiotic resistant bacteria 
in the patient’s microbiota (van der Meer et al., 2013). 
However, a recent meta-analysis of 64 clinical studies failed to demonstrate that 
SDD increased the number of infections caused by antibiotic resistant pathogens 
(Daneman et al., 2013). An important limitation of all studies included in this meta-
analysis is that they relied on conventional culture techniques, which are unable to 
capture anaerobic commensals, such as Clostridia and Bacteroidetes. Anaerobic 
bacteria constitute the majority of the gut microbiota and can carry a large reservoir 
of antibiotic resistance genes, i.e. the resistome (Sommer et al., 2009; Qin et al., 
2010). Antibiotics may select for antibiotic resistance genes carried by gut 
commensal bacteria and thereby facilitate horizontal gene transfer to opportunistic 
pathogens (Shoemaker et al., 2001).  Consequently, to fully evaluate the safety of 
SDD in ICU-settings, its effect on the patient gut resistome needs to be assessed. 
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Here, we describe the dynamics of the gut microbiota and the resistome in detail in 
a single patient admitted to the ICU after a traffic accident and who received SDD 
for 17 days. Samples were taken at days 4, 14 and 16 in ICU, at day 28 (during post-
ICU hospitalisation) and at day 313 (270 days after hospital discharge). We 
subsequently studied the dynamics of two aminoglycoside resistance genes in the gut 
microbiota of 12 ICU-patients who received SDD. Our data indicate that SDD can 
have large, but highly individualized effects on the patient resistome. 
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Materials and methods 
Patient information 
The patient who was the main subject of this study had no previous history of 
hospitalisation and disease. Upon ICU admission, the patient presented with an 
acute neurological trauma due to a basal skull fracture after a traffic accident. 
Additional screening for trauma showed no abnormalities. Microbiological 
surveillance of the patient was performed according to conventional culturing 
techniques on an almost daily basis. Rectal cultures were grown on blood agar, 
MacConkey agar and malt agar. Sputum cultures were grown on blood agar 
containing optochin, MacConkey agar, malt agar, and Haemophilus chocolate agar. 
Blood samples were monitored in a BD BACTEC FX machine according to standard 
laboratory practice. Culture-based diagnostics failed to detect any pathogenic, 
antibiotic resistant bacteria at any time point in any sample (Table S1). The patient 
received SDD, with 1000 mg of cefotaxime intravenously four times daily for 4 days 
and an oropharyngeal paste containing polymyxin E, tobramycin and amphotericin 
B (each at a concentration of 2%) and administration of a 10 ml suspension 
containing 100 mg polymyxin E, 80 mg tobramycin and 500 mg amphotericin B via 
a nasogastric tube, four to eight times daily throughout ICU stay. Additional 
information on the antibiotic therapy that the patient received throughout the study 
period is provided in Table S2.  
 
Strains and growth conditions 
Escherichia coli EP1300-T1R (Epicentre, Madison, WI, USA) was used for fosmid 
library construction (further described below) and E. coli TOP10 (Invitrogen, Life 
Technologies Europe BV, Netherlands) for other genetic manipulations. E. coli was 
grown in Luria Broth (LB; Oxoid) at 37°C. Antibiotics were used at the following 
concentrations: chloramphenicol 12.5 mg/L, ampicillin 100 mg/L, tobramycin 25 
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mg/L, tetracycline 10 mg/L, erythromycin 500 mg/L, colistin 50 and 10 mg/L, 
cefotaxime 25 mg/L and cefazolin 32 mg/L.  
 
Faeces collection and isolation of high molecular weight DNA 
Faeces from the patient described above were collected upon defecation and stored 
at 4°C between 30 min and 4h, after which the faeces were transferred to -80°C. For 
DNA isolation, an aliquot of approximately 15 g of faecal matter was defrosted and 
homogenised in PBS (138 mM NaCl, 2.7 mM KCl, 140 mM Na2HPO4, 1.8 mM 
KH2PO4, adjusted to pH 7.4 with HCl) by vigorous vortexing and layered on a 
Nycodenz AG gradient (Axis-Shield PoC, Oslo, Norway). The cellular fraction of the 
faecal matter was then separated via centrifugation at 16,000 g for 6 min. After 
removal of the upper layer, the bacterial cellular fraction was recovered and washed 
three times in PBS, as described previously (Jones et al., 2007). High molecular 
weight DNA was extracted from the cell pellet as described previously (Ogilvie et al., 
2013), with minor modifications. Briefly, the recovered cells were lysed with 
lysozyme (10 mg/mL; Sigma Aldrich, St Louis, MO, USA) and mutanolysin (100 
U/mL) (Sigma Aldrich), followed by proteinase K (50 mg/mL; Sigma Aldrich) 
digestion and addition of 2.5% n-lauryl sarcosine (Sarkosyl; Sigma Aldrich). Proteins 
were precipitated with 10 M ammonium acetate and DNA extracted with chloroform 
by using phase-lock tubes (5 Prime, Gaithersburg, MD, USA) and ethanol 
precipitation. The quantity and purity of DNA was measured using a Nanodrop 
spectrophotometer (ND-1000, Thermo Scientific, Wilmington, DE, USA).  
 
Phylogenetic profiling of the gut microbiota  
The faecal DNA isolated above was used to phylogenetically profile the gut 
microbiota using HITChip analysis, as described previously (Rajilic-Stojanovic et al., 
2009). 
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Metagenomic shotgun sequencing and sequence analysis  
DNA library construction and sequencing was performed by BGI (Shenzhen, China) 
using 91-nt paired end sequencing on an Illumina HiSeq 2000 system as described 
elsewhere (Qin et al., 2012). Between 125 and 221 million high-quality reads were 
generated for the five samples. Using SOAPdenovo (http://soap.genomics.org.cn), 
sequence data was assembled into contigs larger than 500 nt for which between 78.6 
and 89.0% of the reads could be used in the assemblies. Further details on the results 
of the metagenomic shotgun sequencing and de novo assembly are provided in 
Table S3. We used BLAST to detect the presence of antibiotic resistance genes in 
the different assemblies of each sample (Altschul et al., 1997). We initially extracted 
a set of antibiotic resistance gene sequences from the Resistance Determinants 
DataBase (RED-DB) (http://www.fibim.unisi.it/REDDB). To reduce redundancy in 
this database, we first clustered the nucleotide sequences using CD-HIT with a 
threshold of 99% identity (Fu et al., 2012). The clustered resistance gene database 
was used as a query in a local BLAST search on each assembled sample. All hits with 
a nucleotide identity of 90% or higher and covering > 50% of the query length were 
considered to be resistance genes that were encoded on the assembled contigs.  
Relative quantification of the resistance genes per sample was performed as follow. 
First, the average sequencing depth over the entire assembly was calculated, and 
then the coverage of the individual contigs, determined using soap.coverage 
(http://soap.genomics.org.cn), encoding resistance genes was divided by the 
average sequencing depth over the entire assembly. Data were then log-2 
transformed and plotted onto a heatmap using Multi Experiment Viewer 
(http://www.tm4.org/mev/). Non-transformed abundance data for each resistance 
gene are provided in Table S4. 
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Construction of fosmid libraries 
The construction of fosmid libraries was performed using the CopyControl Fosmid 
Library Production Kit (Epicentre) according to the manufacturer’s instructions with 
slight modifications. Size selection of approximately 40 kb DNA fragments was 
performed using PFGE using the CHEF-DR II system (Bio-Rad) with the following 
settings: initial switch time 0.1 s, final switch time 10 s, 4 V/cm, and running time 17 
h. The DNA was excised from the gel at the height of a 40 kb marker (Fosmid Control 
DNA, Epicentre), recovered using GELase (Epicentre) and end-repaired using the 
End-It kit (Epicentre). DNA was then purified using SureClean (Bioline, London, 
UK), and used for ligation. Packaged phage extracts were diluted in 0.5 mL phage 
dilution buffer and added to 5 mL of phage-resistant EP1300-T1 E. coli for 1 h at 
37°C. Serial dilutions of the transduced E. coli were plated on LB-agar plates 
containing chloramphenicol. Libraries were harvested by scraping the plates and 
suspending the colonies in LB containing 20% glycerol and chloramphenicol, and 
frozen in liquid nitrogen and stored at -80°C. 
 
Identification and characterization of antibiotic-resistant clones in 
fosmid libraries 
The fosmid libraries were plated in 10-, 100- and 1000-fold dilutions on LB agar with 
chloramphenicol supplemented with tobramycin, ampicillin, tetracycline, 
erythromycin, cefotaxime, colistin and cefazolin and incubated at 37°C overnight. A 
vector-only control (E. coli EP1300-T1R with the fosmid library vector pCC1FOS) was 
also included and only produced colonies on plates supplemented with 
chloramphenicol but not on plates containing chloramphenicol and the other 
antibiotics. Quantification of resistant clones was performed in duplicate by plating 
serial dilutions of the libraries on LB agar supplemented with chloramphenicol in 
addition to the antibiotic of interest. The total number of clones in the library was 
determined by plating on LB with chloramphenicol only.  
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To ensure that resistant clones were due to the fosmid insert and not because of 
spontaneously occurring mutations, five clones per library and per antibiotic were 
randomly selected from plates and were restreaked on LB plates containing the 
appropriate antibiotics. After overnight growth of the restreaked clones, clones were 
picked and subsequently cultured in LB broth containing the appropriate antibiotics 
for fosmid isolation. Fosmids were induced to high-copy by the CopyControl Fosmid 
Autoinduction solution from Epicentre prior to fosmid isolation to increase total 
DNA yield. Fosmids were purified using the Qiagen (Venlo, The Netherlands) Mini-
prep kit. The elution buffer was heated to 70°C prior to elution of the fosmids from 
the column. The isolated fosmids were then used to transform chemically competent 
EP1300-T1R E. coli by heat shock. The transformed clones were restreaked on LB 
agar with chloramphenicol in addition to the antibiotics used for the initial resistance 
screening. A clone of EP1300-T1R E. coli freshly transformed with the fosmid vector 
pCC1FOS was used as a control throughout. All phenotypes for the selected clones 
were reconfirmed while E. coli with pCC1FOS remained unable to grow.  
To assess fosmid insert diversity, fosmids of the selected clones were digested with 
MslI (New England Biolabs, Ipswich MA, USA). Differences in restriction patterns 
were used as indicators for the diversity among the isolated clones. The most 
prominent clones were subsequently selected for transposon mutagenesis to 
functionally identify the resistance determinants. 
In order to identify the resistance genes on the fosmids that were responsible for 
causing the resistant phenotype in E. coli, transposon mutagenesis was performed 
using the EZ-Tn5 <KAN-2> and EZ-Tn5 <TET-1> in vitro transposon mutagenesis 
kits (Epicentre). Transposon mutagenesis was carried out according to the 
manufacturer’s instructions with the exception that 5 mM MgCl2 was added to LB 
agar when using the EZ-Tn5 <TET-1> kit. After in vitro transposon mutagenesis, 
between 100 and 300 transposon mutants were streaked on LB agar with 
chloramphenicol and LB agar with chloramphenicol and ampicillin, tobramycin, or 
tetracycline to screen for the loss of the resistant phenotype.  
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For each in vitro transposon mutagenesis, between one and five clones could be 
identified that lost their resistance phenotype due to transposon insertion. 
Sequencing primers TET-1 FP-1 Forward Primer, TET-1 RP-1 Reverse Primer, KAN-
2 FP-1 Forward Primer and KAN-2 RP-1 Reverse Primer (provided by Epicentre) 
were used to sequence along the transposon insertion sites and thereby identify the 
resistance genes. Partial sequences from the inserts cloned into the different fosmid 
and transposon insertion sites were obtained by standard Sanger sequencing. To 
identify the resistance genes based on the transposon insertion site sequences, we 
used the RED-DB (http://www.fibim.unisi.it/REDDB/). For each resistant 
phenotype, several clones that had lost their resistant phenotype upon transposon 
insertions were analysed. After analysis of the transposon insertion site sequences, 
we identified the same resistance determinant per antibiotic resistant clone 
(tobramycin, ampicillin and erythromycin) and therefore only chose one fosmid 
clone per antibiotic to be fully sequenced subsequently. We identified two different 
tetracycline resistance determinants, and two representative fosmids were selected 
for sequencing. 
Fosmids were pooled and sequenced via Illumina sequencing on a HiSeq 2000 
system using the Illumina CASAVA pipeline version 1.8.2 generating paired end 
reads (read length 101bp) with an average insert size between 265bp and 384bp. 
Assembly was performed using the CLC Genomics Workbench (CLC Bio, Aarhus, 
Denmark). The DNA sequences of the regions where the faecal DNA was cloned into 
the fosmid backbone and of the resistance gene previously obtained by Sanger 
sequencing were also used to assemble the fosmid insert.  
Finally, fosmid insert sequences (ISs) were closed by sequencing of PCR products 
that spanned the gaps between the contigs in the assembly of each IS. Taxonomic 
classification and identification of putative source organism of fosmid ISs was 
performed using WebCARMA (Gerlach et al., 2011). Annotation of the fosmid ISs 
was generated using the prokaryotic annotation pipeline offered by Integrative 
Services for Genome Analysis (Hemmerich et al., 2010).  
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Annotations were visualised using the Geneious software package 
(http://www.geneious.com/). The ACLAME server was used to identify and classify 
putative mobile genetic elements within the fosmid sequences (Leplae et al., 2010). 
IS elements were identified by IS Finder (Siguier et al., 2006).   
 
Quantification of aph(2”)-Ib and the aadE-like gene in ICU patient 
microbiota by quantitative PCR (qPCR) 
To further determine the effect of the ICU hospitalization and SDD on the relative 
abundance of aph(2”)-Ib and the aadE-like aminoglycoside resistance gene in the 
gut microbiota of patients, faecal samples were collected from 12 patients that were 
hospitalized in the ICU for 9 days or longer. Two or three faecal samples per patient 
were collected during their ICU stay. DNA was isolated from 200 mg stool samples 
using the repeated mechanical bead beading method combined with the QIAmp 
DNA stool Minikit (QIAgen) as described elsewhere (Salonen et al., 2010). The DNA 
samples were used in qPCRs to quantify the copy number of aph(2”)-Ib and the 
aadE-like gene. All qPCRs were carried out in MicroAmp Fast Optical 96-well 
Reaction Plates (Applied Biosystems), sealed with optical adhesive film (Applied 
Biosystem), and using a StepOnePlus™ Real-Time PCR cycler (Applied Biosystems) 
with StepOnePlus software version 2.2 (Applied Biosystems). Total reaction volume 
was 25 μl using Maxima SYBR Green/ROX qPCR Master Mix (Fermentas) according 
to the manufacturer’s instructions with a primer concentration of 200 nM and 1ng 
DNA. Primers were designed for the targeted resistance genes aph(2”)-Ib (forward 
primer: 5’-GAAAAGGATGCCCTTGCATA-3’; reverse primer: 5’-
TCACCAGAGCATCTGAAAACA-3’) and the aadE-like gene (forward primer: 5’-
GCATGATTTCCTGGCTGATT-3’; reverse primer: 5’-CCACAATTCCTCTGGGACAT-
3’) using Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/).  
The universal primers for 16S rRNA genes were previously described by Gloor et al. 
(2010) and PCR conditions were previously described by van den Bogert et al. (2011). 
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Melting curves were included for each qPCR run. Relative abundance of the 
resistance genes was calculated using the 2-ΔΔCT-method with 16S rRNA as the 
universal housekeeping gene (Livak et al., 2001). The relative abundance of the 
resistance genes in the first faecal sample that was collected during ICU 
hospitalisation was normalised to 1, and subsequent samples were compared to this 
first sample. The qPCRs were performed with three technical replicates.  
 
Statement of ethical approval 
The protocol for this study was reviewed and approved by the institutional review 
board of the University Medical Center Utrecht (Utrecht, The Netherlands) under 
number 10/0225. Informed consent for faecal sampling during hospitalization was 
waived. Written consent was obtained for the collection of faecal samples after 
hospitalization. 
Data availability  
Metagenomic shotgun sequence reads are deposited in the Sequence Read Archive 
(European Nucleotide Archive) with the primary accession number PRJEB3977. 
Assemblies can be accessed through MG-RAST with accession numbers 4508944.3, 
4508945.3, 4508946.3, 4508947.3 and 4508948.3. Fosmid sequences are deposited 
at Genbank under accession numbers KF176928 - KF176932.   
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Results  
We first monitored the dynamics of the resistome and the gut microbiota 
composition in a previously healthy patient that was hospitalised in our hospital’s 
ICU after a traffic accident. The patient had no history of hospitalization or antibiotic 
use. The patient received SDD from the first day in ICU for 17 days, after which the 
patient was transferred to the neurology department, where he remained 
hospitalised until hospital discharge, 43 days after admittance. Faecal samples were 
collected at four time points during hospital stay (day four, 14 and 16 in ICU and day 
28 in the neurology ward) and at day 313 (270 days after hospital discharge) (Fig. 
1a). Diagnostic cultures were performed throughout the patient’s stay in hospital 
and did not yield growth of antibiotic resistant bacteria (Table S1). The antibiotics 
administered to the patient during hospital stay are shown in Fig. 1a (further details 
are provided in Table S2). No antibiotics were prescribed following hospital 
discharge. Culture-independent techniques were used to profile the diversity of the 
gut microbiota and its resistome at the five time points at which faeces were collected 
during and after hospitalization.  
 
Phylogenetic profiling of patient gut microbiota  
16S rRNA gene-based profiling of the gut microbiota revealed that, during 
hospitalization, the most prevalent groups were Bacteroidetes (from 29 to 67% of 
the total microbiota) and Clostridium clusters XIVa and IV (from 21 to 69% of the 
total microbiota), which are all common inhabitants of the intestinal microbiota of 
healthy humans (Fig. 1b; the full data set is provided as Tables S5 and S6) (Rajilic-
Stojanovic et al., 2007 and 2009).  The relative abundance of these three groups 
fluctuated considerably during hospitalization. Unusually, at day 28 (11 days after 
ICU discharge and discontinuation of SDD), Bacilli represented 10% of the 
microbiota, which was mainly caused by an increased abundance of enterococci 
(5.1% of the microbiota).  
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Enterococci are usually quantitatively minor species in the healthy gut microbiota 
but can become more prominent during hospitalization (Qin et al., 2010; Ubeda et 
al., 2010).  At other points in time, Bacilli were less abundant (≤1%). The 
composition of the patient’s microbiota had markedly changed at day 313 (270 days 
after hospital discharge). At this time point, the gut microbiota consisted almost 
exclusively of bacteria belonging to the phylum Firmicutes, and was dominated by 
Clostridium cluster XIVa (87.5% of the total microbiota). Bacteroidetes were present 
at only 0.67% (Fig. 1b). As this patient had not received antibiotics during 270 days 
after hospital discharge, this may well reflect the normal, undisturbed state of this 
particular individual’s microbiota. 
Figure. 1. Patient history and gut microbiota composition. (a) The timeline indicates the major 
events throughout the patient’s hospital stay and the times at which faeces were collected. Yellow boxes 
indicate the antibiotics (E: erythromycin, F: flucloxacillin, V: vancomycin, Ce: cefazolin) that were 
administered to the patient. Further details are provided in the Methods section. Diagnostic culturing was 
performed for rectum, sputum, throat, urine and blood samples and no antibiotic resistant bacteria were 
found at any point in time (Table S1). (b) The patient’s gut microbiota composition was monitored by a 
16S rRNA-based microarray profiling approach (HITChip). The bars indicate the relative abundance of 
the most dominant bacterial phyla in the gut microbiota at the time points indicated on the x-axis. The 
colours code for the different phyla and classes as displayed in the figure key. Low-abundance phyla and 
classes are grouped together as “Others”. Detailed information on the relative abundances of all phyla and 
classes detected by HITChip analysis are provided in the supplemental data Table S5. 
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Expansion of the resistome during ICU stay  
The resistome of the patient substantially expanded during ICU stay and 
administration of SDD, this was most pronounced at days 14 and 16 (Fig. 2a). The 
reservoir of resistance genes had decreased at day 28, but genes conferring resistance 
to several classes of antibiotics were still detectable in the absence of antibiotic 
selective pressure at day 313 (270 days after hospital discharge). Specifically, there 
was a 6.7-fold increase in the relative abundance of aminoglycoside resistance genes 
at day 16, compared to the first sampling point at day four and the last sampling 
point at day 313 (Fig. 2).  
Due to the inclusion of an aminoglycoside (tobramycin) and a β-lactam antibiotic 
(cefotaxime) in the SDD regimen, we focused on genes that were predicted to confer 
resistance to these antibiotics. In particular, the aminoglycoside resistance genes 
aph(2”)-Ib, aph(3’)-IIIa and an aadE-like gene increased in abundance during ICU 
stay (Fig. 2b and Tables S4 and S7). In addition, the copy number of the β-lactam 
resistance gene cblA rose during ICU stay but increased further after ICU discharge 
(day 28; Fig. 2b and Tables S4 and S7). Notably, the abundance of aminoglycoside 
resistance genes was lower at day 28 and had dropped even further at day 313 (Fig. 
2a), although aminoglycoside resistance genes remained the most abundant class of 
resistance genes in the resistome at this point in time.  
In addition to aminoglycoside resistance genes, genes conferring resistance to 
macrolides and tetracycline were the most abundantly present classes of resistance 
genes. The abundance of macrolide and tetracycline resistance genes remained 
relatively stable throughout hospital stay, but dropped sharply upon hospital 
discharge. The observed high levels of macrolide resistance genes throughout 
hospitalization may have been triggered by the usage of erythromycin, which the 
patient received to enhance gastric emptying during ICU stay. Tetracyclines were not 
administered to this patient and the high prevalence of these resistance genes is in 
line with the previously reported high abundance of tetracycline resistance genes in 
healthy individuals (Forslund et al., 2013; Hu et al., 2013).  
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Figure. 2. Resistome dynamics determined by shotgun metagenomic sequencing.  
(a) Cumulative abundance of antibiotic resistance gene families in metagenomic assemblies during ICU 
stay (day 4, 14 and 16), further hospitalisation (day 28) and 270 days after hospital discharge (day 313). 
The cumulative abundance of each resistance gene family represents the summed coverage data for 
resistance genes (normalised to average sequencing depth per assembly) per resistance gene family. 
Resistance gene families are indicated by the coloured bars which are coded as in panel (b). (b) Heat map 
of the relative abundance (log2-transformed and normalised to average sequencing depth per assembly) 
of antibiotic resistance genes that are present in the patient’s gut microbiota during and after 
hospitalisation. Cluster analysis was performed using standard Pearson’s correlation. Colour codes 
indicate resistance gene families (B: β-lactams; A: aminoglycosides; M: macrolides; T: tetracyclines; G: 
glycopeptides; S: sulphonamides; C: chloramphenicols; Tr: trimethoprim).  
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Resistance genes on mobile genetic elements in anaerobic gut 
commensals 
Metagenomic shotgun sequencing and subsequent assembly generally resulted in 
contigs of limited size, precluding assessment of the genetic context of the identified 
resistance genes (data not shown). We therefore constructed fosmid libraries (with 
inserts of approximately 40 kbp) to functionally screen for antibiotic resistance 
genes and to further explore the genetic context of these genes. 
Five fosmid libraries were constructed in E. coli from metagenomic DNA obtained 
from the faeces samples used for metagenomic sequencing. The total size of these 
libraries ranged from 0.8 to 2.6 Gbp (Table S8). Libraries were screened for clones 
that were resistant to ampicillin, cefotaxime, cefazolin, tobramycin, erythromycin, 
tetracycline and colistin (Figure S1). No clones that were resistant to colistin or 
cefotaxime were isolated, but we were able to isolate resistant clones for the other 
antibiotics.  
The number of clones resistant to tobramycin, ampicillin, or erythromycin increased 
during ICU stay. At day 28 the number of tobramycin- and, to a lesser extent, 
erythromycin-resistant clones had decreased, whereas the number of ampicillin-
resistant clones remained relatively stable, confirming the trends observed by 
metagenomic shotgun sequencing. The number of tetracycline-resistant clones was 
relatively stable throughout the monitored period. At day 313, tetracycline was the 
only antibiotic for which resistant clones could be isolated (Figure S1). From the 
resistant clones, five genes were identified that conferred resistance against 
tobramycin, ampicillin, erythromycin and tetracycline in E. coli. The identified genes 
were: aph(2”)-Ib (conferring resistance to tobramycin), cblA (ampicillin), ermBP 
(erythromycin), and tetW and tetO (tetracycline). Sequencing of the vector/insert 
junction of ten clones in which resistance genes were identified showed that identical 
resistance determinants were present within different clones and genetic 
backgrounds.  
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Subsequently, the inserts of one selected fosmid clone per resistance gene were 
sequenced to characterize the genetic context of the resistance genes and to predict 
the bacterial sources of the cloned ISs. This revealed that the cloned resistance genes 
were harboured by anaerobes from the phyla Firmicutes (Subdoligranulum, 
Clostridia), Bacteroidetes (Bacteroides uniformis) and Actinobacteria (Fig. 3), 
which are all common members of the human gut microbiota (Rajilic-Stojanovic et 
al., 2007; Qin et al., 2010).  In all sequenced fosmid inserts, the antibiotic resistance 
genes were associated with IS elements or genes of putative phage or plasmid origin, 
including genes that are predicted to be involved in plasmid replication and 
mobilization (Fig. 3). This suggests that the antibiotic resistance genes are located 
on mobile genetic elements that are harboured by anaerobic gut commensals.  
Figure. 3. Fosmid ISs for resistant clones identified by functional metagenomics. To identify 
and classify putative mobile genetic elements within the ISs of antibiotic-resistant fosmid clones, the 
ACLAME and ISFinder servers were used (Leplae et al., 2010; Siguier et al., 2006). Red arrows indicate 
antibiotic resistance genes. Light blue arrows indicate genes predicted to be of plasmid origin. Dark blue 
arrows indicate genes predicted to be of plasmid origin and putatively to be involved in plasmid 
mobilization and conjugation. Green arrows indicate genes to be of phage origin and yellow arrows 
indicate genes identified as IS-elements. The origins of the cloned resistance genes were predicted using 
CARMA3 (Forslund et al., 2013). 
SDD affects the gut microbiota in ICU patients 
 
103 
 
Heterogeneous effects of SDD on abundance on aminoglycoside 
resistance genes in ICU patients 
Because metagenomic sequencing demonstrated an increasing abundance of 
aminoglycoside resistance genes in the patients’ microbiota during ICU 
hospitalization, we decided to perform qPCRs to determine the levels of two 
aminoglycoside resistance genes in 12 additional, ICU-hospitalised patients who 
received SDD and from whom multiple faecal samples were collected during ICU 
stay.  
The metagenomics DNA samples of the patients of whom the resistome was profiled 
by metagenomics shotgun sequencing and functional metagenomics was also 
included. Notable, none of the studied patients was treated therapeutically with an 
aminoglycoside (Figure 1 and Figure S2). Consequently, the patient’s only 
exposure to aminoglycoside antibiotics was due to the use of tobramycin in SDD. The 
two targeted aminoglycoside resistance genes that were targeted by qPCR were 
aph(2”)-Ib, which was identified in our functional metagenomic screen, and the 
aadE-like  gene, which was the most abundant aminoglycoside resistance gene found 
by metagenomic shotgun sequencing. The qPCR data indicated that the relative 
abundance of both resistance genes is highly divergent among the different patients. 
The copy number of the resistance genes changed between 1.5 x 104 and 8.1 x 10-8-
fold (for aph(2”)-Ib) and 1.0 x 102 and 4.5 x 10-11-fold (for the aadE-like gene) relative 
to the first sampling point during ICU stay (Fig. 4). Our findings indicate that the 
effect of SDD, and ICU hospitalisation in general, is highly individualized and that 
both a strong enrichment and a complete eradication of aminoglycoside resistance 
genes can be the result of SDD. 
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Figure. 4. Relative abundance of the aminoglycoside resistance genes aph(2”)-Ib and 
aadE-like in ICU patients receiving SDD. 
The relative abundance of aph(2”)-Ib (A) and the aadE-like gene (B) was determined by qPCR from faecal 
samples of 13 patients during ICU hospitalisation. The relative abundance of both resistance genes was 
determined for all sampling time points relative to the 16S rRNA gene and the change throughout ICU 
stay was calculated relative to the first sampling point during ICU stay. The resistome of patient 58 was 
previously characterized by metagenomic shotgun sequencing and functional metagenomics in this study. 
Information on the antibiotic use of other patients is provided in Fig. S2
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Discussion 
The prophylactic use of antibiotics in SDD is one of the most successful interventions 
to reduce patient morbidity and mortality in ICU, but whether SDD will lead to the 
selection of antibiotic resistant bacteria is a topic of considerable controversy (de 
Smet et al., 2009; Oostdijk et al., 2010; Daneman et al., 2013; van der Meer et al., 
2013). With this study, in which several metagenomics approaches were combined, 
we provide data indicating that the patient gut microbiota, and the resistance genes 
carried by the gut microbiota, can be profoundly affected by ICU hospitalization and 
SDD. Our functional metagenomics analyses indicate that the identified antibiotic 
resistance genes are all carried by anaerobic gut commensal and are associated with 
mobile genetic element. 
Based on sequence analysis of a fosmid insert confering resistance to tobramycin, 
the aminoglycoside resistance determinant aph(2”)-Ib was harboured by a strain 
from the genus Subdoligranulum. This genus belongs to Clostridium cluster IV and 
is commonly present in the microbiota of healthy individuals (Holmstrom et al., 
2004; Qin et al., 2010). Interestingly, strict anaerobes such as Bacteroidetes and 
Clostridia are generally thought to be intrinsically resistant to aminoglycosides, 
because these bacteria lack an electron transport system that is needed for the 
energy-driven uptake of aminoglycosides into the cell (Bryan et al., 1979). 
Nevertheless, aminoglycoside resistance genes can be readily identified in several 
Clostridium isolates (including strains that were isolated from human faeces) by 
either comparative genomic hybridisation (Janvilisri et al., 2010) or by sequence 
analysis of publicly available Clostridium genomes (data not shown). These 
observations not only show that Clostridium and closely related genera may serve as 
a reservoir for aminoglycoside resistance genes, but also suggest that these resistance 
genes may have a, hitherto unrecognised, function in Clostridia. Alternatively, the 
resistance genes may form part of a larger genetic element that confers a fitness 
benefit to Clostridia and are retained for this reason.    
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In all sequenced fosmid inserts, we found evidence for the presence of IS elements 
and genes of putative phage or plasmid origin, including genes that are predicted to 
be involved in plasmid replication and mobilization. This observation suggests that 
these resistance genes may be part of larger genetic elements that can be mobilised 
and/or which have been acquired through horizontal gene transfer. Evidence for the 
extensive transfer of antibiotic resistance genes in the gut microbiota has been 
observed before in Bacteroidetes and Firmicutes (Shoemaker et al., 2001; Jones et 
al., 2010). Consequently, the enrichment of antibiotic resistance genes in the 
patient’s gut microbiota during SDD and their association with mobile genetic 
elements is a cause of concern as this may facilitate transfer of resistance genes to 
aerobic nosocomial pathogens. In fact, our experimental design, using functional 
metagenomics, proved that these resistance genes can be expressed and are 
functional in E. coli, which is a common cause of hospital-acquired infections.  
Based on our findings in a single patient, we subsequently determined the relative 
abundance of two aminoglycoside resistance genes (aph(2”)-Ib and the aadE-like 
gene) in 12 other ICU patients who were hospitalized in the ICU for at least 9 days 
and who received SDD during this period. The relative abundance of both genes 
appeared very dynamic, indicating highly variable effects of SDD on the studies 
aminoglycoside resistance genes in individual patients. This may result from 
differences between the studied patients with respect to the bacterial hosts that carry 
the antibiotic resistance genes. For instance, the aph(2”)-Ib gene, which was 
harboured by the Gram-positive bacterium Subdoligranulum in the patient in which 
we characterized the resistome by metagenomic approaches, can also be harboured 
by Gram-negatives such as E. coli (Chow et al., 2001). In addition, the aadE-like 
gene is also found in the genome sequences of both Gram-positive and Gram-
negative gut commensals such as Faecalibacterium prausnitzii and Bacteroides 
uniformis (data not shown). In patients that carry aph(2”)-Ib in a Gram-negative 
host, such as E. coli, the relatively copy number of this gene may rapidly decrease 
during SDD due to the action of colistin, as this antibiotic specifically targets Gram-
negative bacteria, while not inhibiting the growth of Gram-positive bacteria.  
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This study suggests that ICU hospitalization and SDD may have a large effect on the 
gut microbiota and the resistome. Previous, culture-based studies failed to 
demonstrate that SDD increased the prevalence of colonisation by antibiotic-
resistant bacteria in the ICU (Daneman et al., 2013). This observation indicates that 
the selection for resistance among anaerobic gut commensals during ICU stay may 
not directly impact on the resistance levels in aerobic bacteria, possibly because these 
are eradicated by other components of SDD. However, once patients are discharged 
from the ICU and SDD has been discontinued, the expanded resistome of the 
patients’ gut microbiota may facilitate transfer of resistance genes to aerobic 
pathogens, once these recolonize the patient gut. This mechanism might explain the 
previously observed increase in antibiotic-resistance among Enterobacteriaceae 
after cessation of SDD (Oostdijk et al., 2010).   
Notably, microbiological cultures that were routinely performed in our diagnostic 
laboratory failed to yield the growth of any antibiotic-resistant bacterium throughout 
the period in which this patient was hospitalized. This discrepancy between 
traditional culture approaches and metagenomics analysis is likely to be due to 
antibiotic resistance genes being mostly carried by strictly anaerobic gut 
commensals, which are effectively impossible to culture in routine diagnostic 
settings. We note that the introduction of metagenomic shotgun sequencing as a tool 
in clinical diagnostics will allow the comprehensive identification and quantification 
of the resistome in individual patients. Although such approaches are currently still 
restricted by the costs of metagenomic shotgun sequencing and subsequent data 
analysis, our findings highlight the potential of these approaches as a future 
monitoring tool for the assessment of the impact of antibiotics on the gut resistome 
and to guide personalized antibiotic treatment. Most importantly, our findings 
indicate that the benefits of SDD on patient outcome and infections rates must be 
carefully balanced against the potential collateral selection and amplification of 
antibiotic resistance genes among anaerobic gut commensals. 
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ABSTRACT 
Objectives. To determine the dynamics of the gut microbiota and resistome of ICU-
patients during and after SDD.  
 
Methods. Feces were collected during and after ICU stay (38 samples from eleven 
patients) and from ten healthy subjects (twice, with a one-year interval). Gut 
microbiota and resistome composition were determined using 16S rRNA 
phylogenetic profiling and nanolitre-scale quantitative PCRs, targeting 81 
antimicrobial resistance genes (ARGs).  
 
Results. Compared to the microbiota of healthy subjects, the microbiota of ICU 
patients was significantly less diverse. The microbiota of ICU patients was 
characterized by a reduction of butyrate-producing bacteria (up to 19-fold) and 
Escherichia coli (108-fold), while abundance of enterococci was 42-fold higher, all 
compared to healthy subjects. During ICU stay, the abundance of eleven ARGs, 
mostly associated with E. coli, were reduced, whereas the abundance of four ARGs, 
which were associated with Gram-positive cocci and included the staphylococcal 
mecA gene, significantly increased in the patients’ microbiota.  
 
Conclusions. SDD suppresses both butyrate-producing bacteria and E. coli and 
selects for Gram-positive cocci and their associated resistance genes.  
 
Keywords: Anti-Bacterial Agents; Antibiotic Prophylaxis; Drug Resistance, Microbial; 
Intensive Care; 
Microbiome
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Introduction 
The human gut microbiota comprises 1013 - 1014 bacterial cells that belong to 
hundreds of different species. The gut microbiota plays an important role in 
numerous metabolic, physiological, nutritional and immunological processes of the 
human host (Sekirov et al., 2010). In healthy individuals, the gut microbiota mostly 
consists bacteria that have a commensal or mutualistic relationship with the human 
host. In critically ill patients, however, intestinal overgrowth by multi-drug resistant 
opportunistic pathogens, such as the ESKAPE pathogens (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, 
Pseudomonas aeruginosa, and Enterobacter), Escherichia coli or Clostridium 
difficile, is a common event and an important risk factor for the subsequent 
development of nosocomial infections (van der Waaij, 1989; Boucher et al., 2009; 
Ubeda et al., 2010; Buffie et al., 2013; Britton et al., 2014). To lower the risk of 
nosocomial infections with opportunistic pathogens in ICU patients, Selective 
Digestive tract Decontamination (SDD), have been implemented as prophylactic 
antibiotic therapy (van der Waaij et al., 1990).  
 
During SDD therapy, a paste containing colistin, tobramycin, and amphotericin B is 
applied to the oropharynx and a suspension of colistin, tobramycin, and 
amphotericin B via a nasogastric tube. These antibiotics are applied until ICU 
discharge. In addition, a third-generation cephalosporin (usually either cefotaxime 
or ceftriaxone) is administered intravenously during the first 4 days of ICU stay. 
Previous studies indicated that SDD lowers patient mortality during ICU stay in 
settings with a low prevalence of antibiotic resistance and lower the costs associated 
with ICU hospitalization (de Jonge et al., 2003; de Smet et al., 2009). However, 
selection for resistance to the antimicrobial agents used in SDD remains a major 
concern, in particular because the gut microbiota of patients is exposed to high 
quantities of antibiotics (Wunderink, 2010; Philips, 2014). However, based on the 
conventional culture results of clinical trials, there was no evidence for increased 
antibiotic resistance due to the implementation of SDD (Daneman et al., 2013).  
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The patient gut is not only a potential source for opportunistic pathogens, but also 
forms a large reservoir for antibiotic resistance genes, termed the gut resistome 
(Sommer et al., 2009; Wunderink, 2010; Daneman et al., 2013; van Schaik, 2015). 
The use of antibiotics may favor the selection for antimicrobial resistance genes 
(ARGs) among members of the gut microbiota, thus increasing the likelihood of 
horizontal spread of ARGs between commensals and opportunistic pathogens co-
residing in the gut (Salyers et al., 2004). During ICU stay, the gut resistome of 
patients is primarily monitored by the cultivation of resistant bacteria from rectal 
swabs or faeces, as part of routine diagnostics. However, methods that rely on 
microbial culture capture only a fraction of the gut resistome, since anaerobic gut 
commensals, which are the main reservoir of ARGs in the gut microbiota, are 
difficult to culture (Sommer et al., 2009; , Qin et al., 2010; Buelow et al., 2014). Thus, 
culture-independent methods need to be employed to assess the impact of topical 
antibiotic prophylaxis on the microbiota and resistome of ICU patients. 
 
Here, we used the 16S ribosomal RNA (rRNA) gene-targeted Human Intestinal Tract 
Chip (HITChip) and nanolitre-scale quantitative PCR (qPCR) targeting a broad 
range of ARGs, to determine the dynamics of gut microbiota composition and 
resistome in patients receiving SDD during ICU hospitalization. We contrast these 
findings in ICU patients with the composition of the microbiota and resistome of 
healthy subjects.  
Microbiota and resistome of ICU patients 
 
117 
 
Methods 
The protocol for this study was reviewed and approved by the institutional review 
board of the University Medical Center Utrecht (Utrecht, The Netherlands). Patients 
included in the study did not receive antibiotics prior to ICU admission. All patients 
received selective digestive tract decontamination (SDD), during ICU stay until ICU 
discharge. SDD consists of 1000 mg of cefotaxime intravenously four times daily for 
four days, an oropharyngeal paste containing polymyxin E, tobramycin and 
amphotericin B (each in a 2% concentration) and administration of a 10 mL 
suspension containing 100 mg polymyxin E, 80 mg tobramycin and 500 mg 
amphotericin B via a nasogastric tube, four to eight times daily throughout ICU stay. 
All patients received additional antibiotics during ICU stay ranging from 2-11 
antibiotic courses.  
Faecal samples of patients were collected at different time points during 
hospitalization by nursing staff (Fig. S1). Faeces were collected upon defecation and 
stored at 4°C for 30 min to 4 h, after which the samples were transferred to -
80°C.Routine surveillance for colonization with aerobic Gram-negative bacteria in 
ICU patients was performed through culturing of rectal swabs on sheep blood agar 
and MacConkey agar. All suspected Gram-negative colonies were analyzed by Maldi-
TOF for species identification.  
Faecal samples of healthy subjects were collected as part of the ‘Cohort study of 
intestinal microbiome among Irritable Bowel Syndrome patients and healthy 
individuals’ (CO-MIC) study at two time-points with a one-year interval between 
sampling. None of the individuals in this cohort received antibiotics. The protocol 
for this study was reviewed and approved by the Ethics Committee of Gelderse Vallei 
Hospital (Ede, The Netherlands). All included patients and subjects were ≥18 years 
of age.  
DNA of faecal samples of patients and healthy subjects was isolated as described 
elsewhere (Salonen et al., 2010).  
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Gut microbiota profiling by HITChip 
Gut microbiota composition profiles were determined using the HITChip, as 
described previously ( Rajilić-Stojanović  et al., 2009). The full-length 16S rRNA 
gene was amplified from fecal DNA, and PCR products were further processed and 
hybridized to the microarrays as described previously (Jalanka-Tuovinen et al., 
2011). Data analyses were performed using R (www.r-project.org), including the 
microbiome package (https://github.com/microbiome). Bacterial associations in 
the different patient groups and healthy subjects were assessed using Principal 
Component Analysis (PCA) as implemented in CANOCO 5.0 (Ter Braak et al., 2012). 
Differences in microbiota composition in the study groups at the genus-like level 
were assessed by the Wilcoxon test for unpaired data (healthy vs ICU) and the Mann-
Whitney test for paired data (different time points within healthy and ICU groups). 
All P-values were corrected for false discovery rate (FDR) by the Benjamini and 
Hochberg method, and corrected P-values below 0.05 were considered significant. 
 
qPCR analysis 
To sensitively quantify the levels of E. coli in samples, the number of E. coli 16S rRNA 
gene copies relative to total 16S rRNA gene copies were determined by quantitative 
PCR using previously described primers for E. coli (Furet et al., 2009) using serial 
dilutions of genomic DNA of E. coli DH5α to generate a standard curve and total 16S 
rRNA (Gloor et al., 2010). The qPCR analysis for the quantification of antibiotic 
resistance genes was performed using the nanoliter-scale 96.96 BioMark™ Dynamic 
Array for Real-Time PCR (Fluidigm Corporation, San Francisco, CA), according to 
the manufacturer’s instructions, with the exception that an annealing temperature 
of 56°C was used. Faecal DNA was first subjected to 14 cycles of Specific Target 
Amplification using a 0.18 μM mixture of all primer sets, excluding the 16S rRNA 
primer sets, in combination with the Taqman PreAmp Master Mix (Applied 
Biosystems), followed by a 5-fold dilution prior to loading samples onto the Biomark 
array for qPCR.  
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Thermal cycling and real-time imaging was performed on the BioMark instrument, 
and Ct values were extracted using the BioMark Real-Time PCR analysis software. 
Primers were designed for the ARGs that are most commonly detected in the gut 
microbiota of healthy individuals (Forslund et al., 2013; Hu et al., 2013) and 
clinically relevant ARGs, including genes encoding extended spectrum β-lactamases 
(ESBLs), carbapenemases, and proteins involved in vancomycin resistance A total of 
81 antimicrobial resistance genes and 14 resistance gene classes (Table S1) were 
used and also 10 genes encoding transposases, and a gene encoding an integrase as 
representatives of mobile genetic elements (Zhu et al., 2013).  Primer design was 
performed using Primer3 (Untergasser et al., 2012) with its standard settings with a 
product size of 80 – 120 bp and a primer melting temperature of 60°C.  
The universal primers for 16S rRNA genes were previously described (Gloor et al., 
2010). Forward and reverse primers were evaluated in silico for cross hybridization 
using BLAST (Altschul et al., 1990) and were cross-referenced against ResFinder 
(Zankari et al., 2012) to ensure the correct identity of the targeted genes. All primers 
that aligned with more than 10 nucleotides at their 3’ end to another primer sequence 
were discarded and redesigned. Additionally, all primer sets were aligned to all 
resistance genes that were targeted in this PCR analysis to test for cross hybridisation 
with genes other than the intended target resistance gene. Primers that aligned with 
more than 10 nucleotides at their 3’ end sequence with a non-target resistance gene 
were discarded and redesigned. Finally all primers were cross-referenced A reference 
sample consisting of pooled fecal DNA from different patients was loaded in a series 
of 4-fold dilutions and was used for the calculation of primer efficiency.  
All primers whose efficiency was experimentally determined to be between 80% and 
120% were used to determine the normalized abundance of the target genes. The 
detection limit on the Biomark system was set to a CT value of 20, as recommended 
by the manufacturer. In addition, to assess primer specificity we performed melt 
curve analysis using the Fluidigm melting curve analysis software (http://fluidigm-
melting-curve-analysis.software.informer.com/).  
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All PCRs were performed in triplicate and sample-primer combinations were only 
included in the analysis when all triplicate reactions resulted in a CT-value below the 
detection limit. After completion of the nanolitre-scale qPCR assays, the presence of 
the transferable colistin resistance gene mcr-1 was evaluated. To detect and quantify 
mcr-1, we developed primers (qPCR-mcr1-F: 5’-TCGGACTCAAAAGGCGTGAT-3’ 
and qPCR-mcr1-R: 5’-GACATCGCGGCATTCGTTAT-3’) for use in a standard qPCR 
assay. The mcr-1 gene was synthesized based on the sequence described previously 
(Liu et al., 2016) by Integrated DNA Technologies (Leuven, Belgium) and used as a 
positive control in our assays. The qPCR was performed using Maxima SYBR 
Green/ROX qPCR Master Mix (Thermo Scientific, Leusden, The Netherlands) and a 
StepOnePlus instrument (Applied Biosystems, Nieuwekerk a/d IJssel, The 
Netherlands) with 5 ng DNA in the reaction and the following program: 95°C for 10 
min, and subsequently 40 cycles of 95°C for 15 sec, 56°C for 1 min.  
For each sample, the normalized abundance of resistance genes was calculated 
relative to the abundance of the 16S rRNA gene (CTARG – CT16S rRNA), resulting 
in a log2-transformed estimate of ARG abundance. Statistical analysis was 
performed using GraphPad Prism (La Jolla, CA). The Mann-Whitney test was used 
to test for differences in the normalized abundance of ARGs between the different 
groups of patients and healthy subjects.  
Fisher’s exact test was used to test for differences between groups in the number of 
samples in which each ARG could be detected. For resistome analysis only ARGs 
were considered and the remaining genes on mobile genetic elements (MGEs) were 
analyzed separately. Seven MGE-genes were detected by qPCR but no significant 
differences could be observed between patients and healthy subjects (data not 
shown). Therefore we decided to not include this set of genes in the subsequent 
analyses. Cumulative abundance was calculated based on the sum of delta-delta CT 
values (2^(-(CTARG – CT16S rRNA)) per resistance gene family. Visualization of the 
qPCR data in the form of a heat map was generated using Microsoft Excel. 
Correlations between resistance genes and bacterial taxa were calculated using 
Pearson’s r.  
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Results 
Patient data 
The included patients (n = 11) were treated with SDD during their hospitalization in 
the ICU of the University Medical Center Utrecht (Utrecht, The Netherlands). The 
patients were acutely admitted to the ICU and had not been hospitalized, or treated 
with antibiotics, 6 months prior to ICU hospitalization. A total of 38 faecal samples 
were collected during ICU stay, and, if possible, after transfer to a medium care ward.  
 
The faecal samples of patients were categorized in order to monitor in detail the 
dynamics and diversity of the gut microbiota and resistome into the following, 
mutually exclusive groups: “early ICU” samples (the first faecal sample during ICU 
stay of a patient, collected no later than five days after ICU admission; n = 10), 
“during ICU” samples (samples collected more than five days after ICU admission 
and before the final ICU sample; eleven samples from four ICU patients), “final ICU” 
samples (the patient’s last faecal sample collected during ICU stay, ranging from 9 
to 40 days (median 13.5 days) after the start of ICU-hospitalization; n = 10) and 
seven “post ICU” samples from six patients, collected after ICU discharge during 
hospitalization in a medium-care ward (Fig. S1 includes detailed information on 
sampling time points and antibiotic usage of the ICU patients in this study).  
During ICU stay, routine surveillance by conventional microbiological culture was 
performed on all patients. E. coli could be cultured from five patients within one day 
of ICU admission and from one patient after nine days of ICU stay (total=6 out of 73 
rectal swabs). Antibiotic resistance phenotypes of these isolates indicated that one 
patient had an extended-spectrum beta-lactamase (ESBL) phenotype and was 
resistant to tobramycin. The other E. coli strains were susceptible to cephalosporins 
and aminoglycosides. All strains were susceptible to colistin.   
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Microbiota dynamics in ICU patients and healthy subjects  
Global changes in the gut microbiota of healthy subjects and ICU patients were 
visualized in a Principal Component Analysis (Fig. 1A). The microbiota profiles of 
healthy subjects clustered together, indicating that they had stable and broadly 
comparable microbiota profiles, which were clearly distinct from the microbiota 
profiles of patients during and after ICU stay. These profiles covered a larger area in 
the PCA plot, indicating that the differences in the microbiota composition of 
patients are larger than in healthy subjects. The diversity of the microbiota, as 
quantified by Shannon’s diversity index (Fig. 1B), was highest in the healthy 
subjects at both time points (5.95 ± 0.15 at the first sampling time-point, 5.86 ± 0.24 
at the second sampling time point), and was significantly lower in the “during ICU” 
(5.08 ± 0.36) and “final ICU” (4.93 ± 0.40) groups, but not in the “early ICU” group 
(5.66 ± 0.33). 
    
Figure 1: Dynamics of gut microbiota composition and diversity in ICU patients and healthy subjects. 
Panel A: Principal Component Analysis (PCA) of gut microbiota composition of ICU patients and healthy 
subjects, sampled at two time-points with a one-year interval (t=0 and t=1). Panel B: Diversity of the 
microbiota of ICU patients and healthy subjects.  Diversity of the microbiota was estimated by the 
Shannon diversity metric. Diversity is shown in box plots with whiskers extending from the 25th 
percentile to 75th percentile and outliers; lines within each box indicate median diversity of a sample 
group. Differences in diversity between groups are significant (Student’s t-test, p < 0.01) if the letters at 
the top of the graph are different.   
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Compared to healthy subjects, the microbiota of patients during ICU hospitalization 
was characterized by an increase in Bacilli, particularly of Enterococcus and 
Granulicatella groups (Fig. 2). The abundance of Enterococcus and Granulicatella 
was 42- and 34-fold higher, respectively, in the “final ICU” group than in the healthy 
subjects. Conversely, levels of several anaerobic commensal bacteria in the 
Firmicutes phylum, were reduced in the “during ICU” and “final ICU” groups, 
compared to healthy subjects. The most affected groups of bacteria were the butyrate 
producers Faecalibacterium prausnitzii et rel. (16.2-fold lower abundance in the 
“final ICU” group versus healthy subjects), Eubacterium rectale et rel. (10.7-fold 
lower), and Roseburia intestinalis et rel. (10.6-fold lower). 
We performed quantitative PCRs to accurately determine the abundance of E. coli, 
one of the primary targets of SDD, in the gut microbiota of patients and healthy 
subjects (Fig. 3). The abundance of E. coli in the “final ICU” samples was 
significantly lower compared to the “early ICU” group and the healthy subjects (325-
fold and 108-fold, respectively). The decrease in E. coli abundance during ICU stay 
in nine patients for which both “early ICU” and “final ICU” samples were collected, 
ranged from 9.4-fold (patient #180) to 7.6 x 104-fold (patient #108), with a 301-fold 
decrease as median value. The abundance of E. coli rebounded in four of six patients 
after cessation of SDD and transfer to a medium-care ward, reaching levels that were 
comparable to, and, in one patient, surpassing those found in healthy individuals. 
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Figure 2. Differences in bacterial composition of the gut microbiota. The bacterial genus-like 
groups that are significantly different (Kruskal-Wallis p < 0.03; FDR < 0.05) among the sample groups 
are shown. Colors indicate the differences in log-10 abundance compared to the average abundance of a 
given taxon in the entire data set. Bacterial groups are indicated as follows: A: Actinobacteria and 
Bacteroidetes; B: Bacilli and Proteobacteria; C: Other Firmicutes; D: Clostridium clusters IV and XIVa.  
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Figure 3. Quantification of E. coli 16S rRNA gene copies relative to total 16S rRNA gene 
copies. The quantification was performed by qPCR with three technical replicates. Error bars indicate 
standard deviation. The order of the samples is identical to panel (A). Statistical differences between the 
“final ICU” group vs the “early ICU” group and the healthy controls were analyzed by Student’s t-test with 
correction for multiple testing (**: FDR < 0.01). 
 
Resistome dynamics in ICU patients and healthy subjects 
A total of 48 unique ARGs conferring resistance to 14 different classes of 
antimicrobials were detected in the DNA isolated from faecal samples of hospitalized 
patients and healthy subjects (Fig. S2). The number of detected resistance genes per 
sample ranged between 6 and 38. Thirteen resistance genes were detected in >80% 
of healthy subjects and critically ill patients and these include tetracycline resistance 
genes (tetO, tetQ, tetM, tetW), the bacteroidal β-lactam resistance gene cblA, and 
two aminoglycoside resistance genes (aph(3′)-III and an aadE-like gene).  
Genes encoding for extended-spectrum beta-lactamases (ESBLs) were not detected 
in healthy subjects. In four samples of three ICU patients, ESBL genes could be 
detected (n = 1 for blaCTX-M, n = 2 for blaCMY, n = 2 for blaDHA; a single patient sample 
(#179B) was positive for both blaCMY and blaDHA). Three of the four ESBL-positive 
samples were collected after ICU discharge and cessation of topical antibiotic 
prophylaxis.  
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The carbapenemase blaKPC was detected in a single patient (patient #180),  in the 
first sample collected after 5 days in ICU. The blaAMPC β-lactamase was present in 
41.3% of samples, including 9 of 11 patients and 8 of 10 healthy subjects, whereas the 
blaTEM β-lactamase was present in 27.6% of samples, corresponding with 6 of 11 
patients and 4 of 10 healthy subjects, respectively. None of the samples were positive 
for the carbapenemases blaNDM and blaOXA, or for the recently described (Liu et al., 
2016) transferable colistin resistance gene mcr-1 (data not shown).  
Among resistance genes that are associated with Gram-positive pathogens, the 
staphylococcal methicillin resistance gene mecA was detected in 13 samples from 8 
of 11 patients, but not in samples of healthy subjects. The vancomycin resistance gene 
vanB was present in 5 samples from 3 of 11 patients and 6 samples from 4 of 10 
healthy subjects.  
 
Resistome dynamics during ICU stay  
To assess resistome stability, we plotted the average abundance of detected ARGs in 
healthy subjects at the two time sampling points and the average abundance of ARGs 
of the nine patients for which both “early ICU” and “final ICU” samples were 
available. Based on linear regression fitting of the different ARGs the resistome 
appeared more stable in healthy subjects (r = 0.96) than in ICU patients (r = 0.56) 
(Fig. 4). When comparing the presence of individual ARGs in the “final ICU” group 
versus the “early ICU” group and samples from healthy subjects, four ARGs were 
found to be enriched (Fig. 5), while eleven ARGs were reduced (Fig. 6) in 
abundance at the end of ICU stay. Increased abundance was demonstrated for genes 
contributing to aminoglycoside resistance (aac(6’)-Ii), resistance to erythromycin 
(ermC), methicillin resistance in staphylococci (mecA), and non-susceptibility to 
antiseptics (qacA). Decreased abundance of ARGs in the “final ICU” group was 
demonstrated for eleven genes, which were involved in β-lactam resistance 
(blaAMPC), chloramphenicol resistance (cat), the efflux of toxic compounds (acrA, 
acrF, macB, mdtF, mdtL, mdtO, tolC), resistance to polymyxins (arnA) and 
tetracycline resistance (tetW). 
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Abundances of blaAMPC, acrA, acrF, macB, mdtF, tolC and arnA were highly 
correlated with each other (r ≥ 0.9) and with levels of E. coli (r = 0.86 for arnA, r ≥ 
0.95 for the other ARGs), as determined by qPCR.  
 
 
 
Figure 4: Dynamics of the resistome in ICU patients and healthy subjects. The averages of log2-
transformed abundances for 48 ARGs (normalized to the 16S rRNA gene) that were detected in samples 
of nine patients for which both early ICU (time point 1)and final ICU (time point 2) samples were collected 
(blue circles) and for the healthy subjects (orange circles; n = 10, sampled twice with a one year interval) 
are plotted to depict resistome dynamics over time. Trend lines and correlation coefficients are shown. 
The dashed lines indicate the detection limit of the qPCR assay. 
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Figure 5. ARGs with increased abundance upon prolonged ICU hospitalization. ARGs that are present 
at higher abundance in the “final ICU” group, compared to the “early ICU” group and healthy subjects 
(sampled at two time points with a one year interval: t=0 and t=1). Testing for statistically significant 
differences between the six groups was performed by Kruskal-Wallis analysis with correction for multiple 
testing (FDR < 0.019). The horizontal line denotes the median value. For ARGs that fit this criterion, 
testing for statistical differences between “final ICU” and “early ICU” and the two groups of healthy 
subjects was performed using Dunn’s post-hoc test (* = p < 0.05; ** = p < 0.01). The detection limit of the 
qPCR assay is indicated with the dashed line. 
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Figure 6. ARGs with decreased abundance upon prolonged ICU hospitalization. ARGs that are present 
at lower abundance in the “final ICU” group, compared to the “early ICU” group and healthy subjects 
(sampled at two time points with a one year interval: t=0 and t=1). Testing for statistically significant 
differences between the six groups was performed by Kruskal-Wallis analysis with correction for multiple 
testing (FDR < 0.019). The horizontal line denotes the median value. For ARGs that fit this criterion, 
testing for statistical differences between “final ICU” and “early ICU” and the two groups of healthy 
subjects was performed using Dunn’s post-hoc test (* = p < 0.05; ** = p < 0.01; *** = p < 0.001). The 
detection limit of the qPCR assay is indicated with the dashed line.
Chapter 5 
 
130 
 
Discussion 
Current guidelines in the Netherlands recommend topical antibiotic 
decontamination in ICU patients with an expected ICU stay of two days or longer. 
Yet, the original claim that these interventions do not affect harmless anaerobic 
intestinal bacteria (van der Waaij et al., 1990), has recently been questioned (Buelow 
et al., 2014; Benus et al., 2010). While culture-based studies did not demonstrate 
selection for antibiotic-resistant opportunistic pathogens during SDD-treatment (de 
Smet et al., 2009; Daneman et al.,2013; Plantinga et al., 2015), concerns remain that 
selection for antibiotic resistance genes occurs in the gut microbiota of patients.  
The current study describes the diversity and dynamics of the gut microbiota of ICU-
patients receiving SDD during ICU-stay. the gut microbiota of ICU patients was 
characterized by a low diversity, the increased abundance of facultatively aerobic 
Gram-positive bacteria (predominantly Enterococcus, Granulicatella and, in a 
single patient, Staphylococcus) and decreased abundance of anaerobic Gram-
positive, butyrate-producing bacteria, particularly those of the Clostridium clusters 
IV and XIVa. These findings expand on previous findings of selection of Gram-
positive cocci (Daneman et al., 2013; Buelow et al., 2014; van der Bij et al., 2016) 
and depletion of F. prausnitzii during SDD (Benus et al., 2010). In addition, we were 
able to demonstrate that the abundance of E. coli was reduced by 301-fold (median) 
during ICU-stay. The suppression of E. coli in the SDD-treated ICU patients 
observed here, starkly contrasts with other studies in critically ill patients not 
receiving SDD, in which high-level E. coli gut colonization is a common event 
(Donskey, 2006; Taur et al., 2012; Zaborin et al., 2014). Yet, levels of E. coli 
increased again after ICU-discharge in four of six patients, reaching levels in the gut 
similar to, or even surpassing, those in healthy individuals. These findings suggest 
that a rapid regrowth or recolonization of the intestinal tract by E. coli, and possibly 
other aerobic Gram-negative bacteria, occurs upon cessation of prophylactic 
antibiotic therapy. In the only prospective evaluation, SDD treatment during ICU 
stay was not associated with higher infection rates upon ICU discharge (de Smet et 
al., 2009). 
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It, therefore, remains to be determined whether rapid post-ICU recolonization by E. 
coli increases the risk for infections with this bacterium. In addition, the reduction 
of butyrate-producing bacteria through SDD could possibly cause long-term gut 
health consequences as the production of butyrate is important for gut health and 
human metabolism (Canfora et al., 2015).  
The qPCR-based analysis of the resistome confirms previous metagenomic studies, 
in showing that tetracycline and aminoglycoside resistance genes and bacteroidal β-
lactamases are widespread in the human intestinal microbiota (Sommer et al., 2009; 
de Vries et al; 2011; Forslund et al., 2013; Hu et al., 2013; Buelow et al., 2014). All 
resistance genes that increased in abundance during ICU-stay, were associated with 
Gram-positive bacteria. The aminoglycoside resistance gene aac(6’)-Ii gene is a 
specific chromosomal marker for the nosocomial pathogen Enterococcus faecium 
(Costa et al., 1993). The increased abundance of the macrolide resistance gene ermC 
may have been selected for by the use of low doses of the macrolide erythromycin, 
which was used as an agent to accelerate gastric emptying during ICU stay in six out 
of eleven patients. The mecA gene was only detected in ICU patients, and confers 
methicillin-resistance to staphylococci, including S. aureus. Yet, coagulase-negative 
staphylococci are the most frequent carriers of the mecA gene ( Suzuki et al., 1992; 
Conlan et al., 2012; Becker et al; 2014).  
 
Previous studies on the implementation of SDD in ICUs have not found evidence for 
increased rates of MRSA colonization or infection (Daneman et al., 2013; Plantinga 
et al., 2015). Whether increased levels of mecA in the gut microbiota increases the 
likelihood of transfer of the mecA gene among staphylococci, through the mobile 
genetic element staphylococcal cassette chromosome mec (SCCmec) (Wielders et al., 
2001; Jansen et al., 2006), remains to be determined. Finally, the enriched qacA 
gene confers resistance to a number of disinfectants, including the biguanidine 
compound chlorhexidine and the quaternary ammonium compound benzalkonium 
chloride (Tennent et al.,1989; Mitchell et al., 1998).  
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Disinfectants are widely used in ICUs as cleaning and infection control agents 
(McDonnell et al., 1999) and its use could select for qacA in the gut microbiota of 
patients. In contrast, eight ARGs that were correlated with levels of E. coli were 
eliminated during ICU stay. These findings confirm the association of these 
resistance genes with the E. coli chromosome (Blattner et al., 1997). The tetracycline 
resistance gene tetW is present in anaerobic gut commensals, including the butyrate-
producer F. prausnitzii (Scott et al., 2000), and the effects of SDD on butyrate-
producing anaerobes may be responsible for the lower abundance of tetW in the gut 
microbiome of ICU-hospitalized patients. 
 
Although SDD improves survival of ICU-patients, its use remains controversial due 
to the perceived risk for selection of antibiotic resistance among bacteria that 
populate the patient gut. Based on the results from culture-independent techniques 
we conclude that SDD contributes to the selection for enterococci and the resistance 
genes associated with these bacteria. Enterococci are frequently multi-drug 
resistant, can cause difficult-to-treat infections and may serve as hubs for the spread 
of antibiotic resistance genes (Werner et al., 2013). Despite the selection for 
enterococci during SDD, rates of enterococcal infections among ICU-patients have 
not increased upon introduction of SDD (de Smet et al., 2009; Daneman et al., 
2013). We also conclude that SDD reduces the abundance of E. coli, and the 
resistance genes associated with this species, although this effect seems restricted to 
the duration of application of SDD. SDD is mostly used in the Netherlands, where 
the prevalence of multi-drug resistant bacteria in ICUs is low. In other countries, 
particularly in those where vancomycin-resistant enterococci, MRSA and ESBL- or 
carbapenemase-producing Enterobacteriaceae are more prevalent, the clinical 
benefits of SDD remain to be determined. Our findings demonstrate that monitoring 
of the resistome during ICU hospitalization by high-throughput qPCR provides more 
detailed information on the presence and abundance of antibiotic resistance genes, 
which may contribute to the prudent use of SDD in ICU patients, as it will enhance 
to rapidly detect and allow quantification of high-risk antibiotic resistance genes in 
the gut microbiota of patients during antibiotic prophylaxis.  
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Supplementary data 
 
Figure S1. Patient details. The antibiotics used in treatment of patients during hospitalization and 
time points at fecal samples were collected are indicated. SDD indicates the administration of topical 
components of SDD, Black lines indicate hospitalization at the ICU, blue lines indicate hospitalization at 
a medium-care ward. 
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Figure S2: Resistome of hospitalized patients and healthy subjects. ARGs are grouped and 
color-coded according to resistance gene families (B: bacitracin, C: chloramphenicol; M: macrolides; P, 
polymyxins; Qa: quaternary ammonium compounds, Q: quinolones; S: sulphonamides; Tet: tetracyclines; 
T: trimethoprim; V: vancomycin). Abundance (log2-transformed) is visualized relative to 16S rRNA.The 
time points at which samples were collected are indicated and color-coded as in Fig. 1. 
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Table S1. Primers used in this study. Primers were developed to target targeted the indicated ARGs. 
Primer sequences in bold indicate ARGs which were detected in ≥1 sample.  
Antimicrobial resistance Accession 
b
Forward primer Reverse primer 
acrB YP_002396537 CACGGTGACACAGGTTATCG AAGGTCAGGGTGATCTGCAC 
acrF CAR04877.2 ACTGACACCGGTTGATGTG
A
GAGCAATAATCGAGGCGTTC 
tolC BAG78840.1 CTGAAAGAAGCCGAAAAAC
G
CGTCGGTAAGTGACCATCCT 
acrA ACI36997.1 GAAGGTAGCGACATCGAAG
C
CTTTCGCCAGATCACCTTTC 
aph(3’)-III ACB90577.1 CCGGTATAAAGGGACCACC
T
CTTTGGAACAGGCAGCTTTC 
aph(2”)-Ib AF207840.1 ATCAAATCCCTGCGGTAGT
G
CAAGGGCATCCTTTTCCTTT 
aadE-like gene AAW34138.1 GCATGATTTCCTGGCTGAT
T
CCACAATTCCTCTGGGACAT 
aac(6’)-aph(2”) ABY79711.1 TCCAAGAGCAATAAGGGCA
TA
TGCCCTCGTGTAATTCATGT 
aac(6')-Ii WP_002293
8
AGACAGCTCGGCAGAAGAA
G
ACCGTATTGAGGGATTGCAC 
aac(3’)-Ii(acde) HQ246166.1 TGACGTATGAGATGCCGAT
G
GAGAATGCCGTTTGAATCGT 
aac(6’)-Ib KM387722.1 TTGCAATGCTGAATGGAGA
G
TGGTCTATTCCGCGTACTCC 
aadA ADW23165.1 GAACATAGCGTTGCCTTGGT GCTGCGAGTTCCATAGCTTC 
aac(6')-IIa ACR24243.1 GAACACTACCTGCCCAGAGC GCGACGTACGACTGAGCATA 
aph(2”)-I(de) AAC14693.1 CGGAGGTGGTTTTTACAGG
A
TTGCTTCGGCAGATTATTGA 
aph(3’)-Ia, -Ic  CAQ58482.1 ATTCTCACCGGATTCAGTCG ATTCCGACTCGTCCAACATC 
strB CAJ77026.1  GGCGATTATAGCCGATCAA
A
CGCGACTGGAGAACATGATA 
bacA_2 ABR38862.1 GAGGCATTGATCCTTGGTG
T
AAACAATGCCGAACCGATAG 
bacA_1 CAH05846.1 GGCTGCGTTACTGTCGTTTT GGCCAATGATAAATGCATCC 
bacA ACL18936.1 AACTTCCCGTTCTGGTGCTA CATAACGGGGATAGCGAGAA 
blaGES ABG47465.1  CTGCTGCAATGACGCAGTAT TATCTCTGAGGTCGCCAGGT 
blaIMP AJ640197.1 GCTACCGCAGCAGAGTCTTT CCCACCCGTTAACTTCTTCA 
blaVIM  AM183120.1 TGTCCGTGATGGTGATGAGT TTTCAATCTCCGCGAGAAGT 
blaACC   AJ870923.1  TTGTTACGCTACGTGCAAGC CGATTTGAAATAGCCGGTGT 
blaDHA AHN96243.1 AAAGTGCGCAAAGCCAGTA
T
AAGATTCCGCATCAAGCTGT 
blaIMI U50278.1 AGTCGATCCCAGCAGCTTTA CCAAGAAACTGTGCATTCCA 
blaCMY  AF357598.1 GATCTGCTGCGTTTTGTGAA CTACCGAGTAATGCCCTTGG 
blaAMPC  ABF06289.1 ACCGCTAAACAGTGGAATG
G
GCAAGTCGCTTGAGGATTTC 
cepA CR626927.1 ATGTCCTGCCCTGGTAGTT
G
CTTGCCCGTCGATAATGACT 
cepA_2 AE016945.1 TGCACCAAGACGAAAGTCT
G
ACAGTGCTTCTTTGCGGAAT 
blaBIC-1  GQ260093.1  CCATCAGCGCACAACATAGT CCAGAACGTTTTCCAGAAGC 
cblA AAA66962.1  TGCCTGCGACATCTTGATA
G
CCGTCTTCTGTTTCCGAGAG 
cfxA AY769933.1 GCGCAAATCCTCCTTTAACA ACAATAACCGCCACACCAAT 
blaCMY AAZ99133.1 CGATCCGGTCACGAAATAC
T
CCTGCCGTATAGGTGGCTAA 
blaCTX-M ABG46354.1 ACTATGGCACCACCAACGA
T
GGTTGAGGCTGGGTGAAGT
A
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blaTEM NP_775035.1 AAGCCATACCAAACGACGA
G
TTGCCGGGAAGCTAGAGTAA 
blaSHV AAV83796.1 CTTTCCCATGATGAGCACCT AGATCCTGCTGGCGATAGTG 
blaNDM CAZ39946.1 ATATCACCGTTGGGATCGAC TAGTGCTCAGTGTCGGCATC 
blaOXA AAP70012.1 GTGGCATCGATTATCGGAAT AGAGCACAACTACGCCCTGT 
    
    
Antimicrobial resistance Accession 
b
Forward primer Reverse primer 
blaKPC AEL12451.1 TGGCTAAAGGGAAACACGA
C
TAGTCATTTGCCGTGCCATA 
cat ABO92401.1 CAATCCTCAATCGACACGA
A
GATTGTGTAGCAAGGCAGCA 
mdtL CAR15381.2 CGGACAAACCACGAGAAAA
T
GAAGGTGAGGATCACCGAA
AmdtF KEL93478.1 GGACCCGCAAAAACTCAAT
A
AGTTGACCACCGGAAATCTG 
ermF BAD66041.1 AGCACCCGCTTTTTCCTTAT GATCAAGAGGGGCTTTAGGG 
ermB BAH18720.1 GGTTGCTCTTGCACACTCA
A
CTGTGGTATGGCGGGTAAGT 
ermG 122586.NMB0
66
TGCTGTCTTTTACAGGCCACT GCATATGTTCCAGTCCCTTCA 
ermC BAE05991.1 TGAAATCGGCTCAGGAAAA
G
GGTCTATTTCAATGGCAGTT
ACGmefA_10 583346.CKR CCTGCAAATGGCGATTATT
T
CCAAAGACCGCATAGGGTAA 
mefA_3 286636.M6_
SPY 66
TTACCCTATGCGGTCTTTGG GAACCAGCTGCTGCGATAAT 
macB ACR63203.1 GGCTGGAAGACCGTACAGA
G
GTTGGTTCATCGGCAAGAAT 
fosB NP_372857.1  TTGAGCTTGCAGGCCTATG GCCAATATTTAAATTCGCTGTCA 
ISS1N M37395 GACAGAGCACCGAACTGTG
A
TGCCCTTAATCGTGGAAGAG 
IS613 AB042549 GTGGCGGTTATTGACGACT
T
TTCAGCGTGTCCTTCTGATG 
TnAs3 CP000645 CTCTGTTACCTGCGCTTTCC CCGTACTCGTTCCAGCTTTC 
Tn610 X53635 GAGAGAGCTTTTGGCATTG
G
AGAGGTAGGCTGTCGCTCTG 
ISecp1 AJ242809 TGAAAAGCGTGGTAATGCT
G
TCGCCCAAAATGACTTTAGC 
IS26 X00011 ACCTTTGATGGTGGCGTAA
G
TACCGGAACAACGTGATTGA 
IS614B AY682394 TTTCACTGAGGGGATGGAA
G
TTGCCTTCCCATTTCTCAAC 
ISAzs19 NC_013860 GAACCGCTCCGAGAAAGATT GCTCATCGCCTTTGAGAAAC 
ISSW1 M37396 TTGAACAAGACCATCGTCC
A
TCTCCATCCCCTTAATCGTG 
cfr  YP_00389602 CAAACGAAGGGCAGGTAGAA GACCACAAGCAGCGTCAATA 
mfsA  WP_002584 AATATGCTCTCCGGGCTTTT TTTGCACACCGTAAAATGGA 
ermA AB047088.2 GAGGGGTTTACCGCTTCTTT ATCGGATCAGGAAAAGGACA 
mecA YP_184944.1 TCCAGGAATGCAGAAAGAC
C
GGCCAATTCCACATTGTTTC 
arnA  CAR03684.2 GAAATTCACCGTCTGGTCG
T
GTGGTGCAACAGAAATCACG 
mdtO BAI33519.1 TTGTTGGCCTCTATCCAACC TTAAGCGCTTGATGCATTTG 
qacA YP_536864  GACCCTTCTGGTACCCAAC
A
TCCCCATTTATCAGCAAAGG 
qacC CAA86016.1  TGGGCGGGACTAGGTTTAG ACGAAACTACGCCGACTATGA 
acrP AKL33057.1 CAGGCACTCCTTTCAGCTTC GAGGCCGTGTTCAATTTGTT 
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chvD CDX10534.1 ATTCTGTGGCTGGAGCAGTT GATCCACTTCGCAGATCCAT 
qacE NC_001735.4 TCGGTGTTGCTTATGCAGT
C
ATCAAGCTTTTGCCCATGAA 
qnrA ACA43024.1 ATTTCTCACGCCAGGATTTG ACTGCAATCCTCGAAACTGG 
qnrB AFD54601.1  CGATCTGACCAATTCGGAG
T
ACGATGCCTGGTAGTTGTCC 
qnrC ACK75961.1 GCAGAATTCAGGGGTGTGAT AACTGCTCCAAAAGCTGCTC 
qnrS AEG74318.1  TGGAAACCTACCGTCACACA AATCGCATCGGATAAAGGTG 
spc AAL05549.1 TGACGAACGCAATGTGATT
T
TCAGCTGCCAGATCTTTTGA 
vatA AAF24087.1 AACAGCTTCTGCAGCAATGA CCTTGAAAGGGGACATTGAA 
vatB AAA86871.1 TGGGAAAAAGCAACTCCAT
C
TTCTGACCAATCCACACATC
AaadE CAZ55809.1 TGTGCCGCAAAGAGATACTG TTATCCCAACCTTCCACGAC 
sul1 ADB23338.1 AGGCTGGTGGTTATGCACT
C
AAGAACCGCACAATCTCGTC 
tetQ Y08615.1 GCAAAGGAAGGCATACAAG
C
 AAACGCTCCAAATTCACACC 
tetX ABQ05845.1 CGGTACGCTGGATTTACACA CATCGGAATTGCCTTTTTGT 
tetW ACD97480.1 GGTGCAGTTGGAGGTTGTT
T
AAATGACGGAGGGTTCCTTT 
Antimicrobial resistance Accession 
b
Forward primer Reverse primer 
tetM ACO22036.1 TTGATGCGGGAAAAACTAC
C
TACCTCTGTCCACGCTTCCT 
tetO EAQ71799.1 GCGTCAAAGGGGAATCACT
A
CGGTATACTTCCGCCAAAAA 
tetB AAL09908.1 CAAAACTTGCCCCTAACCA
A
GCTTTCAGGGATCACAGGAG 
dfrA BAF39170.1 AGCACGATAGTAGCCGCAGT AAGGTTTTGGGGAAATCGTC 
dfrF AEBU010001
6
GATTGTTGCGAGGTCAAAG
AA
CGCCCCATAATAACCACATT 
vanUG ACR77286.1 ATTTGCGAAACTCGGAAAAA ACACCTCATTTTCGGGTACG 
vanR CAJ68489.1 TGAAGCTGTATGGGGAGAAAA TTTCGGGTTTTTAGAAGGTTCA 
vanA ACP19236.1 GTGCGGTATTGGGAAACAGT TGCGTTTTCAGAGCCTTTTT 
vanB WP_0324897
6
CCTGCCTGGTTTTACATCGT GCTGTCAATCAGTGCAGGAA 
vanX  NP_878017.1 CCGGTTGACGGTTATGAAGT CAGCCAGTTCTTTTGCCTTC 
int AAA25857.1 AGGATGCGAACCACTTCAT
C
GCTGTTCTTCTACGGCAAGG 
cfr_2 AJ249217.1 GCCGGAGCTTTTCCTCTACT GGTGCCGAAAGTCAAAACAT 
16S rRNA (9) CAACGCGARGAACCTTACC ACAACACGAGCTGACGAC 
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Abstract 
Patients in the intensive care unit (ICU) are generally susceptible to hospital-
acquired infections due to their immunological and clinical conditions. The 
application of prophylactic antibiotic therapies in critically ill patients aims to reduce 
the incidence of infections by Gram-negative bacteria, Staphylococcus aureus and 
yeast without disrupting the anaerobic microbiota. However, the impact of the 
prophylactic antibiotic therapy on the commensal gut microbiota and its associated 
resistome remain controversial. In this study we mapped the diversity and 
colonization dynamics of antibiotic resistant bacteria in ICU patients receiving 
prophylactic antibiotic therapy by using culture dependent and independent 
approaches. 
A total of 39 samples was collected from 11 ICU patients during and after ICU 
hospitalization where the patients received prophylactic antibiotic therapy. Diversity 
and dynamics of gut microbiota composition during the study period were evaluated 
by phylogenetic analysis using the Human Intestinal Tract Chip (HITChip) and 
cultivation under aerobic and anoxic conditions. Isolates were further characterized 
by antibiotic resistance phenotyping, and by detection of genes conferring resistance 
to macrolides, vancomycin and methicillin, in aerobic potential Gram-positive 
pathogens.  
HITChip analysis indicated that the relative abundance of Enterobacteriaceae was 
reduced during antibiotic therapy, whereas the relative abundance of Enterococcus 
spp. increased. Moreover, the relative abundance of Clostridium cluster IV and 
XIVa, representing an important fraction of the anaerobic microbiota, was reduced 
during therapy. We observed three distinct patterns based on the relative abundance 
of Firmicutes and Bacteroidetes phyla, however, no significant association could be 
established with specific antibiotic treatment, hospital-acquired infection, 
comorbity or length of ICU stay.  
A total of 130 bacterial isolates were retrieved, comprising 70 aerobes and 60 
anaerobes, including 17 butyrate producing bacteria. 
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Seventhy-two percent (n=94) of all isolates was multidrug resistant, with resistance 
to tetracycline (73 out of 130 isolates) and macrolides (87 out of 130 isolates) being 
most frequently observed. The ESBL phenotype was detected in four Escherichia coli 
isolates, while the class C cephalosporinase (AMPc) phenotype was detected in two 
Enterobacter cloacae isolates. Antibiotic resistance genes were detected in 
enterococci (ermB and vanC1 gene) and in staphylococci (ermC and the methicillin 
resistance encoding ccr cassette in non-aureus isolates).  
In conclusion, we show that prophylactic antibiotic therapy affects the diversity and 
dynamics of colonization with antibiotic resistant bacteria in ICU patients, with 
suppression of Enterobacteriaceae and functionally relevant anaerobes, and 
increase in enterocci.  
Keywords: antibiotic therapy, antibiotic resistance, commensal bacteria, colonization, gut 
microbiota 
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Introduction  
The human gut microbiota constitutes a complex community composed of 
approximately 1011 -  1012 microbial cells per gram of content (Ley et al., 2006). The 
principal members of this complex community are strict anaerobes followed by 
facultative anaerobes and aerobes (O’ Sillivan, 1999). In healthy humans, the gut 
microbiota plays an important role in several metabolic, nutritional, physiological 
and immunological processes (McNeil, 1984; Maloy et al., 2011). For example, the 
maintenance of gut homeostasis and epithelial integrity is supported by butyrate-
producing bacteria that convert dietary polysaccharides to short-chain fatty acids 
(SCFAs) such as butyrate, acetate and propionate. Particular interest has been 
attributed to butyrate as the main energy source for colonocytes (Hamer et al., 
2008). Marcia et al. (2012) indicated that impaired epithelial integrity is associated 
with emerging diseases such as inflammatory bowel disease. During such damage, 
butyrate producing bacteria are generally reduced in abundance (Clemente et al., 
2012).  
Previous studies have shown that gut microbiota composition can be affected by a 
range of external factors, including diet and antibiotics (Ley, 2000; Ley et al., 2006). 
During antibiotic administration the ecological balance of the gut microbiota can be 
disrupted. This could lead, for example, to overgrowth of microorganisms with 
natural resistance, establishment of new (resistant) pathogenic bacteria, and 
reduction of colonization resistance (Jernberg et al., 2010). 
Several factors, including the target spectrum and mechanism of action of 
antibiotics, dosage and duration of therapy, as well as the degree of absorption of 
orally and parenterally administered antibiotics, influence the extent to which a 
given antibiotic will affect microbiota composition (Bartosh et al., 2004). 
Furthermore, different multidrug antibiotic cocktails can differently affect the 
microbial community (Robinson et al., 2010; Vrieze et al., 2014; Reijnders et al., 
2016). In intensive care unit (ICU) patients, hospital-acquired infections constitute 
a common problem associated with high risk of morbidity, mortality and increased 
hospitalization costs.  
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Frequently, these infections are caused by multidrug resistant bacteria, which 
represent one of the most important problems in public health (Vincent, 2013). 
During ICU stay, prophylactic antibiotic therapy, and more specifically Selective 
Digestive Decontamination (SDD), has been implemented in order to prevent 
secondary colonization with Gram-negative bacteria, Staphylococcus aureus and 
yeasts, through the application of non-absorbable antimicrobials in the oropharynx 
and gut without disrupting the anaerobic intestinal microbiota (de Smet et al., 
2009). Numerous studies have been performed in order to determine the effects of 
SDD therapy on the dynamics of the gut microbiota, largely focusing on aerobic and 
facultative anaerobic, potentially pathogenic bacterial populations.  
Due to the complexity of the gut microbiota, different techniques have been used to 
increase our knowledge of the microbial diversity in the gut and its dynamics during 
antibiotic treatment.  
By using culture-dependent techniques, microbiologists have been able to study the 
effects of SDD therapy on the bacterial target groups. Recently, Oostdijk and 
collaborators indicated that during SDD therapy, antibiotic resistant 
Enterobacteriaceae can be eradicated from the gut (Oostdijk et al; 2010; Oostdijk et 
al., 2012).  
However, other groups of bacteria, mainly anaerobes, have not been explored due to 
the fact that cultivation techniques are laborious, time consuming, require special 
equipment for working under anoxic conditions, and some bacteria require specific 
nutrients or the presence of metabolic products from other species for growth 
(MacFarlane et al., 1994). The anaerobic commensal microbiota represents an 
important reservoir of antibiotic resistance genes and plays an important role in the 
horizontal gene transfer to potential pathogens (Shoemarker et al., 2001; Sommer 
et al., 2009; van Schaik, 2015). Culture dependent techniques have been thought to 
underestimate the bacterial community size due to the fact that only a small fraction 
of the gut microbiota is currently considered cultivable (10%), and thus microbiota 
composition and the associated resistome can be determined only in a small group 
of microorganisms (MacFarlane et al., 2004).  
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Interestingly, Browne et al. recently showed that a considerable proportion of the 
intestinal spore-forming bacteria can be recovered from the gut microbiota by using 
a single growth medium, suggesting that more than 10% of the gut bacteria are 
culturable (Browne et al., 2016). 
Advances in culture independent molecular methods have led to an increased 
interest in identifying both cultivable as well as uncultivable gut bacteria 
(Akkermans et al., 2000; Vaughan et al., 2000). Benus et al. (2010) studied the effect 
of SDD in comparison with standard care (SC) by using 16S ribosomal RNA (rRNA)-
targeted Fluorescent In Situ Hybridization (FISH), showing that during SDD therapy 
the abundance of Enterobacteriaceae and the Faecalibacterium prausnitzii group 
was significantly reduced while the Enterococcus population increased compared to 
SC . Recently, Dubourg et al. (2014) implemented the use of culture dependent and 
independent techniques to determine the impact of antibiotics on the gut microbiota 
from patients treated with a broad-spectrum antibiotic cocktail. Similarly, Rettedal 
et al. (2014) demonstrated that the combination of novel cultivation conditions with 
high-throughput sequencing of 16S rRNA genes allowed to identify and characterize 
previously uncultivated species. In a previous study, by using culture independent 
techniques, we were able to demonstrate that ICU hospitalization and SDD therapy 
dramatically affected gut microbiota composition and resistome (Buelow et al., 
2014).  
In this study, our aim was to determine the diversity and dynamics of colonization 
with antibiotic resistant bacteria in ICU patients receiving SDD therapy by 
combining cultivation-indendent community profiling using the Human Intestinal 
Tract Chip (HITChip) microarray platform and cultivation on a variety of culture 
media, and further biochemical and phenotypical characterization of aerobic and 
anaerobic isolates. 
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Materials and Methods 
 
Sample collection  
Eleven patients were included in this study after ICU admission at University 
Medical Center (UMC) Utrecht, The Netherlands. Selection criteria included no 
antibiotic administration prior to ICU admission. The protocol for this study was 
reviewed and approved by the institutional review board of the UMC Utrecht, The 
Netherlands. 
During ICU stay, Selective Digestive Decontamination (SDD) was applied. This 
therapy consists of the administration of 1000 mg of cefotaxime intravenously four 
times daily for four days, an oropharyngeal paste containing polymyxin E, 
tobramycin and amphotericin B (each at a concentration of 2% ) and administration 
of a 10 mL suspension containing 100 mg polymyxin E, 80 mg tobramycin and 500 
mg amphotericin B via a nasogastric tube, four to eight times daily throughout ICU 
stay. Systemic antibiotics were applied under clinical indications.  
A total of 39 fecal samples were collected upon defecation at different time points 
during hospitalization and stored at 4°C for 30 min to 4 h, after which the samples 
were split in three parts (approximately 0.5 g each) for eventual phylogenetic 
microarray analysis using the HITChip as described previously (Rajilic-Stojanovic et 
al., 2009) and for cultivation of aerobes and anaerobes.  
In brief, for cultivation of aerobes, fecal samples were suspended in 5 ml of oxic 
phosphate buffer (pH 7.0) to a final concentration of 10% (w/v) and preserved with 
40% glycerol. For anaerobes, feces samples were suspended in 5 ml of 20mM anoxic 
phosphate buffer (pH 7.0) supplemented with 0.5 mg/ml of resazurine and 0.5g of 
cysteine to a final concentration of 10% (w/v). An aliquot (1ml) was transferred to an 
anaerobic bottle containing 4 ml of PBS and glycerol (50%). A few drops of sterile-
filtered titanium citrate were added to the bottle to ensure anoxic conditions. All 
aliquots were transferred to -80°C.  
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Fecal samples were classified as follows, based on time of collection: “Initital ICU” 
(n=7) samples collected within 72 hours after ICU admission, “ICU stay” (n=23) 
samples collected during ICU stay after the initial 72h (average of 15-20 days) and 
“post ICU” (n=9) samples collected after ICU discharge.  
A schematic representation of the different approaches used in this study is shown 
in Figure 1. 
 
Figure 1. Schematic representation the different approaches used to study the diversity on colonization 
with antibiotic resistant bacteria.  
Abbreviations*: BPB, Butyrate Producing Bacteria; SCFA, Short Chain Fatty Acids; HITChip, Human 
Intestinal Tract Chip. 
 
Microbial phylogenetic profiling 
Fecal DNA isolation and phylogenetic profiling of the gut microbiota using the 
HITChip was performed as described previously (Rajilic-Stojanovic et al., 2009). 
The data was analised by using R (www.r-project.org), including the microbiome 
package (https://github.com/microbiome).  
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The dynamics of microbiota composition was studied per patient, as follow: patients 
were stratified based on the relative abundance of most predominant phyla observed 
in samples obtained during ICU stay – SDD, which led to the definition of three 
different groups: Group A: high relative abundance of Bacteroidetes, patients in this 
group have higher Bacteroidetes in more than 50% of the samples collected during 
ICU stay; Group B: high relative abundance of Firmicutes; and Group C: shift in the 
relative abundance of Firmicutes and Bacteroidetes, between first and second 
samples obtained during ICU stay. Moreover, differences in the gut microbiota 
composition at genus-like level based on signal probe intensities was assessed by the 
Wilcoxon test for unpaired data between time points (initial ICU, ICU stay and post-
ICU) as implemented in the "wilcox.test" R-script (https://stat.ethz.ch/R-
manual/R-patched/library/stats/html/wilcox.test.html). The diversity of the 
microbiota based on probe signal intensities was determined by Shannon’s diversity 
index. Statistical differences (p-values < 0.05) were corrected for false discovery rate 
(FDR) by the Benjamini and Hochberg method (Benjamini et al., 1995). 
 
Cultivation of aerobic (potential pathogens) and anaerobic bacteria 
An aliquot of the fecal suspension preserved in aerobic and anaerobic conditions, 
respectively, was diluted to a final concentration of 1% (w/v) and inoculated (10 mL) 
in ten different culture media: For cultivation of aerobes, the following culture media 
were used: Columbia Colistin Nalidixic Agar (CNA) with 5% sheep blood 
(staphylococci and streptococci) (Becton Dickinson, Breda, The Netherlands), Bilis 
Esculin Agar (BEA) (enterococci) (Oxoid B.V., Landsmeer, The Netherlands), 
MacConkey (enterobacteria) (Oxoid), Brain Heart Infusion Agar (BHI) (non-
selective) (Oxoid). All plates were incubated in aerobic conditions at 370C for 3 days. 
For anaerobes we used the following culture media: Fastidious Anaerobic Agar 
supplemented with 5% horse blood (FAA) (Lab M Ltd., Bury, England), Bacteroides 
Supplemented BHI medium (BHIS) (BHI Agar, 5 mg haemin, 1 mg vitamin K, 5g 
yeast extract, 0.5g L-cysteine, resazurine 500mg / L), Reinforced Clostridial Agar 
(RCA) (Oxoid), Lactobacillus MRS Agar (MRS) (Oxoid), Peptone Yeast Glucose Agar  
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(PYG) (Leibniz-Institut DSMZ, Braunschweig, Germany), Bifidobacterium medium 
(DSMZ). All plates were incubated in anoxic conditions (N2/CO2 (80:20)) at 370C for 
5 days. 
Different combinations of antibiotics were used on BHI, FAA and PYG media in 
order to isolate and identify the cultivable fraction of antibiotic resistant bacteria 
present during the specific collection time (Table 1). Bacterial growth was 
quantified by colony forming units (CFU/ml), and colonies were further 
characterized by macroscopic features as well as microscopically by Gram staining. 
In order to isolate potential secondary fermenting bacteria, notably those involved 
in butyrate production, a bicarbonate-buffered anaerobic medium was used as 
described previously (Stams et al., 1993) supplemented with agar (15% w/v) and 
SDD cocktail (Polymyxin 25 μg, tobramycin 5 μg and cefotaxime 10 μg). As a carbon 
source, lactate (40mM), acetate (40mM), lysine (40mM) or a combination of lactate 
and acetate (40mM each) were added. All plates were cultured anaerobically in an 
athmosphere of N2/CO2 (80:20) at 370C for 5 days. 
Colonies were selected from the plates based on their morphology for subsequent 
transfer on the same medium in duplicate to obtain pure cultures and for 
identification and characterization of the isolates. 
Table 1. List of antibiotics and concentration used per culture media 
Culture media Antibiotics Concentration (μg/ml) 
Aerobes   
Brain Heart Infusion Agar TOB / POL 10 / 5 
Anaerobes   
Fastidious Anaerobes Agar AMP / TET / ERY 10 / 10 / 50 
Peptone Yeast Glucose Agar AMP / TET / ERY 10 / 10 / 50 
 
Abbreviations: Ampicillin (AMP), Erythromycin (ERY), Polymyxin (POL), Tetracycline (TET), 
Tobramycin (TOB). 
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Identification of isolates  
Identification of aerobic and anaerobic isolates was performed by colony PCR for the 
amplification of the bacterial 16S rRNA genes using the 27-F and 1492-R primers as 
described previously (Weisburg et al., 1991). The amplified fragments were selected 
for partial sequence analysis of the 16S rRNA gene (~800bp) using the 1392R primer 
5’- ACGGGCGGTGTGTRC -3’ (GATC Biotech, Cologne, Germany). 16S rRNA 
sequences of all isolates were 99-100% similar to those of previously cultivable 
species.  
The group of butyrate producing bacteria was subjected to a PCR for the detection of 
the butyryl-coenzyme A (CoA) CoA transferase gene (but) as described previously 
(Louis et al., 2007) using Eubacterium halli and Faecalibacterium prausnitzii 
(Culture collection, Laboratory of Microbiology, Wageningen University, The 
Netherlands) as a positive control. 
From all the isolates in which the but-gene was detected, substrate utilization was 
determined. In brief, a cell suspension of individual isolates was inoculated in 
anaerobic bicarbonate-buffered medium containing acetate and lactate as a 
substrate at a final concentration of 40 mM each, incubated at 37 0C for 48h. End 
products were determined by HPLC as described previously (van Gelder et al., 2012).  
Carbohydrate metabolism was determined for Gram-positive anaerobes by using 
API 50 CH (BioMerieux, Benelux B.V., Zaltbommel, The Netherlands). 
 
Antimicrobial susceptibility 
Aerobic isolates were tested for antimicrobial susceptibility by the disk diffusion 
method in Mueller Hinton Agar (MHA) (Oxoid) plates using the guidelines of the 
Clinical Laboratory Standard Institute (CLSI – Aerobic bacteria, 2013). For testing 
of antimicrobial susceptibility of aerobic Gram-positive bacteria, i.e. mainly 
staphylococci and enterococci, we used the following disks (Oxoid) : vancomycin (30 
μg), oxacillin (1 μg), amoxicillin-clavulanic acid (20/10 μg), tetracycline (10 μg), 
chloramphenicol (10 μg), and ampicillin (10 μg).  
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Erythromycin (15 μg) and clindamycin (10 μg) were used to determine the phenotype 
of resistance to Macrolide Lincosamide Streptogramin B (MLSB) by double diffusion 
test (Thumu et al., 2014). The minimal inhibitory concentration (MIC) of 
vancomycin was determined by E-test (Oxoid).  
 
For the antimicrobial susceptibility in Gram-negative bacteria, i.e. mainly 
enterobacteria, we used: imipenem (10 μg), meropenem (10 μg), piperacillin-
tazobactam (100/10 μg), ceftriaxone (30 μg), cefotaxime (30 μg), ceftazidime (30 
μg), amoxicillin-clavulanic acid (20/10 μg), cefoxitin (30 μg), tetracycline (30 μg) 
and colistin (10 μg). 
 
Anaerobic isolates were tested for antimicrobial susceptibility by ATB™ ANA EU 
(08) (BioMerieux) following the manufacturer’s recommendations and by Agar 
dilution test as recommended by CLSI (CLSI – Anaerobic bacteria, 2013). 
 
Detection of antibiotic resistance genes in Gram-positive aerobes 
Staphylococcal and enterococcal isolates were tested for the presence of genes 
conferring resistance against vancomycin (vanA, vanB, and vanC1/2) and 
erythromycin (ermA, ermB, ermC, mefA, mefE). In addition, the staphylococcal 
methicillin-resistance gene cassette (chromosomal mec type assignment genes) was 
tested in staphylococcal isolates by single and multiplex PCR (Depardieu et al., 2004; 
Zou et al., 2011; Klaassen et al., 2005; Kondo et al., 2007).  
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Results 
We studied the diversity and colonization dynamics of antibiotic resistant bacteria 
in 39 fecal samples obtained from 11 ICU-hospitalized patients who received 
prophylactic antibiotic therapy. The number of samples collected during the study 
period ranged from two to seven for the different patients due to the medical 
conditions, constipation, prolonged stay and administration of systemic antibiotics 
for the control of nosocomial infections. Eight out of 11 patients developed 
nosocomial infections by multidrug resistant enterococci, staphylococci or 
enterobacteria. Characteristics of the patients included in this study are shown in 
Table 2. 
Phylogenetic profiling indicated that prophylactic antibiotic therapy modified the 
gut microbiota composition (Fig. 2). The relative abundance distribution at the 
phylum level indicated an indivual-specific, diverse and dynamic gut microbiota 
composition during hospitalization in the different patients. Three different patterns 
were observed based on the dynamics of the gut microbiota, including Group A: High 
relative abundance of Bacteroidetes (Fig 2a), Group B: High relative abundance of 
Firmicutes (Fig 2b), Group C: shift in relative abundance between Bacteroidetes 
and Firmicutes during ICU stay (Fig 2c). The relative abundance of Actinobacteria 
and Proteobacteria increased slightly during ICU stay in five patients. To highlight 
the most significant differences at the genus level, we observed a significant increase 
in the relative abundance of Enterococcus and Granulicatella (p < 0.05) during ICU 
stay, whereas the relative abundance of Enterobacteriaceae and members of 
Clostridium clusters IV and XIVa was reduced in the tree groups.  
The diversity of the microbiota calculated by Shannon’s diversity index showed no 
significant differences between groups (group A: 5.0 ± 0.5, group B: 5.3 ± 0.6 and 
group C: 5.3 ± 0.4 (p > 0.05)). In contrast, the diversity of the microbiota observed 
in initial ICU samples (<72h) (5.6 ± 0.4), ICU stay (5.1 ± 0.4) and post-ICU samples 
(4.8 ± 0.5) showed a decrease during ICU hospitalization (p < 0.01).  
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Table 2. Characteristic of the patients included in this study. 
Characteristic 
patients 
Age 
(years) 
Reason for 
 ICU admission 
Comorbid 
conditions 
Length 
of ICU 
stay 
(days) 
Additional 
antibiotic 
treatment* 
Site  
of infection 
Microorganisms 
isolated from the 
site of infections 
1 52 Lung transplant Diabetes type I 
Corticosteroids 
therapy 
30 COT, FLX, 
CTR 
Urinary tract E. faecium,  
S. epidermidis 
2 71 Post-operative Cardiac disease 11 E - E. coli (ESBL)** 
3 53 Trauma Diabetes type II 14 CAZ, VAN - E. cloacae*,  
S. aureus** 
4 74 Post-operative Liver failure 57 CZL, VAN, 
E, CAZ, 
CPR,MER, 
CTR 
Skin 
Bloodstream 
Cateter-related 
Pleural 
efussion 
S. epidermidis,  
S. aureus 
E. cloacae,  
E. faecium 
5 72 Heart failure Cardiac disease 5 CZL, E Respiratory 
tract 
E. coli,  
E. cloacae,  
S. maltophilia, 
 C. braakii,  
P. putida 
6 48 Heart transplant - 28 CRX, VAN, 
E 
Cateter-related 
Urinary tract 
Respiratory 
tract 
E. faecalis,  
S. epidermidis 
7 61 Post-operative Cardiac disease 22 CZL,VAN,
E, CLN 
Cateter-related S. epidermidis 
8 38 Trauma Hypotyroidism 15 E, CTR, 
MTZ,AMX 
Cateter-related E. faecalis 
9 49 Trauma Hypertension 15 VAN, CAZ, 
CTR 
Cateter related S. marcescens,  
E. faecalis 
C. striatum 
10 89 Trauma - 23 FLX, LEV Respiratory 
tract 
S. aureus, 
 S. maltophilia 
11 N.A N.A N.A 23 CTR N.A N.A 
Abbreviations*: COT, Cotrimoxazole; FLX, Flucloxacillin; CTR, Ceftriaxone; E, Erythromycin; CAZ, 
Cefatzidime; VAN, Vancomycin; CZL, Cefazolin; CPR, Ciprofloxacin; MER, Meropenem; CRX, 
Cefuroxime; CLN, Clindamycin; MTZ, Metronidazole; AMX, Amoxacillin; LEV,Levofloxacin, N.A., not 
available. ** Isolates obtained from rectal swabs samples. 
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Figure 2. Relative abundance of the gut microbiota at phylum level (pie chart) per patient 
and per time point where samples were taken. Coloured dots indicate whether cultures were 
obtained for the following groups: red (Gram-positive aerobes), blue (Gram-negative aerobes), yellow 
(Gram-negative anaerobes), green (Gram-positive anaerobes). Orange arrows indicate the end of SDD 
therapy. Group A: Higher relative abundance of Bacteroidetes in more than 50% of samples collected 
during ICU stay – SDD therapy, Group B: High relative abundance of Firmicutes and Group C: Shift in 
the relative abundance of Bacteroidetes and Firmicutes. 
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Figure 2. continued. 
 
Microbial cultivation of aerobes and anaerobes  
Overall, 130 isolates were obtained from the samples collected at initial ICU (19 
isolates), ICU stay (72 isolates) and Post-ICU (39 isolates). Positive cultures for 
aerobes were obtained between 24-48h after incubation, while positive cultures for 
anaerobes were obtained mostly after 72h of incubation. A total of 70 aerobes and 
60 anaerobes, including butyrate producing bacteria, were isolated on a range of 
different selective and non-selective culture media and further identified by 16S 
rRNA gene sequencing (Table 3).  
The highest colony counts, considering all the positive cultures obtained per media 
per sample, expressed as CFU/ml were observed in BEA (1.79 E+ 5.0) and CNA (7.8 
E+ 4.0) media for aerobes and in FAA (6.1 E+4.0), RCA (5.3 E+4.0) and BM (6.4 
E+4.0) for anaerobes.  
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Table 3. Distribution of isolates by culture media used. Isolates were idendified based on their 16S rRNA 
gene sequence 
 
 
In order to evaluate the effect of prophylactic antibiotic treatment on one of the 
functionally important microbial groups, potential secondary fermenting bacteria 
were quantified on bicarbonate-buffered anaerobic medium using either lactate, 
lactate and acetate or only acetate as the carbon source. Overall the total count of 
colonies differed between the carbon source used. Highest counts were observed 
when the combination of acetate/lactate was used (between 1.0 E+4.0 CFU/ml – 1.5 
E+5.0 CFU/ml). When acetate and lactate were used as a single carbon source, less 
than 1.0 E+ 4.0 CFU/ml were obtained. 
Culture media Aerobes 
Number of 
isolates 
BEA Enterococci 48 
C.N.A Staphylococci 13 
EMB -BHI Enterobacteria 9 
 Total of aerobic isolates 70 
   
 Anaerobes  
RCA Clostridium spp 11 
MRS Lactobacillus lactis 1 
Bifidobacterium media Bifidobacterium animalis 2 
PYG Blautia coccoides 1 
 Eggerthella lenta 2 
 Alistipes sp 2 
FAA Anaerostipes sp 6 
BM Bacteroides sp 17 
 Odoribacter splancnicus 2 
 Veillonella sp 1 
 Parabacteroides sp 4 
CP Acetate/Lactate Anaerostipes sp 7 
 Eubacterium limosum 1 
 Ruminococcus sp 1 
CP Acetate Anaerostipes sp 1 
CP Lactate Anaerostipes sp 1 
 Total of anaerobic isolates 60 
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Pronounced inter-individual variation in the number and identity of aerobes and 
anaerobes isolated at the different time points was observed (Table 4a,4b,4c). A 
total of 61 Gram-positive and nine Gram-negative aerobic bacteria (total number of 
aerobes=70, comprising 13 species) were isolated in this study. From the group of 
Gram-positive aerobic bacteria, the most predominant genus identified in all groups 
was Enterococcus (48 isolates). A more detailed description of the enterococci, 
including their phenotypic and genotypic characterization, is provided in Chapter 6 
of this thesis. The number of positive culture for Staplylococcus sp (n=13) increase 
in five patients during ICU stay. Co-colonization with E. faecium and/or E. faecalis 
and Staphylococcus epidermidis was observed during ICU stay in three patients. 
Only in the group of samples collected at post-ICU, we isolated and identified five 
additional Enterococcus species (E. gallinarum, E. casseliflavus, E. dispar, E. 
avium, E. canintestini) and two other Staphylococcus species (S. haemoliticus and 
S. warneri). From the group of Gram-negative aerobes, we obtained isolates of 
Escherichia coli (n=6) and Enterobacter cloacae (n=3) from three patients 
belonging to group A and C. 
We identified a total of 23 Gram-positive and 26 Gram-negative anaerobes using 
traditional culture media. From the group of Gram-positive anaerobes, the most 
predominant genus identified was Clostridium (11 isolates), including three different 
species (C innocuum, C. aldenense and C. orbiscindens). Members of two additional 
genera, Lactococcus lactis (n=1) and Blautia coccoides (n=1), were identified in 
samples obtained during the first 72h. Moreover, two different species of 
Anaerostipes (A. caccae, 4 isolates, and A. rhamnosivorans, 2 isolates) were 
identified during ICU stay. Other species identified corresponded to 
Bifidobacterium animalis (n=2) and Eggerthella lenta (n=2).  
From the group of Gram-negative anaerobes, Bacteroides (17 isolates) was the most 
predominant genus, including five different species (B. dorei, B. tethaiomicron, B. 
sp, B. fragilis and B. salyersiae). Two different species of Parabacteroides (3 P. 
distasoni and 1 P. goldsteini), Orodibacter splancnicus (n=2) and two different 
species of Alistipes (A. indistinctus and A. sp.), were isolated during ICU stay. A 
single isolate of Veillonella was obtained from a post-ICU sample.  
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By using bicarbonate-buffered anaerobic medium supplemented with acetate, 
lactate or lysine used as a single carbon source and a combination of acetate and 
lactate, nine positive culture were obtained on acetate/lactate from five out of ten 
patients (37 samples in total; samples from patient 11 were not included due to 
limited number of samples available). In one of these five patients, an additional 
positive culture was obtained when lactate was used as a single carbon source. One 
isolate was obtained only in the presence of acetate as a carbon source. No positive 
culture was obtained with lysine as a single carbon source. By using 16S rRNA gene 
sequence analysis, we were able to identify the following bacteria: nine Anaerostipes 
caccae, one Ruminococcus sp, and one Eubacterium limosum. All isolates were 
found positive for PCR targeting the presence of the but gene that encodes butyryl 
CoA:acetate CoA transferase, one of the key enzymes of the butyrate producing 
pathways. The fermentative capacity of the isolates was tested by HPLC, with butyric 
acid representing 89% of the SCFA detected. The other SCFA include isobutyric acid 
in four out of 11 isolates. A summary of butyrate producing bacterial isolates is shown 
in Table 5. 
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Table 4. Number and identity of aerobes and anerobes isolated per patient, per group during ICU-
hospitalization. Isolates were identified based on their 16S rRNA gene sequence, and showed in all cases 
99-100% sequence identity with the 16S rRNA gene of cultured reference strains. 
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Table 5. Identification of butyrate producers obtained by cultivation on bicarbonate-buffered anaerobic 
medium in the presence of acetate, lactate or a combination of both as the sole carbon source. 
Butyrate producers/samples Substrate utilization (%) 16S rRNA gene identity 
Patient 1 sample A Acetate/Lactate Anaerostipes caccae (99) 
Patient 1 sample C Acetate/Lactate Anaerostipes caccae (99) 
Patient 1 sample D Acetate/Lactate Anaerostipes caccae (99) 
Patient 1 sample E Acetate/Lactate Anaerostipes caccae (99) 
Patient 1 sample F Acetate/Lactate Anaerostipes caccae (99) 
Patient 3 sample E Acetate/Lactate Anaerostipes caccae (99) 
Patient 3 sample E Lactate Anaerostipes caccae (99) 
Patient 4 sample B Acetate/Lactate Ruminococcus sp (99) 
Patient 6 sample A Acetate/Lactate Eubacterium limosum (99) 
Patient 5 sample B Acetate Anaerostipes caccae (99) 
Patient 5 sample C Acetate/Lactate Anaerostipes caccae (99) 
 
Antimicrobial susceptibility of aerobic isolates 
Overall, a high prevalence of resistance to erythromycin (13/13 staphylococci) was 
detected. The majority of these isolates displayed the constitutive erythromycin 
resistance phenotype (cMLSb), and no other MLSb phenotype was identified in the 
isolates.  
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The erythromycin ribosomal methylase genes ermC was detected in ten out of 13 
staphylococci isolates. No vancomycin resistance was detected in the staphylococcal 
isolates. 
A screening for methicillin resistance was performed by using oxacillin - penicillin 
disks and multiplex PCR for the mec gene and the ccr cassette. All staphylococcal 
isolates were resistant to oxacillin and penicillin, and the presence of the mecA gene 
was detected in 11 out of 13 isolates. Five of these carried SCCmec type IV (ccr4 – 
ccrA and ccrB) and SCCmercury (ccrC), three carried SSCmec type II (ccr2 – ccrA 
and ccrB) and SCCmercury, and a single Staphylocccus epidermidis isolate carried 
SSCmec types II and IV together with the SCCmercury. In two mecA positive isolates 
identified as Staphylococcus haemoliticus and Staphylococcus aureus, the ccr gene 
was not detected. An increased resistance to amoxacillin-clavulanic acid was 
detected in four Staphylococcus isolates (two. S. epidermidis, one S. haemoliticus 
and one S. aureus) during ICU stay in three patients who developed a secondary 
infection caused by Gram-negative bacteria. 
Resistance to tetracycline was detected in three S. epidermidis isolates and in five 
Escherichia coli isolates, whereas resistance to chloramphenicol was detected only 
in two S. epidermidis isolates identified in a single patient during ICU stay.  
Regarding the resistance profile obtained for the aerobic Gram-positive bacteria 
during the study period indicated that during ICU hospitalization, an increase in 
antibiotic resistant Gram-positive bacteria was observed as compared to the initial 
ICU samples (Fig. 3a and 3b). Among the extended spectrum beta-lactamase 
(ESBL) phenotype investigated in the Gram-negative isolates, the BLEE phenotype 
was detected in four E. coli isolates from one patient during the post-ICU sampling 
period. Two of the three E. cloacae isolates from one patient showed the 
cephalosporinase AmpC inducible and AmpC hyper-production phenotype, 
respectively. No resistance to carbapenem and colistin was detected among the 
Gram-negative aerobic isolates. The susceptibility to tobramycin and polymyxin E 
was tested in Enterobacter cloacae isolates obtained in BHI media, however, no 
resistance to these antibiotics was detected. 
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Fig 3. Resistance phenotype observed in A) enterococci and B) staphylococci during the study period. 
Abbreviations: E, Erythromycin; CLN, Clindamycin; VAN, Vancomycin; AMP, Ampicillin; AMC, 
Amoxacillin-clavulanic acid; TET, Tetracycline; CHLO, Chloramphenicol. 
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Antimicrobial susceptibility of anaerobic isolates 
A high prevalence of resistance to tetracycline (38 out of 60 anaerobic isolates) was 
observed, with 15 Gram-positive isolates including Blautia coccoides (n=1), 
Bifidobacterium animalis (n=2), Lactobacillus lactis (n=1), Anaerostipes (n=6) and 
Clostridium innocuum (n=5), and 23 Gram-negative isolates including 16 out of 17 
Bacteroides isolates, Odoribacter splancnicus (n=2), Alistipes indistinctus (n=2), 
Veillonella sp. (n=1) and Parabacteroides distasonis (n=2). Besides tetracycline, 
also resistance to erythromycin and the lincosamide clindamycin was highly 
prevalent among anaerobic isolates, including 12 Gram-positive isolates: 
Anaerostipes caccae (n=4), Clostridium innocuum (n=5), Blautia coccoides (n=1) 
and Bifidobacterium animalis (n=2), and three Gram-negative isolates, including 
Veillonella sp. and Alistipes indistinctus isolates. No resistance to vancomycin was 
observed in Anaerostipes or Clostridium isolates.Resistance to metronidazole was 
found only in Bacteroides tethaiomicron (n=3) isolates. From the beta-lactams class 
of antibiotics, resistance to ampicillin was observed in Anaerostipes caccae (n=4), 
and Odoribacter splancnicus (n=2) isolates, whereas carbapenems (meropenem and 
imipenem) resistance was observed in two Bacteroides dorei isolates, two 
Parabacteroides isolates (P. distasonis and P. goldsteini), and in a single B. 
tethaiomicron isolate during and after ICU stay. Resistance to cefotaxime was 
limited (8%), and observed in four isolates identified as Bacteroides tethaiomicron 
(n=2), Bifidobacterium animalis (n=1) and Parabacteroides distasonis (n=1).  
For the group of butyrate producing bacteria detected by cultivation on bicarbonate-
buffered anaerobic medium supplemented with lactate and acetate as a single carbon 
source, only one out of 11 isolates were resistant to ampicillin (Anaerostipes caccae).  
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Discussion 
During ICU hospitalization, patients are exposed to a selective pressure of antibiotic 
treatment, parenteral nutrition and use of drugs for example to accelerate gastric 
motility. These factors, together with the host physiological stress, can contribute to 
the disruption of the ecological balance of the gut microbiota with, as a consequence, 
reduced microbial diversity, changes in microbial composition, and selection of 
resistance genes in the remaining community (Zaborin et al., 2014). In spite of the 
fact that prophylactic antibiotic therapies such as SDD have been shown to reduce 
the morbidity and mortality in ICU patients, the impact of such therapies on 
colonization with antibiotic resistant bacteria, and especially regarding anaerobes, 
remains poorly characterized (Ochoa-Ardila et al., 2011). Therefore, we followed the 
dynamics and diversity of the gut microbiota of eleven ICU hospitalized patients 
under SDD therapy using HITChip phylogenetic analysis and cultivation in aerobic 
and anoxic conditions.  
HITChip phylogenetic analysis revealed three different patterns at the phylum level 
in the studied patients, allowing for stratification based on the relative abundance of 
Bacteroidetes and Firmicutes. However, no association of any of the three groups 
(A, predominant Bacteroidetes; B, predominant Firmicutes; C, shifting) with 
specific antibiotic treatment, hospital-acquired infection, comorbity or length of ICU 
stay could be detected. In addition, no statistical differences were observed between 
groups based on the diversity of microbiota composition. It has been previously 
shown that the gut microbiota is particular per individual and that internal and 
external factors influence the composition (Ley et al., 2006). In this study we showed 
pronounced dynamics of gut microbiota diversity and composition during ICU 
hospitalization. We can, however, not exclude that in addition to the SDD therapy, 
other factors, including application of additional antibiotics for the control of 
nosocomial infections, also affected the gut microbiota. Previously, Dubourg and 
collaborators (2014) showed, that during antibiotic treatment, the total number of 
bacteria was not affected systematically, but that especially prolonged treatment 
with broad spectrum antibiotics can affect microbial composition. 
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At the genus level, the relative abundance of Enterobacteriaceae was decreased, in 
line with the goal of the SDD protocol, and low rate of infection by members of this 
family were found during the study period. In contrast, the relative abundance of 
enterococci increased, confirming that these are not targeted by the therapy. 
Furthermore, during ICU stay, also a reduction in the relative abundance of 
Clostridium clusters XV and XIVa was observed. Members of these bacterial groups 
play important roles in maintaining colonization resistance and represent the main 
source for butyrate production, which promotes the growth of colonocytes and 
contributes to mucosal stability (Pride et al., 2002). Our results confirm that SDD 
therapy has an impact on the composition of the anaerobic gut microbiota as 
previously reported (Benus et al., 2010).  
By using traditional cultivation-based approaches, we were able to capture a broad 
range of taxonomic groups, which allowed us to determine the antibiotic resistance 
phenotype of individual isolates directly, and link this information with the HITChip 
phylogenetic analysis.  
For the group of aerobic bacteria that in many cases represent potential pathogens, 
a high preavelence of antibiotic resistant-enterococci was detected in all the patients 
throughout the study. A more detailed analysis of the resistance phenotype, 
resistance genes and virulence factors present in these isolates is provided in Chapter 
6 of this thesis. Besides enterococci, staphylococcal isolates carrying methicillin-
resistance genes were detected during and after ICU stay in the three patient groups, 
and similar to enterococci, an association with staphylococcal nosocomial isolates 
could not be established. Neither vancomycin resistant enterococci (VRE) nor 
methicillin resistant Staphylococcus aureus (MRSA) were found in this study, in line 
with their low prevalence in ICU patients receiving SDD therapy as previously 
described (Daneman et al., 2013). On the other hand, low prevalence of antibiotic 
resistant Enterobacteriaceae was found. Two particular cases of faecal carriage of 
antibiotic resistant Enterobacteriaceae are represented by patient 2 and 3.  
 
Colonization dynamics of the gut microbiota in ICU patients 
 
173 
 
Patient 2 carried extended-spectrum betalactamase (ESBL)-producing 
Enterobacteriaceae during and after SDD without developing nosocomial infection, 
whereas patient 3 carried a cephalosporin resistant E. cloacae at the beginning of the 
ICU stay, and developed a bloodstream and pleural infection during ICU stay by a 
cephalosporin resistant E. cloacae. Previous studies indicated that the prevalence of 
ESBL and cephalosporin resistance in Gram-negative bacteria decreased during 
SDD therapy (Oostdijk et al., 2012; Camus et al., 2016).  
For the group of Gram-positive anaerobes, members of Clostridium and 
Anaerostipes were most often retrieved. From the group of Clostridium isolates, C. 
innoccum and C. aldenense have been infrequently associated with human infections 
(Crum-Ciaflone et al., 2009; William et al., 2010), whereas C. orbiscindens is known 
for the ability of cleaving flavonoids compounds, which have beneficial effects on 
human health based on a variety of properties (Shoefer et al., 2003). All of these 
isolates were obtained only at the initial ICU time point and in the first sample 
obtained after 72h of SDD therapy initiation. Among these isolates, only C. innoccum 
isolates were resistant to tetracycline, macrolides, lincosamides and carbapenems, 
in line with what has been described previously (Stark et al., 1993). Two different 
species of Anaerostipes, A. caccae and A. rhamnosivorans, were isolated from 
samples obtained from a single patient during ICU stay. Both species have been 
previously recognized as members of the butyrate producing bacteria present in the 
gut microbiota (Schwiertz et al., 2002; Bui et al., 2014). Both species were resistant 
to tetracycline, while only A. caccae isolates were also resistant to macrolides, 
lincosamides and ampicillin. Resistance to tetracycline is the only resistance 
phenotype reported for Anaerostipes caccae (Antibiotic Resistance Genes Database 
(ARDB;http://ardb.cbcb.umd.edu/cgi/search.cgi?db=L&field=ni&term=ZP_02419
744). To the best of our knowledge, this is the first report that describes this 
resistance phenotype in A. caccae. Furthermore, by using bicarbonate-buffered 
anaerobic medium, nine additional A. caccae isolates were obtained from the same 
patient in addition to another two patients. From one of them, another ampicillin 
resistant A.caccae isolate was detected. 
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Considering that in this particular culture medium, the SDD cocktail was used, only 
a selective group of Gram-positive anaerobic bacteria was able to grow.  
Our data showed that six of the eleven patients carried enterococci and Clostridium 
with the same resistance phenotype (macrolide and tetracycline resistance), 
suggesting that a transfer of resistance genes between Gram-positive aerobes and 
anaerobes might occur as previously indicated (Salyers et al., 2004). Antibiotic 
resistance in bacteria used as probiotics has been previously reported (Gueimonde 
et al., 2013). In this study we isolated representatives of two bacterial genera of 
which strains are often marketed as probiotics, i.e. Bifidobacterium and 
Lactobacillus. All isolates were found to be resistant to tetracycline and macrolides. 
Since efflux pumps are involved in resistance to both groups of antibiotics as a 
common mechanism, and since both genera are frequently used as a probiotics, 
particular attention is required with respect to the antibiotic resistance of probiotics 
strains.  
For the group of Gram-negative anaerobes, Bacteroides and Parabacteroides 
constituted the most predominant genera. Resistance to tetracycline was detected in 
94% of the Bacteroides isolates (16 out of 17) and 50% of Parabacteroides isolates 
(2 out of 4). Multidrug resistance was detected only in two species of Bacteroides (B. 
fragilis and B. dorei), and in one Parabacteroides distasonis isolate. In fact, a trend 
towards increased resistance of these species to carbapenems and cephalosporins 
such as cefoxitin in Europe has been reported recently (Nagy et al., 2011; Trevino et 
al., 2012). Resistance to macrolides and lincosamides was detected only in isolates 
identified as Veillonella and Alistipes indistinctus, while resistance to metronidazole 
was found in B. tethaiomicron isolates. Veloo and van Winkelhoff recently studied 
the antibiotic susceptibility profile of anaerobic pathogens in the Netherlands by E-
test and MIC determination and observed an increase in the prevalence of resistance 
to clindamycin in B. fragilis while no resistance to metronidazole were detected 
(Veelo et al., 2015).  
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It has to be acknowledged that the study reported here was constrained by a number 
of limitations: a) the limited numbers of patients, b) the heterogeneous set of 
samples obtained per patient due to constipation, administration of opioids and 
clinical conditions, c) absence of a control group, since the majority of ICUs in The 
Netherlands uses the SDD protocol for the control of infection in ICU patients, d) the 
unavoidable use of systemic antibiotics, e) the lack of control for cross-transmission 
and re-colonization, and f) the absence of biotyping for clinical isolates.  
To conclude, in this study we observed that the diversity and dynamics of the gut 
microbiota composition was affected during SDD therapy. Molecular analysis 
indicated that the relative abundance of Enterobacteriaceae was reduced during 
SDD therapy, whereas enterococci were significantly increased. In addition, SDD 
therapy seemed to negatively affect the anaerobic gut microbiota. Furthermore, 
cultivation on a range of complementary media yielded a diverse and dynamic range 
of aerobic and anaerobic bacteria, including butyrate producing bacteria. To this 
end, we observed an increased prevalence of antibiotic resistance in Gram-positive 
bacteria, and mainly among enterococci, and the suppression of resistance within 
enterobacteria. The variety of taxonomic groups obtained by anaerobic cultivation 
supports the idea that these groups of microorganisms act as reservoir for the 
accumulation of antibiotic resistance genes that can be acquired by and/or 
transferred to other commensal bacteria and pathogens.  
In general, high prevalence of resistance to tetracycline, macrolides and 
lincosamides was detected in this group of isolates, however, it should be considered 
that antibiotic resistance patterns can vary between species, hospital, country and 
antibiotic administration and that only a selective group of antibiotics was tested in 
all the isolates. Future analysis on antibiotic resistance patterns in anaerobes, 
identification of the resistance genes and monitoring the antibiotic resistance in 
commensals and potential pathogen isolates could contribute to a more quantitative 
estimation of the spread of antibiotic resistance.  
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Abstract 
Enterococci have emerged as important opportunistic pathogens in intensive care 
units (ICUs). In this study, the dynamics of Enterococcus spp. colonization in ICU 
hospitalized patients receiving prophylactic antibiotic therapies was investigated. In 
total 48 Enterococcus spp. strains were isolated and characterized from 11 patients 
at different time points during and after ICU hospitalization, including E. faecalis 
(n=17), E. faecium (n=26), E. gallinarum (n=1), E. dispar (n=1), E. avium (n=2) and 
E. canintestini (n=1). Multi locus sequence typing revealed a high prevalence of ST 
6 in E. faecalis isolates (59%) and ST 117 in E. faecium (46%). Also a new sequence 
type, ST 589, was identified, representing four E. faecalis isolates.  
Furthermore, the antibiotic resistance phenotyping and the presence of vancomycin 
and macrolide resistance as well as virulence factor-encoding genes (asa1, esp-fm, 
esp-fs, hyl and cyl) was investigated in all Enterococcus strains. Fourty-five out of 
48 isolates displayed the cMLSb phenotype, and 34 of them harboured the ermB 
gene. Vancomycin resistance was detected only in a single strain (E. gallinarum), 
encoded by the vanC1 gene. Furthermore, 31 (65%) and 23 (48%) of the isolates were 
resistant to ampicillin and tetracycline, respectively. The most prevalent virulence 
genes were asa1 in E. faecalis (65%) and esp (esp-fm (69%), esp-fs (59%)).  
Our results show that multiple Enterococcus species carrying several antibiotic 
resistance and virulence genes, occurred simultaneously in five individual patients. 
Furthermore, simultaneous presence and/or replacement of E. faecium sequence 
types was observed, further reinforcing the importance of enterococci as a potential 
cause of nosocomial infections in critically ill patients.  
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Introduction 
The genus Enterococcus encompasses indigenous commensal bacteria reported 
from the human and animal gut as well as the oral cavity and vagina in humans, 
where they have adapted to a nutrient-rich, oxygen-depleted and ecologically 
complex environment (Kayaoglu and Ørstavik , 2004). 
In the human gut, the genus Enterococcus can constitute up to 1% of the total 
bacterial microbiota in healthy individuals, with Enterococcus faecium and 
Enterococcus faecalis as most common species (Sghir et al., 2000). In contrast to 
their commensal role, over the past decades E. faecium and E. faecalis have also 
emerged as agents of nosocomial infections such as endocarditis, bacteraemia, 
meningitis, wound and urinary tract infections (Klein, 2003; Dwormiczek et al., 
2012). In addition, other enterococcal species including Enterococcus durans, 
Enterococcus avium, Enterococcus gallinarum, Enterococcus casseliflavus, 
Enterococcus raffinosus, and Enterococcus hirae have sporadically been associated 
with infections in humans (Klein, 2003). 
Most of the E. faecium and E. faecalis infections are opportunistic and are 
increasingly difficult to treat due to high rates of resistance to β-lactams, 
aminoglycosides and vancomycin, which are mostly associated with E. faecium 
strains (Cattaneo et al., 2000; Huycke et al., 1998).  
In addition, both E. faecium and E. faecalis can carry a variety of genes that 
contribute to virulence in the immunocompromised patient. For E. faecalis these 
include e.g. genes encoding aggregation substance (asa1) (Hallgren et al., 2009), 
cytolysin (cyl) (Jett et al., 1994), enterococcal surface protein (esp-fs) 
(VanKerckhoven et al., 2004) and haemolysin (hly) (Libertin et al., 1992), whereas 
for E. faecium genes associated with virulence encode, among others, a putative 
hyalorunidase (hyl) (Fisher and Phillips, 2009) and enterococcal surface protein 
(esp-fm) (Hendrickx et al., 2012).  
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Modes of action include i) colonization of a specific niche such as enterococcal 
adherence to renal tubular cells and neutrophils (Guzman et al., 1989; Joyanes et al., 
2000), ii) evasion or inhibition of the immune response by e.g., destruction of red 
blood cells and secretion of toxins that affect the host defence systems (Kreft et al., 
1992; Olmestd et al., 1994), iii) biofilm formation (Top et al., 2013), or iv) obtaining 
nutrients from the host (Vergis et al., 2002). Similar to resistance genes, virulence 
genes are also frequently encoded on mobile elements and are therefore thought to 
disseminate frequently via intra- and interspecies horizontal gene transfer within the 
genus Enterococcus (Laverde et al., 2011; Coburn et al., 2007). 
Intestinal commensal enterococci in healthy humans rarely harbour genetic 
elements that contribute to antibiotic resistance or confer virulence, and for decades 
enterococci have been used as probiotics both in humans and farm animals (Mundy 
et al., 2000; Arias et al., 2012). In contrast, Enterococcus isolates derived from 
clinical and animal sources frequently carry virulence factors and in several cases 
have been associated with high levels of antibiotic resistance (Eaton and Gasson, 
2001; Franz et al., 2001). The genomic diversity of E. faecalis and E. faecium isolates 
encountered in hospitals is of particular interest. Studies using Multi Locus 
Sequence Typing (MLST) have shown that there is a remarkable difference in the 
population structure between E. faecalis and E. faecium (Palmer et al., 2014). In E. 
faecium, high-risk clonal-complexes exist, which exhibit high levels of antibiotic 
resistance and are significantly associated with clinical infections in hospitalized 
patients (Leavis et al., 2006; Willems et al., 2012; Lebraton et al., 2013). 
Patients in an intensive care unit (ICU) are at a high risk for developing nosocomial 
infections with multi-drug resistant bacteria due to impaired health and often strong 
selective antibiotic pressure (Streit et al., 2004). Several studies have shown that the 
exposure of patients to broad-spectrum antibiotics, combined with prolonged 
hospital stay, can result in colonization by multi-drug resistant enterococci leading 
to nosocomial transmission and infection (Austin et al., 1999; Carmeli et al., 2002).  
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The prophylactic therapies Selective Oropharyngeal Decontamination (SOD) and 
Selective Digestive Decontamination (SDD) aim to prevent secondary infection with 
potential pathogens in ICU hospitalized patients and decrease mortality in these 
patients, compared to standard care (de Smet et al., 2009). While SOD and SDD can 
efficiently suppress gut colonization by Gram-negative bacteria, an increase of 
enterococci during SDD therapy was observed when compared to other regimens 
(van der Bij et al., 2016).  
This reflects the fact that enterococci were not considered a target during the 
introduction of SDD in the ICU, and it has been demonstrated that, for example, E. 
faecalis colonization increases during similar usage of topical antibiotics (Bonten et 
al., 1995).  
Previous studies on the effect of colonization by enterococci during SOD and SDD 
therapies have only addressed the presence or absence of enterococci (de Smet et al., 
2009). Therefore, we decided to investigate the dynamics of Enterococcus colonizing 
ICU hospitalized patients receiving SOD and SDD therapy and to evaluate in more 
detail the genetic relatedness of E. faecalis and E. faecium isolates, using MLST and 
Bayesian analysis of the population structure (BAPS). Furthermore, we determined 
carriage of genes encoding antimicrobial resistance and virulence determinants in 
this population. 
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Materials and Methods 
Patients, bacterial culture conditions and initial characterization 
Enterococci were isolated from 28 out of 40 faecal samples obtained from 11 
hospitalized patients: two patients received SOD (patients 100 and 101) and nine 
received SDD (patients 1 - 9). The SOD and SDD protocols were reviewed and 
approved by the institutional review board of the University Medical Center Utrecht 
(Utrecht, The Netherlands). The SOD protocol consisted of an oral application of 0.5 
g of a paste containing 2% tobramycin 2% polymyxin E and 2% amphotericin B, 
given four times daily. The SDD protocol comprised the application of oral 
antibiotics identical to the SOD regime. In addition, a suspension containing 80 mg 
tobramycin, 100 mg polymyxin E and 500 mg amphotericin B was administered 
through a gastric tube four times daily, and cefotaxime (4x 1000 mg) was given 
intravenously for the first four days after ICU admission. The isolates were obtained 
from faecal samples taken during hospitalization and classified according to the 
collection time: Intitial ICU (samples taken during the first 72h at ICU, n=5), during 
ICU (samples taken after the first 72h at ICU; individual patients stayed in the ICU 
for up to 40 days, n=27) and post-ICU (samples taken after ICU discharge – ward / 
SDD-SOD discontinuation, n=8).  
In order to isolate enterococci from faecal samples, we used Bile-Esculin Agar (BEA) 
(Oxoid B.V., Landsmeer, The Netherlands). Typical colonies were selected for 
phenotypic and biochemical characterization by standard methods (Winn et al., 
2006). Haemolysis was determined by cultivation on Blood Agar supplemented with 
5% sheep blood (Oxoid) after incubation at 37oC for 24 hours.  
DNA isolation was performed using the protocol for Gram-positive bacteria of the 
QIAamp® DNA Mini Kit (Qiagen Benelux B.V., Venlo, The Netherlands). DNA was 
used for the identification of the isolates and detection of antibiotic resistance and 
virulence genes by Polymerase Chain Reaction (PCR) as described below. 
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Identification and classification of isolates 
The complete bacterial 16S ribosomal RNA (rRNA) gene was amplified from genomic 
DNA using T7prom-Bact-27-F and Uni-1492-R primers as described previously 
(Rajilic-Stojanovic et al., 2009). The amplified fragments were selected for partial 
sequence analysis of the 16S rRNA gene (~800bp) using the 16S-1392R primer 5’- 
ACGGGCGGTGTGTRC -3’ (GATC Biotech, Cologne, Germany).  
Partial 16S rRNA gene sequences obtained in this study were deposited at GenBank 
under accession numbers KX577731, KX577732, KX577733, KX577734.  
 
Antimicrobial susceptibility 
Vancomycin resistance of enterococci was tested on Mueller-Hinton Agar (MHA) 
(Oxoid) containing 6 μg/ml vancomycin. Colonies were tested by E-test 
(Biomerieux) to determine the minimal inhibitory concentration (MIC) of 
vancomycin, following CLSI guidelines (CLSI, 2013). Resistance to macrolides and 
lincosamides, more specifically to erythromycin and clindamycin, was tested by 
using a double disk diffusion test (Thumu and Halami, 2014), in order to determine 
the Macrolide Lincosamide Streptogramin B phenotype (MLSB). In brief, isolates 
were grown on MHA in the presence of an erythromycin (15μg) disk and one 
containing the lincosamide clindamycin (10 μg), separated by 20mm. As 
erythromycin would act as an inducing agent, isolates carrying erythromycin 
resistance genes will grow in the presence of clindamycin. A D-shaped inhibition 
zone around the clindamycin disk indicates an inducible MLSB phenotype (iMLSB). 
Resistance to both antibiotics, i.e. lack of any inhibition zone, indicates a constitutive 
MLSB phenotype (cMLSB). Isolates carrying the mef gene will show resistance to 
erythromycin and sensitivity to clindamycin with a circular zone of inhibition around 
clindamycin indicating the M phenotype (Thumu and Halami, 2014). In addition, 
the disk diffusion method was used to test for susceptibility to ampicillin (10 μg) and 
tetracycline (30 μg) (CLSI, 2013). 
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Detection of antibiotic resistance- and virulence factor-encoding genes 
Antibiotic resistance genes were detected using a multiplex PCR for the vancomycin-
resistance genes vanA, vanB, and vanC (vanC1 – vanC2/vanC3) (Depardieu et al., 
2004), and a single PCR for ermA, ermB, ermC and mefA/mefE genes (Zou et al., 
2011). PCR products of mefA and mefE genes were discriminated by BamHI 
restriction analysis, as only mefA carries a single restriction site, giving rise to 
fragments of 284bp and 64bp as described previously (Klaassen and Moutin, 2005). 
Genes coding for virulence factors, i.e. enterococcal surface protein (esp-fm, esp-fs), 
aggregation substance (asa1), cytolysin (cylB) and hyalorunidase (hyl), were 
selected for detection by PCR as described previously (Hallgren et al., 2009; 
Vankerkhoven et al., 2004). E. faecalis ATCC29212, E. faecium (E5) and E. faecalis 
(E507) (Department of Medical Microbiology, Utrecht Medical Centre, UMC, The 
Netherlands) and E. gallinarum HSIEG1 (van den Bogert et al., 2013) (Laboratory 
of Microbiology, Wageningen University, The Netherlands) were used as positive 
controls for the detection of antibiotic resistance and virulence factor encoding 
genes. Amplicons were visualized by agarose gel electrophoresis.  
 
Clonal relatedness and analysis of population structure 
In order to establish the clonal relationship of Enterococcus isolates, we applied the 
MLST schemes proposed by Ruiz-Garbajosa et al. 2006 and Homan et al. 2002 for 
E. faecalis and E. faecium, respectively. Sequences were compared with published 
alleles, and sequence types (STs) were assigned using the MLST database 
(http://pubmlst.org/efaecium/ and http://pubmlst.org/efaecalis/). BAPS groups 
were determined as previously described (Willems et al., 2012). 
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Results 
Diversity of intestinal Enterococcus isolates from intensive care patients 
A total of 48 isolates was obtained from 40 fecal samples of 11 ICU hospitalized 
patients and classified to the enterococcal species level by 16S rRNA gene 
sequencing. The most commonly found species were E. faecium (26 isolates) and E. 
faecalis (17 isolates). Other enterococcal species identified included E. avium (2 
isolates), E. canintestini (1 isolate), E. gallinarum (1 isolate) and E. dispar (1 isolate), 
all of which were isolated only during the post-ICU phase (Figure 1, 
Supplementary Table S1). From five of the 11 patients, faecal samples could be 
collected during the first 72h after ICU admission, three of which were colonised with 
E. faecalis (n=2) and E. faecium (n=3). The same strains were also found in samples 
taken later from these patients during ICU stay and post-ICU. During ICU stay (i.e. 
from day 4 until the end of SOD - SDD therapies), isolates of E. facalis (n=13) and E. 
faecium (n=15) were retrieved from nine patients. Throughout post-ICU, E. faecalis 
isolates (n=2) were identified in only two patients, while E. faecium isolates (n=8) 
were identified in four patients. In addition, five isolates belonging to other species 
were obtained after SDD therapy in two of the patients. 
 Six patients receiving SDD developed nosocomial enterococcal infections during 
ICU stay (Figure 1), including one pleural infection caused by E. faecium, six 
urinary tract infections (two episodes in a single patient) caused by E. faecalis (five 
cases) and E. faecium (one case), and one central line catheter associated infection 
caused by E. faecalis (two episodes in a single patient). Unfortunately, however, 
these isolates were not available for further analysis. 
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Figure 1. Overview of the dynamics of colonization by Enterococcus species and carriage of antibiotic 
resistance and virulence genes during and after ICU hospitalization. The black dots indicate days where 
fecal samples were taken during hospitalization. The different species isolated are indicated by differently 
coloured dots: orange (E. faecalis), green (E. faecium), dark grey (E. canintestini), blue (E. dispar), brown 
(E. gallinarum) and light grey (E. avium). Isolates not connected to a black dot were obtained from the 
sample closest to the left. The presence of antibiotic resistance genes is indicated by red (ermB) and purple 
dots (vanC1). Virulence factors are shown in heptagonal shapes (a-asa1), (e-esp-fm and esp-fs), (h-hyl). 
Patients that developed nosocomial infections during ICU stay with E. faecalis and E. faecium are 
indicated by green (E. faecium) and orange (E. faecalis) triangles. Grey and blue boxes indicate systemic 
antibiotics given under clinical indications (ERY= erythromycin, VAN = vancomycin). 
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Antimicrobial susceptibility 
Vancomycin susceptibility testing showed that a single isolate of E. gallinarum 
obtained during the post-ICU phase was resistant to vancomycin (MIC 16 μg/ml). 
All other isolates were susceptible to vancomycin (MIC 1.5-2 μg/ml). Forty-five out 
of 48 enterococcal isolates were resistant to both erythromycin and clindamycin 
(constitutive phenotype – cMLSB). No other erythromycin – clindamycin phenotype 
was detected. 
Ampicillin resistance was detected in 31 out of 48 isolates (24 E. faecium, 6 E. 
faecalis and 1 E. avium). The highest prevalence of resistant strains was found 
amongst E. faecium, the majority of them being obtained from the group of patients 
that received SDD therapy.  
Ampicillin resistant isolates were obtained from samples taken during and after ICU 
stay and in two patients during the first 72h after ICU admission. Resistance to 
tetracycline was detected in 23 out of 48 isolates (11 E. faecalis, 9 E. faecium, 1 E. 
dispar, 1 E. avium and 1 E. canintestini), the majority of which was obtained during 
ICU stay and in one patient during the first 72h after admission. A complete overview 
of resistance phenotypes is given in Table S1. 
 
Detection of antibiotic resistance- and virulence factor-encoding genes 
Because 45 out of 48 enterococcal isolates displayed the cMLSB phenotype, we 
assayed these for the presence of the ermA, ermB and ermC genes, which encode 
macrolide-lincosamide-streptogramin (MLS) resistance. PCR-based detection of 
antibiotic resistance genes revealed the presence of the ermB gene in 34 out of 45 
erythromycin-resistant isolates that were obtained during the entire study period. 
No other MLSB resistance genes were detected. From the group of vancomycin 
resistance genes tested, only the vanC1 gene was identified in the single E. 
gallinarum isolate that was also found resistant (Figure 1, Table S1). 
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Three out of the four targeted genes encoding enterococcal virulence factors were 
detected. The asa1 gene was frequently present in E. faecalis isolates (n=11), whereas 
the esp gene was more often found in E. faecium isolates (n=18), including three 
isolates obtained during the first 72h after ICU admission. The esp gene was also 
present in one E. avium and one E. gallinarum isolate.  
Finally, the hyl gene was detected post-ICU in a single isolate of E. faecium and E. 
gallinarum. The cylB gene was not detected in any of the isolates (Figure 1). 
We detected the presence of more than two virulence factor genes and/or virulence 
factor and antibiotic resistance genes in 27 out of 48 individual isolates during the 
entire study period. Among these 27 isolates, E. faecium isolates (n=17) were 
associated with the presence of ermB and esp genes and high levels of resistance to 
ampicillin, whereas E. faecalis isolates (n=8) were more frequently associated with 
the presence of asa and ermB genes and low levels of ampicillin resistance. The other 
two isolates included one E. faecalis isolate associated with the presence of esp and 
ermB genes and one E. gallinarum carrying esp, hyl, ermB and vanC1 genes. 
 
Clonal relatedness and analysis of population structure. 
Using MLST, we established the clonal relationship of all E. faecium and E. faecalis 
isolates obtained in this study. In total, we identified seven different STs among the 
E. faecium isolates (Figure 2, Table 1, Table S1). Analysis of their population 
structure using BAPS revealed that these STs belonged to four BAPS (sub) groups, 
which were previously associated with hospitalized patients (Willems et al., 2012). 
The majority of the STs belonged to BAPS group 2.1a (19 isolates), and 16 of them 
were susceptible to tetracycline and resistant to ampicillin (ST117 n=12, ST78 n=3 
and ST730 n=1). Other sub-groups observed included BAPS 3.2 (2 isolates), BAPS 
1.2 (2 isolates) as well as BAPS 3.3a2 (3 isolates). In five patients, we identified two 
or more different STs in the same patient during hospitalization (Figure 2). 
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Among the E. faecalis isolates, we identified three STs (ST6, ST81 and ST16), which 
were previously detected among hospitalized patients (27), as well as a new ST 
(ST589), represented by four isolates (Figure 2 and Table 1). All isolates belonging 
to ST589 were susceptible to ampicillin but resistant to tetracycline, and were 
obtained from a single patient from samples taken throughout the study. Three out 
of these four ST589 isolates showed the cMLSb resistance phenotype, and carried 
the ermB gene. From the group of E. faecalis isolates belonging to ST6 (n=10), seven 
carried ermB, asa and esp genes and were susceptible to ampicillin, while the other 
three isolates carried asa and esp genes and displayed resistance to ampicillin. BAPS 
cluster analysis subdivided the E. faecalis isolates into BAPS groups 1 (11 isolates) 
and 3 (2 isolates) (Table 1). In contrast to the situation in the E. faecium isolates, 
we neither detected simultaneous presence of E. faecalis STs nor clonal replacement 
over time within individual patients. 
Table 1. Sequence type (ST) and BAPS analysis of Enterococcus faecalis and Enterococcus faecium 
isolates. 
 BAPS 
group 
BAPS 
subgroup 
ST number Number of 
isolates 
E. faecalis 
(n=17) 
1 
3 
1 
 6 
81 
16 
589 
10 
1 
2 
4 
E. faecium 
(n=26) 
3 
3 
2 
2 
2 
1 
1 
3.2 
3.3a2 
2.1a 
2.1a 
2.1a 
1.2 
1.2 
271 
17 
78 
117 
730 
361 
60 
2 
3 
3 
12 
4 
1 
1 
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Figure 2. Sequence types (ST) identified per sample, per patient during and after SOD-SDD 
therapy. The differently coloured dots indicate the species: orange (E. faecalis), green (E. faecium). 
Numbers indicate the sequence types. The new ST (589) detected in a single patient is indicated in red. 
Black dots indicate the time point (days) where samples were taken during hospitalization. Isolates not 
connected to a black dot were obtained from the sample closest to the left. 
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Discussion 
In the present study we analysed the dynamics of colonization by Enterococcus 
species isolated from faecal samples of ICU patients receiving prophylactic SOD or 
SDD therapy. We observed a pool of diverse enterococcal species and sequence types 
that harboured virulence and antibiotic resistance genes, with the majority of 
isolates carrying at least two virulence factor- (n=11) and/or virulence factor- and 
antibiotic resistance genes (n=26). During ICU hospitalization and concomitant 
SOD or SDD, we observed dynamic patterns of colonization by enterococcal species, 
probably due to prolonged hospital stay and selective antibiotic pressure.  
The most prevalent species in both groups of patients were E. faecium and E. 
faecalis, both previously identified as important human pathogens associated with 
nosocomial infections (Schaberg et al., 1991). In three patients, these two species 
were detected in samples collected during the first 72h, which could suggest that 
these patients were colonized with the recovered strains before ICU admission. This 
is in line with previous studies, as recently reviewed by Guzman Prieto and co-
authors, showing that enterococci are present in healthy humans as well as in the 
environment, and that the acquisition of resistance genes and mobile elements 
rapidly increases and facilitates the colonization and subsequent infection in 
hospitalized patients (Guzman Prieto et al., 2016). Other identified enterococcal 
species included E. avium, E. canintestini, E. dispar and E. gallinarum, albeit only 
during post-ICU. One possible explanation could be that due to the suspension of the 
antibiotic selective pressure during post-ICU, other strains not belonging to E. 
faecalis and E.faecium were isolated. From these species, E. gallinarum and E. 
avium have been identified in fecal samples of animals and healthy humans (Layton 
et al., 2010; Silva et al., 2011), while E. dispar and E. canintestini have only been 
identified in human and canine fecal samples, repectively (Collins et al., 1991; Naser 
et al., 2005). E. avium, E. dispar and E. gallinarum have been infrequently linked 
to a human enterococcal infections (Tan et al., 2010; Varun et al., 2016).  
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We were furthermore able to identify more than one enterococcal species per sample 
in five out of 11 patients. This highlights the importance of analysing multiple 
colonies per culture to adequately sample the diversity of the enterococcal 
population.  
In our study, we observed a low prevalence of vancomycin resistance among E. 
faecalis and E. faecium isolates. This is in line with the previously reported 
prevalence (<1% for both E. faecium and E. faecalis) of vancomycin-resistance 
among enterococci in clinical infections in the Netherlands, as showed in the 
European Antimicrobial Resistance Surveillance System (EARSS) 
(ecdc.europa.eu/en/activities/surveillance/EARS-Net). The only vancomycin-
resistant isolate was identified as a strain of E. gallinarum (vancomycin MIC of 16 
μg/ml), which carried the vanC1 gene that is naturally present in this species (Toye 
et al., 1997). Practically all isolates (94%) were resistant to macrolides and displayed 
the cMLSb phenotype. In our study, the presence of the ermB gene was detected in 
76% (34 of 45 strains) of the erythromycin-resistant isolates. Similarly, Schmitz et 
al. (2000) found that the ermB gene (93%, n= 70) was most often detected in a set 
of 75 clinical isolates of E. faecium, followed by the ermA gene (4%, n= 3) (Schmitz 
et al., 2000). Hence, our results confirmed that ermB is the most frequent resistance 
gene among erythromycin-resistant enterococci. From the cMLSb phenotype 
isolates obtained in our study, which were negative for the ermB gene, also the ermC 
gene, as well as the mefA and mefE genes encoding an efflux mechanism, could not 
be detected.  
Colonization by ampicillin-resistant Enterococcus (ARE) is frequently associated 
with previous exposure to selective antibiotics, and ampicillin resistance is a specific 
trait for nosocomial isolates (de Regt et al., 2012). In our study we found a high 
prevalence of ARE, being notorious during ICU stay especially among E. faecium 
isolates. Resistance to tetracycline was detected in 48% of all 48 isolates (n=23) and 
predominantly in E. faecalis isolates (n=11), which is in accordance with previous 
studies (Templer et al., 2008). 
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All isolates were further screened for the presence of selected virulence genes. The 
esp gene was the most prevalent virulence determinant detected in throughout the 
study period. Similar results were found by Billstrom et. al. (2008) and Sharifi et. al. 
(2013), where the esp gene was detected in more than 50% of E. faecium isolates 
from hospitalized patients. The asa1 gene was detected in 14 isolates, mainly during 
ICU stay, including two E. faecium, one E. avium, and 11 E. faecalis isolates, in line 
with the prevalence of this gene previously reported by Hallgren et. al. (Hallgren et 
al., 2009). Next, we detected the presence of the hyl gene in one E. faecium and one 
E. gallinarum isolate only post-ICU. It should be noted, however, the hyl gene has 
been identified not only in E. faecium and E. faecalis, but also in E. casseliflavus, E. 
mundtii and E. durans isolated from food-stuffs (Trivedi et al., 2011), showing that 
the hyl gene can be present in a variety of Enterococcus spp. We cannot exclude that 
isolates obtained here contain other virulence genes that were not targeted in the 
present study. 
Finally, the clonal relationship and population structure (BAPs groups) found in E. 
faecium and E. faecalis isolates indicated that the majority of our E. faecium isolates 
(85%) clustered in subgroups 2.1a and 3.3a2, representing separate hospital lineages 
that belong to clade A1, which contains most nosocomial E. faecium isolates 
(Willems et al., 2012). Most E. faecalis isolates (71%) clustered in BAPs group 1, of 
which the majority belonged to ST 6 that was previously found in both hospitalized 
and non-hospitalized patients (Willems et al., 2012; Tedim et al., 2015). In three 
patients, ST 589 (E. faecalis) and ST 117 (E. faecium) were detected during the first 
72h, which were continuously present in all the isolates identified during the study 
period in those patients.  
Unfortunately, we were not able to identify the ST of the clinical isolates responsible 
for the nosocomial infections. It is also not known whether these infections were due 
to translocation from the gut. In our study we described a high diversity of 
Enterococcus spp., including the recovery of multiple species and STs from 
individual patients.  
 
Chapter 7 
 
202 
 
During ICU stay, we observed the simultaneous presence of sequence types and 
clonal replacement over time among E. faecium isolates, whereas this was not the 
case for E. faecalis. Furthermore, we detected the simultaneous presence of more 
than two virulence factors and/or virulence factor and antibiotic resistance genes in 
E. faecalis, E. faecium, E. gallinarum and E. avium isolates. The prevalence of 
Enterococcus in ICU hospitalized patients, combined with the carriage of antibiotic 
resistance and virulence genes, described in this study, underline the importance of 
this group of organisms as a potential cause of nosocomial infections in critically ill 
patients.  
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Table S1. Characteristic of the Enterococcus isolates colonizing ICU patients 
 
 
 
 
Initial ICU/Patient ID Identification MIC Van (μg/ml) Macrolide phenotype Resistance gene Virulence factor MLST
Patient 1 E. faecalis 2 Susceptible N.A no detected 589
E. faecalis 2 cMLSb erm B no detected 589
Patient 3 E. faecium 0.5 cMLSb erm B esp 117
Patient 5 E. faecium 0.75 cMLSb erm B esp 117
E. faecium 0.75 cMLSb erm B esp 117
ICU stay/ Patient ID Identification MIC Van (μg/ml) Macrolide phenotype Resistance gene Virulence factor MLST
Patient 101 E. faecalis 1.5 cMLSb erm B asa,esp 6
E. faecalis 1.5 cMLSb no detected asa,esp 6
E. faecalis 1.5 cMLSb no detected asa,esp 6
E. faecalis 1.5 cMLSb no detected asa 6
Patient 100 E. faecium 1.5 cMLSb ermB no detected 271
E. faecium 1 cMLSb ermB no detected 271
Patient 1 E. faecalis 2 cMLSb no detected no detected 589
Patient 3 E. faecium 0.5 cMLSb ermB esp 117
Patient 4 E. faecium 1 cMLSb ermB esp 117
E. faecium 1 cMLSb ermB esp 730
E. faecium 1 cMLSb ermB esp 117
E. faecium 1 cMLSb ermB esp 730
E. faecium 1 cMLSb ermB esp,asa 730
E. faecalis 1 cMLSb ermB esp,asa 6
E. faecalis 1 cMLSb ermB esp 6
E. faecalis 1 cMLSb no detected esp 6
Patient 6 E. faecalis 1 cMLSb ermB esp,asa 16
E. faecalis 1.5 cMLSb erm B esp, asa 16
Patient 7 E. faecium 0.5 Susceptible N.A no detected 60
E. faecium 1 cMLSb erm B esp 117
E. faecium 1 cMLSb no detected no detected 361
Patient 8 E. faecalis 1 cMLSb ermB asa 6
E. faecalis 1 cMLSb ermB asa,esp 6
E. faecalis 1 cMLSb ermB asa 6
E. faecium 1 cMLSb ermB esp 117
E. faecium 1 cMLSb ermB esp,asa 117
Patient 9 E. faecium 0.75 cMLSb no detected no detected 117
E. faecium 0.75 cMLSb erm B esp 730
Post ICU/ Patient ID Identification MIC Van (μg/ml) Macrolide phenotype Resistance gene Virulence factor MLST
Patient 100 E. faecium 1 cMLSb erm B esp,hyl 78
Patient 1 E. faecium 2 cMLSb no detected esp 78
E. faecium 2 cMLSb erm B esp 78
E. faecalis 2 cMLSb no detected no detected 589
Patient 2 E. canintestini 0.5 cMLSb erm B no detected
E. dispar 0.5 cMLSb erm B no detected
E. gallinarum 16 cMLSb erm B, van C1 esp, hyl
Patient 3 E. faecalis 0.5 cMLSb erm B asa, esp 81
Patient 5 E. faecium 0.75 cMLSb erm B esp 117
E. faecium 0.75 cMLSb erm B esp 117
E. avium 0.5 cMLSb erm B no detected
E. avium 0.5 Susceptible N.A esp, asa
Patient 8 E. faecium 1 cMLSb no detected no detected 117
E. faecium 1 cMLSb no detected no detected 78
E. faecium 1 cMLSb erm B no detected 17
Chapter 7 
 
214 
 
 
 
  
CHAPTER 8 
High throughput cultivation-
based screening on the 
MicroDish platform allows 
targeted isolation of antibiotic 
resistant human gut bacteria 
Dennis Versluis1, Teresita de J. Bello González1, Erwin G. 
Zoetendal1, Mark W.J. van Passel1,2, Hauke Smidt1 
 
In preparation 
1Laboratory of Microbiology, Wageningen University, Wageningen, NL 
2National Institute for Public Health and the Environment, Bilthoven, NL 
Chapter 8 
 
216 
 
Abstract 
 
The emergence of bacterial pathogens that are resistant to clinical antibiotics poses 
an increasing risk to human health. The most important reservoir from which 
bacterial pathogens can acquire resistance is the human gut microbiota. However, to 
date, a large fraction of the gut microbiota remains uncultivated and has been little-
studied with respect to its reservoir-function. Here, our aim was to isolate yet 
uncultivated resistant gut bacteria by a targeted approach. Therefore, faecal samples 
from 20 intensive care patients who had received prophylactic antibiotic treatment 
(selective digestive decontamination [SDD], i.e. tobramycin, polymyxin E, 
amphotericin B and cefotaxime) were inoculated anaerobically on MicroDish porous 
aluminium oxide chip (PAO Chip) placed on top of poor and rich agar media, 
(including media supplemented with the SDD antibiotics). Biomass growing on the 
chips was analysed by 16S ribosomal RNA gene amplicon sequencing, showing large 
inter-individual differences in bacterial cultivability, and enrichment of a range of 
taxonomically diverse operational taxonomic units [OTUs]. Furthermore, growth of 
Ruminococcaceae (2 OTUs), Enterobacteriaceae (6 OTUs) and Lachnospiraceae (4 
OTUs) was significantly inhibited by the SDD antibiotics. Strains belonging to 16 
OTUs were candidates for cultivation up to pure culture as they shared ≤95% 
sequence identity with the closest type strain and had a relative abundance of ≥2%. 
Six of these OTUs were detected on media containing SDD antibiotics, and 
considered as prime candidates to be studied with regards to antibiotic resistance. 
One of these six OTUs was obtained in pure culture using targeted isolation. This 
novel strain, which was initially classified as member of the Ruminococcaceae, was 
later found to share 99% nucleotide identity with the recently published Sellimonas 
intestinalis BR72T. In conclusion, we showed that high-throughput screening of 
growth communities can guide targeted isolation of bacteria that may serve as 
reservoirs of antibiotic resistance. 
 
Keywords: antibiotic resistance / gut microbiota / bacteria / anaerobic cultivation / 
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Introduction 
 
The emergence of bacterial pathogens that are resistant to most clinical antibiotics 
is an increasing threat to public health. A common route through which pathogens 
can acquire resistance is by genetic exchange with human-associated bacteria, and 
especially the gut microbiota. Indeed, it has been shown that the commensal gut 
microbiota harbours diverse resistance genes (Forslund et al., 2013; Hu et al., 2013), 
and that these genes can be acquired by (opportunistic) pathogens (van Schaik, 
2015). Horizontal gene transfer (HGT) is considered the main mechanism by which 
resistance genes are disseminated, and it has been shown that HGT events occur 
exceedingly more often in the gut microbiota than in other environments with 
complex bacterial communities (Smillie et al., 2011). Novel resistance determinants 
are typically described once bacteria are obtained in pure culture.  
 
On the other hand, resistance genes carried by yet uncultivated gut bacteria appear 
to be largely uncovered, which is reinforced by the observation that functional 
metagenomics studies of human gut microbiota consistently yield novel resistance 
genes (Sommer et al., 2009; Cheng et al., 2012). This “black box” of little-studied 
uncultivated bacteria has been estimated to constitute 40-70% of gut microbes 
(Sommer, 2005; Kim et al., 2011). Even though application of culture-independent 
methods (e.g. functional metagenomics) has provided us with useful insights into 
uncultivated bacteria, their cultivation will be essential to comprehensively study the 
antibiotic resistance phenotype, and the potential roles and mechanisms of these 
bacteria in antibiotic resistance dissemination. Nowadays, to isolate members of yet 
uncultivated taxa, innovative culturing techniques that apply high-throughput 
screening and/or better simulate the natural environment of these bacteria are 
increasingly being used. Recent methodical advances include cultivation inside 
chambers placed in the native environment (Ferrari et al., 2005; Bollmann et al., 
2007), the use of custom-designed media (Tripp et al., 2008), application of multi-
well micro culture chips (Ingham et al., 2007), high-throughput identification of 
isolates (Pfleiderer et al., 2013), and microfluidic cultivation (Ma et al., 2014).  
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Furthermore, a recent study by Rettedal and co-authors combined high-throughput 
sequencing with selective cultivation conditions, allowing to cultivate previously 
uncultured species from the human gut by a targeted approach (Rettedal et al., 
2014). To this end, the authors used, among other criteria, the “most wanted” list of 
microbial taxa that has recently been introduced in order to guide efforts towards 
the cultivation of human gut bacteria (Fodor et al., 2012).  
 
In short, the most wanted list contains human-associated bacterial taxa of which the 
genome has not yet been sequenced, not considering whether members of these taxa 
from other environments might already have been sequenced. High priority most 
wanted taxa were defined as those of which the 16S rRNA centroid read shared less 
than 90% identity with either the GOLD-Human or Human Microbiome Project 
(HMP) strains, and which were detected in at least 20% of samples from any body 
habitat analysed. Medium priority taxa are those that share between 90% and 98% 
identity with the same habitat prevalence threshold. 
 
Antibiotics are generally administered upon detection of an infection. In addition, in 
most Dutch hospitals, patients who are admitted to the intensive care unit (ICU) 
receive prophylactic antibiotic therapies, of which selective decontamination of the 
digestive tract (SDD) is currently the most common treatment. SDD combines the 
application of tobramycin, polymyxin E and amphotericin B in the oropharynx and 
gastrointestinal tract with a short systemic administration of a third-generation 
cephalosporin. This therapy aims to eradicate potential pathogens such as 
Staphylococcus aureus, Pseudomonas aeruginosa, Enterobacteriaceae and yeast, 
while maintaining the anaerobic members of the microbiota (de Smet et al., 2012).  
SDD therapy has been shown to decrease infections and mortality of ICU patients 
(de Jonge et al., 2003; de Smet et al., 2009). Although a meta-analysis showed that 
SDD therapy resulted in a decrease in resistance carriage with respect to cultivable 
bacteria (Daneman et al., 2013), a recent case study (Buelow et al., 2014) and a more 
extensive follow-up with 13 ICU patients (Buelow, 2015) indicated that prophylactic 
therapy may in fact increase resistance carriage among mostly uncultivated 
anaerobic gut residents.  
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It was speculated that the expanded resistome, i.e. the collection of all resistance 
genes in a bacterial community (Wright, 2007), might thereby increase the risk of 
future pathogens becoming resistant. Indeed, the risk that pathogens develop 
antibiotic resistance is a major concern that has prohibited wide implementation of 
prophylactic therapies (Daneman et al., 2013). In view of the above, it is clear that 
the role of uncultivated anaerobic bacteria in the emergence of resistance pathogens 
merits deeper investigation. 
 
In this study, we aimed to identify and isolate potential reservoir strains for 
antibiotic resistance in the anaerobic microbiota of the human gut. Therefore, faecal 
material from 20 Dutch ICU patients was inoculated on poor and rich agar media 
under anoxic conditions. These media were prepared without antibiotics, or 
supplemented with the antibiotics that the patients received as part of their SDD 
therapy. Bacteria were cultivated on the MicroDish porous aluminium oxide (PAO 
Chip) that facilitates efficient parallel processing of a large number of samples, and 
reduces potential inhibition of bacterial growth by agar (Ingham et al., 2007).  
 
Chips that were placed on top of different media solidified with agar were inoculated 
with faecal suspensions, and bacterial biomass was investigated by 16S ribosomal 
RNA (rRNA) gene amplicon sequencing, based on which growth patterns were 
analysed and target species were identified for cultivation up to pure culture. 
Accordingly, we isolated a close relative of Sellimonas intestinalis BR72T that grew 
on top of the PAO Chip on agar media containing tobramycin, cefotaxime and 
polymyxin E, and that could serve as an antibiotic resistance reservoir. 
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Materials and Methods 
 
Sample collection  
Faecal samples were collected from 20 patients no later than five days after 
admission to the ICU at Utrecht Medical Center, Utrecht, Netherlands. During this 
period, the patients received SDD therapy. The SDD protocol was reviewed and 
approved by the institutional review board of the University Medical Center Utrecht. 
Faecal samples were collected upon defecation and stored at 4°C for 30 min to 4 h, 
after which an aliquot of the sample (approximately 0.5 g) was suspended in 5 ml of 
anaerobic PBS (pH 7.0). Subsequently, 1 ml of the suspension was transferred to an 
anaerobic bottle containing 4 ml of PBS, 25% (v/v) glycerol, 0.5 g resazurin and 0.5 
g cysteine. To preserve anaerobic conditions, a few drops of titanium citrate (100 
mM) were added to the bottle before storage at -80°C.  
 
Cultivation conditions 
A high throughput cultivation technique using the MicroDish PAO Chip (MicroDish, 
Utrecht, Netherlands) was applied. Faecal bacteria were cultured on ethanol-
sterilized PAO Chip on top of two different media: (i) GIFU anaerobic agar media 
(GAM) (Hyserve, Uffing, Germany), and (ii) bicarbonate-buffered anaerobic media 
(referred to in the text as CP medium) (Stams et al., 1993) supplemented with 1.5% 
(w/v) agar and 1% (v/v) faecal supernatant. The faecal supernatant was prepared 
from a pool of faecal samples obtained from three healthy volunteers who had not 
received antibiotics for at least six months. In brief, equal amounts of faecal sample 
from the three volunteers were added to anaerobic PBS (pH 7.0) to a final 
concentration of 25 % (w/v). Subsequently, the mixture was centrifuged at 14,000 
rpm for 30 min, after which the supernatant was transferred to an anaerobic bottle 
(N2/CO2 – 80:20, v/v) and autoclaved. All samples were cultivated on agar media 
both in the presence and in the absence of the SDD cocktail of antibiotics (25 μg/ml 
tobramycin, 5 μg/ml polymyxin E and 10 μg/ml cefotaxime; the antifungal drug 
amphotericin B was not included in this study).  
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An aliquot (5 μl) of faecal suspension was applied per PAO Chip. Inocula consisted 
of undiluted and 100-fold diluted cryopreserved faecal suspension. In addition, 10-
fold sample dilutions were included for three patients (designated 210, 131 and 148) 
in order to study the effect of dilution on bacterial growth. PAO Chips on top of GAM 
agar and CP agar were harvested two and three days after inoculation under anoxic 
conditions at 37 oC, respectively. Upon harvesting, PAO Chips with bacterial growth 
were placed in an Eppendorf tube containing 1 ml of anaerobic PBS (pH 7.0). The 
tube was vortexed for 30 s to dissociate the cells from the PAO Chip.Subsequently, 
the suspension was split into two fractions; one fraction was used for DNA extraction 
whereas the other fraction was added to an anaerobic bottle containing glycerol (final 
concentration: 25-30%) in PBS, and stored at -80 oC. Biological duplicates were 
analysed for each growth community. 
 
DNA extraction and 16S rRNA gene amplicon sequencing 
Barcoded 16S rRNA gene amplicon sequencing was used to investigate the bacterial 
composition of faecal samples and of the growth communities on the PAO Chips. 
Primers used for 16S rRNA amplicon sequencing are described in Supplementary 
Table S1. The cells in these samples were lysed and (cellular) debris was removed 
with an adapted bead beating protocol (Salonen et al., 2010). In case of cryo-
preserved faecal material, 500 μl of sample was added to a screw-cap tube that 
already contained 0.5 g of 0.1 mm zirconium beads (Biospec Products, Bartlesville, 
United States) and three 5 mm glass beads (Biospec Products). Subsequently, 300 μl 
STAR buffer (Roche, Basel, Switzerland) was added, after which the contents of the 
tube were homogenized in the Precellys 24 (Bertin Technologies, Montigny-le-
Bretonneux, France) at 5.5 ms (3 rounds of 1 min). The sample was then incubated 
at 95 °C at 100 rpm for 15 min. Particles were spun down at 4 oC at >10,000 g for 5 
min, and subsequently the supernatant was transferred to a fresh tube for DNA 
extraction. The DNA yield was improved by another two iterations of beat-beating 
that started with re-suspending the pellet in 300 μl STAR buffer. In case of bacteria 
suspended in PBS (i.e. the growth communities), 150 μl of sample was processed by 
identical methods except at a smaller scale.  
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Therefore, 0.25 g of 0.1 mm zirconium beads and three 2.5 mm glass beads were 
added to the screw-cap tube, and STAR buffer was used in portions of 150 μl. 
Following the bead beating protocol, DNA was extracted from 250 μl of the combined 
supernatants using the Maxwell 16 Tissue LEV total RNA purification kit starting 
from the post lysis step (Promega, Madison, United States). 16S rRNA gene 
amplification, which also attached the barcodes, was done with a 2-step PCR 
protocol (Tian et al., 2016). The product from the second PCR step was analysed on 
a 1% agarose gel and purified using the CleanPCR Kit (GC Biotech, Alphen aan den 
Rijn, Netherlands) according to manufacturers’ instructions. The DNA 
concentration was measured by Qubit® 2.0 (Thermo Fisher Scientific). 
Subsequently the sample was included in a pool that in total contained 48 equimolar 
mixed samples. The pool of samples, which constituted a library, was sent for 
Illumina paired end MiSeq sequencing (2 x 300 bp) at GATC Biotech (Constance, 
Germany). In total, eight libraries were sent MiSeq for sequencing. Technical 
replicates at the level of 16S rRNA amplicon sequencing were analysed for the 
original faecal samples. 
 
Processing of 16S rRNA gene amplicon data, statistical analyses and 
detection of most wanted and novel species 
The 16S rRNA gene amplicon data were analysed using the NG-tax pipeline (Ramiro-
Garcia et al., 2016). In short, NG-tax initially defines operational taxonomic units 
(OTUs) as clusters of 16S RNA gene amplicons that share 100% nucleotide identity. 
Subsequently, the OTUs are expanded by including 16S RNA gene amplicons with 
one nucleotide mismatch. OTUs at <0.1% relative abundance are discarded.  
 
The quality of the sequencing was analysed by including a mock community sample 
in each library (Supplementary Table S2). The output OTU table and centroid 
OTU sequences were used as input for detection of most wanted (Fodor et al., 2012) 
and novel species. For statistical analysis we used a rarefied OTU table with 2,500 
reads per sample, where samples with <2,500 reads were excluded.  
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Pearson correlation coefficients between bacterial communities in inocula (i.e. faecal 
material of ICU patients) and their respective growth communities were calculated 
based on OTU-level data using IBM SPSS statistics 23.0.0.2. Shannon diversity, 
richness and phylogenetic diversity whole tree metrics of bacterial communities were 
calculated using QIIME (Caporaso et al., 2010). The two-tailed t-test without 
assuming equal variance was used to investigate if Shannon, richness and whole-tree 
phylogenetic diversity values of bacterial communities differed significantly when 
grouped according to experimental variables (e.g. growth medium or 
supplementation of the medium with antibiotics). The t-test used averaged values 
for biological and technical replicates.  
 
The QIIME script compare_taxa_summaries.py was used to calculate Pearson 
correlation coefficients of OTU-level taxa between mock communities and their 
theoretical composition. Canonical Correspondence Analysis (CCA) as implemented 
in Canoco 5 (Smilauer et al., 2014) was used to investigate, which variables could 
best explain the variation in bacterial composition between bacterial communities. 
Linear mixed-effect models were fitted by the R package “lmerTest” 
(https://CRAN.R-project.org/package=lmerTest) (R development core team, 2010) 
in order to analyse how media type and addition of antibiotics affected bacterial 
composition. As input an adapted OTU table was used in which values were log1p 
transformed to meet normality assumptions. 
 
Furthermore, OTUs were removed from the table if they were detected in <5 samples 
or by <50 reads across all samples. Parameter-specific p-values were obtained by 
using the Satterthwaite approximation. P-values were corrected for multiple testing 
by the function p-.adjust in the package “stats”, using methods “Bonferroni” and 
“BH”. Bray-Curtis dissimilarity hierarchical clustering was performed using R 
package ‘Vegan’ based on OTU-level relative abundance data of bacterial 
communities.  
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In order to investigate the presence of most wanted taxa (Fodor et al., 2012) and 
novel species, the representative reads of the OTUs were compared by Blastn 
(Altschul et al., 1990) to the V1-V3 sequence data of the most wanted OTUs, and to 
the 16S rRNA genes in the SILVA database of type strains (Quast et al., 2013), 
respectively. A custom Perl script was used to parse the BLAST results for the best 
hits (bitscore sorted). Furthermore, the script tabulated the relative abundance of 
the OTUs and their distribution across all samples. 
 
Targeted cultivation 
Based on analysis of the 16S rRNA gene sequence data of the bacterial growth 
communities, OTUs were selected for targeted isolation. Therefore, the original 
faecal inoculum and the enriched growth fractions that contained the target OTU 
were re-plated under identical conditions, i.e. on PAO Chips placed on the same 
media. A dilution series was inoculated to yield single colonies. Per PAO Chip, three 
colonies per unique colony morphology were transferred to a fresh PAO Chips. 
Subsequently, the 16S rRNA gene was amplified using the 27F and 1492R primers 
(Jiang et al., 2006), and the PCR products were Sanger sequenced at GATC Biotech 
(Cologne, Germany) using the 907R primer (Schauer et al., 2000). The 16S rRNA 
gene sequences were compared by BLASTn to those in the NCBI ribosomal 16S RNA 
sequences database for species identification. Only for target species the near full-
length 16S rRNA gene was then Sanger sequenced using the 27F and 1492R primers.  
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Results 
 
Bacterial growth on PAO Chips 
As inoculum, faecal samples were used from 20 patients that at the time of sampling 
had received SDD treatment for no longer than five days. Three 10-fold serial 
dilutions of the samples, starting at undiluted, were inoculated in duplicate on PAO 
Chips on top of GAM and CP agar media, either with or without supplementation of 
the SDD antibiotic cocktail. Agar media inoculated at the lowest dilution of faecal 
material and in absence of antibiotics always yielded confluent growth on GAM 
media, whereas on CP media confluent growth was observed on 34 of 40 PAO Chips 
(Supplementary Table S3). In general, less biomass grew on media if the faecal 
material was inoculated at a higher dilution, if the media contained the SDD cocktail 
of antibiotics, and if the faecal material was inoculated on CP media. Growth on most 
PAO Chips (371 of 480) was confluent as opposed to colonies that could be visually 
distinguished (Figure 1A).  
 
                       
 
Figure 1A. Close-up pothograph of microbial growth on a PAO Chip that was placed on top of CP agar. 
The PAO Chip was inoculated with 10X diluted cryo-preserved faecal sample from patient 188. The area 
that was inoculated is visualized as a smear in which individual colonies can be distinguished. The white 
dots in the picture represent air bubbles in the agar medium.  
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Faecal inocula (in duplicate) and a selection of PAO Chips with bacterial growth, 
including chips inoculated with undiluted and 100-fold diluted faecal suspensions, 
as well as with 10-fold diluted suspensions for three samples, were analysed by 16S 
rRNA gene amplicon sequencing, which amounted to a total of 324 samples. The 
NG-tax pipeline was used to process the sequencing data of our samples as well as 
mock communities with known composition that were added to each library 
(Ramiro-Garcia et al., 2016). The average Pearson correlation value of OTU-level 
taxa between the included mock communities and their theoretical composition was 
0.82 (min-max 0.77-0.88), supporting the reliability of the applied approach (data 
not shown). Samples with 0 reads (n=4) assigned were removed from all further 
analysis yielding 319 samples with an average read depth of 40,999 ± 49,592 reads 
(Supplementary Table S4), and 3,832 assigned OTUs. 
 
Comparison of bacterial growth communities 
 
Bacterial diversity 
Averaged across all faecal samples, the most abundant bacterial phyla were 
Firmicutes (61.0% ± 24.0), Bacteroidetes (34.0% ± 25.0), Proteobacteria (2.6% ± 
6.4), Actinobacteria (1.6% ± 5.0) and Verrucomicrobia (0.5% ± 1.2) (Figure 2A). 
The corresponding growth communities on GAM and CP media were dominated by 
Firmicutes and Bacteroidetes, together comprising on average >80% of the bacterial 
community. On GAM agar without antibiotics the relative abundance of 
Proteobacteria on average constituted 5.1% ± 17.0 of the communities whereas on 
GAM agar with the SDD cocktail (GAM-SDD), was 0.03% ± 0.1. Similarly, on CP-
SDD media the Proteobacteria had reduced relative abundance (a decrease from 
13.6% ± 27.7 to 9.8% ± 2.9) as compared to CP media without antibiotics. Notably, 
Cyanobacteria were not detected in the faecal samples or on GAM media, but they 
were detected on CP media averaging 0.5% ± 6.4 relative abundance.  
 
 
 
Cultivation-based screening of human gut bacteria on microdish 
 
227 
 
As expected, the average Shannon diversity of faecal samples was significantly higher 
than that of growth communities grouped by medium, addition of antibiotics or 
dilution (two-tailed t-test, p = <0.01 for all comparisons) (Figure 2B). Lower 
Shannon diversity values were also observed in growth communities inoculated with 
more diluted faecal sample. However, this difference was only significant between 
communities on CP-SDD agar that were inoculated with undiluted and 100-fold 
diluted faecal sample (two-tailed t-test, p = 0.01). The addition of the SDD antibiotics 
significantly reduced the Shannon diversity on GAM media (p = <0.01) but not on 
CP media.  
 
 
Figure 2. A) Bacterial phyla that were detected in the faecal samples of 20 intensive care patients and in 
their corresponding growth communities on GAM and CP agar media. Growth on these media was further 
subdivided based on the addition of the SDD antibiotics. Phyla with a relative abundance <0.5% are not 
shown. The relative abundance values are based on the combined reads of all samples in the different 
experimental groups. B) Boxplots depicting the distribution of Shannon diversity values of bacterial 
communities in the different experimental groups. Asterisks indicate that Shannon values of bacterial 
communities in experimental groups were significantly different (p = <0.05) based on the two-tailed t-
test. Medium (i.e. GAM vs. CP) did not significantly affect Shannon values of bacterial growth 
communities. Shannon values of faecal samples were in all cases higher than those for growth 
communities, irrespective of medium, dilution and addition of antibiotics (p = <0.01 for all comparisons). 
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Differences in OTU richness and whole-tree phylogenetic diversity between the 
sample groups followed the same trends as differences in Shannon diversity i.e. 
higher values were obtained for faecal samples and lower values were obtained if 
media were inoculated with more diluted faecal material or included antibiotics 
(Figure S1). However, surprisingly, a higher dilution of the faecal inoculum did not 
affect whole-tree phylogenetic diversity on CP media without antibiotics (p = 0.81). 
Canonical correspondence analysis (CCA) of OTU-level data from all bacterial 
communities (faecal inoculates and cultivable fractions) indicated that cultivation 
medium and presence/absence of antibiotics could explain in total 3.7% of the 
variation in bacterial composition (p = 0.002) (Figure 3). However, bacterial 
growth on CP agar was not found to be significantly affected by the addition of the 
SDD cocktail of antibiotics. The dilution factor of faecal inocula was also evaluated 
as explanatory variable but was found to not affect bacterial composition. 
                        
Figure 3. Canonical correspondence analysis (CCA) of OTU-level data was used to investigate to what 
extent growth conditions can explain the variation in the composition of bacterial communities. Included 
in the analyses were the faecal samples (inocula) as well as their corresponding growth communities on 
GAM agar and CP agar. Growth on agar media was further distinguished based on the addition of the SDD 
antibiotics. 
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 Inter-individual differences in communities 
While bacterial communities grouped by experimental variables (i.e. medium or 
addition of antibiotics) showed significant differences, we were also interested in 
potential differences between patients. Hierarchical clustering of OTU-level data 
using Bray-Curtis dissimilarity indicated high dissimilarity between individual faecal 
samples with mutual dissimilarity values being >0.8 in all but two cases (Figure 4).  
 
 
 
 
Figure. 4. Hierarchical clustering using Bray-Curtis dissimilarity based on 16S rRNA gene amplicons 
generated from faecal samples of intensive care unit patients and corresponding biomass retrieved from 
PAO chips on GAM and CP agar. Growth on these media was further distinguished based on the addition 
of the SDD antibiotics. Hierarchical clustering was performed at the OTU-level. The heatmap corresponds 
to relative abundance values of class-level phylogenetic groups. The dissimilarity tree shows that bacterial 
dissimilarity between faecal samples is high. 
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Growth communities derived from only 9 of 20 patients all clustered together 
indicating that other factors besides inoculum influenced bacterial growth. For 
example, growth communities of patient 131 all clustered together with mutual 
dissimilarity values <0.25 whereas for growth communities of patient 236 
dissimilarity values exceeded 0.8. Moderate clustering by medium and 
presence/absence of antibiotics confirmed that cultivation conditions affected 
growth as was shown before by CCA. We also evaluated by Pearson correlation to 
what extent bacterial growth communities resembled the faecal samples from which 
they were derived (Figure S2).  
 
For different individuals the average Pearson correlations ranged from 0.02 to 0.99, 
indicating that there were large inter-individual differences in bacterial cultivability. 
No trends were discovered between the applied medium, antibiotics and/or dilution 
of faecal inoculum, and how well the growth communities resembled the faecal 
samples. 
 
Effects of media composition and antibiotics on bacterial growth 
In the following, we aimed to identify OTUs that were enriched as a result of specific 
cultivation conditions. We fitted linear mixed-effect models on OTU-level data so 
that also differences between individual patients could be taken into account 
(Supplementary Table S5). A total of 35 OTUs were significantly enriched under 
the different cultivation conditions (Table 1). Considering Bonferroni-corrected p-
values, a total of seven OTUs belonging to the families Bacteroidaceae (5 OTUs), 
Staphylococcaceae (1 OTU) and Enterococcaceae (1 OTU) were present in 
significantly higher abundance on GAM media as compared to the respective faecal 
samples. In contrast, on CP media, OTUs belonging to the families Halomonadaceae 
(2 OTUs), Lachnospiraceae (6 OTUs), Ruminococcaceae (1 OTU), Streptococcaceae 
(1 OTU), Enterococcaceae (3 OTUs), Porphyromonadaceae (2 OTUs), and 
Oxalobacteraceae (1 OTU) were enriched.  
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A significantly lower abundance of Ruminococcaceae spp (1 OTU), 
Enterobacteriaceae spp (6 OTUs) and Lachnospiraceae spp. (4 OTUs) was detected 
on media supplemented with the SDD antibiotics in comparison to media without 
antibiotics, indicating that the antibiotics inhibited the growth of these bacteria. 
 
Table 1. Linear mixed-effect models of OTU-level composition data of bacterial growth were applied to 
investigate which OTUs varied in abundance as a results of cultivation conditions. This table lists the 
taxonomic affiliations of OTUs that were found to be enriched at Bonferroni corrected p-values of <0.05. 
Bacterial communities were cultivated on GAM agar and CP agar, both in the presence and absence of the 
SDD antibiotics. 
 
  
Taxonomy 
 
Enriched on 
No. of 
OTUs Family Genus 
GAM agar 5 Bacteroidaceae Bacteroides 
1 Staphylococcaceae Staphylococcus 
1 Enterococcaceae Enterococcus 
CP agar 2 Halomonadaceae Halomonas 
6 Lachnospiraceae Unspecified 
1 Ruminococcaceae Unspecified 
1 Streptococcaceae Streptococcus 
3 Enterococcaceae Enterococcus 
2 Porphyromonadaceae Parabacteroides 
1 Oxalobacteraceae Undibacterium 
Media (CP and GAM) without antibiotics 1 Ruminococcaceae Unspecified 
6 Enterobacteriaceae 
Escherichia-
Shigella 
4 Lachnospiraceae Unspecified 
CP agar without SDD cocktail of antibiotics 1 Ruminococcaceae Unspecified 
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Growth of novel species 
We further aimed to investigate whether novel species or members of taxa on the 
most wanted list were present in the cultivable fraction of the faecal samples. Eleven 
high priority most wanted OTUs were detected in the growth communities; however, 
none of these OTUs was present at a relative abundance of >0.8% (Supplementary 
Table S6). Furthermore, three medium priorities most wanted OTUs (OTUs 236, 
172 and 288) were detected in the cultivable fraction with 1-3% relative abundance. 
Nevertheless, members of medium priority OTUs were not considered candidates 
for isolation because they shared 100% identity with strains that were previously 
isolated. Comparison of OTUs with the SILVA database of type strains yielded 16 
OTUs with >2% relative abundance of which the OTU representative read shared 
<95% identity with the 16S rRNA gene sequence of the closest type strain (Table 2).  
 
Table 2. Faecal samples of 20 patients were inoculated on PAO chips on top of GAM and CP agar media, 
and growth was analysed by 16S rRNA gene amplicon sequencing. This table shows OTUs of which the 
representative read shares <95% identity with the closest 16S rRNA gene sequence in the SILVA database 
of type strains. In addition, the relative abundance of these OTUs was ≥2% on at least one PAO chip. 
 
OTU 
ID 
No. 
samples 
GAM/ 
CP 
medium 
SDD/ 
NAB 
Highest 
rel.ab. 
(%) 
Detected 
in 
inoculum? 
Closest type 
 strain 
Acc. 
number 
% 
identity 
3088 30 GAM/CP SDD/NAB 49.8 yes/no Ruminococcus torques L76604 93.4 
322 15 CP NAB 23.9 yes/no 
Hydrogenoanaerobacterium 
saccharovorans EU158190 89.3 
3797 2 CP NAB 13.2 no 
Thalassiosira pseudonana 
(chloroplast) EF067921 85.9 
2642 4 GAM NAB 7.4 yes Bacteroides ovatus EU136682 94.7 
2024 2 CP SDD 5.6 yes Oscillibacter ruminantium JF750939 91.1 
2026 3 CP SDD 5.5 yes Oscillibacter ruminantium JF750939 91.1 
2082 1 GAM SDD 3.9 no Coprobacter fastidiosus JN703378 94.7 
2724 1 GAM SDD 3.8 no Bacteroides faecis GQ496624 96.7 
2985 2 CP NAB 3.6 no Clostridium clostridioforme M59089 96 
3067 4 GAM NAB 3.0 yes Ruminococcus torques L76604 93 
3103 4 GAM NAB 2.8 yes Ruminococcus torques L76604 93 
2252 3 GAM SDD/NAB 2.6 no Bacteroides nordii EU136693 95 
3375 2 GAM NAB 2.2 yes Coprococcus comes EF031542 97 
2884 2 GAM NAB 2.2 no Clostridium bolteae AJ508452 96 
3070 5 GAM NAB 2.2 yes/no Ruminococcus torques L76604 93 
2893 2 GAM NAB 2.0 no Clostridium bolteae AJ508452 96 
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Therefore, these OTUs were considered to i) potentially represent novel species, and 
ii) to be sufficiently abundant for isolation by colony picking. Among these 16 OTUs, 
OTUs 3088, 322, 3797, 2642 and 2024 were considered prime candidates for 
targeted isolation based on their relative abundance on the PAO Chips (>5%) and 
novelty. OTU3088 shared 93.4% identity with the closest type strain, that is, 
Ruminococcus torques, and was present on GAM-SDD agar at 49.8% relative 
abundance (Supplementary Table S6). OTU3088 was also detected on GAM, CP 
and CP-SDD agar media, albeit at a lower relative abundance. We detected three 
additional OTUs (OTUs 3067, 3103 and 3070) at >2% relative abundance of which 
the closest type strain was also Ruminococcus torques. Since these three OTUs were 
always detected in samples that contained OTU3088, and since their representative 
reads shared high nucleotide identity with OTU3088 (>99%), we considered that 
they may be derived from the same bacterial strains.  
 
The best hits in the SILVA type strain database of strains OTU322 and OTU3797 
were Hydrogenoanaerobacterium saccharovorans and the chloroplast of the 
diatom Thalassiosira pseudonana, respectively, and both were detected at >10% 
relative abundance (OTU322, max. 23.9%; OTU3797, max. 13.2%). Both OTU322 
and OTU3797 were only detected at >1% relative abundance on CP agar media in the 
absence of the SDD antibiotics. The representative read of OTU2642 shared 94.7% 
nucleotide identity with the 16S rRNA gene of Bacteroides ovatus. OTU2642 was 
only detected on GAM media at a maximum of 7.4% relative abundance. Finally, the 
closest type strain of OTU2024 was Oscillibacter ruminantium, and it was detected 
at >1% relative abundance exclusively on CP-SDD media. 
 
Targeted cultivation 
To provide proof of concept, we aimed to isolate strains corresponding to OTUs 3088 
and 2024 as they were considered prime candidates for isolation based on novelty. 
Furthermore, the fact that these OTUs grew on media containing the SDD antibiotics 
suggested they may be antibiotic resistance reservoir species.  
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We prepared dilution series of the growth fractions in which these OTUs were most 
enriched and subsequently inoculated the diluted samples under the exact 
conditions that previously yielded enrichment of the target OTUs. This experiment, 
however, did not yield isolation of the target OTUs. Therefore, the protocol was 
repeated using the original faecal samples as inocula instead of the enriched growth 
fractions. By this method we isolated a member of OTU3088, which was 
demonstrated by the fact that the representative read of OTU3088 shared 100% 
identity with the 16S rRNA gene Sanger read of our isolate (Figure 1B).  
 
BLASTn of the 16S rRNA gene read of the isolate against the NCBI ribosomal 16S 
RNA sequences database showed that closely related strains (98-99% nucleotide 
identity) have recently been isolated in four other laboratories. One closely related 
strain that was isolated from human faeces was recently published as a novel species 
named Sellimonas intestinalis BR72T (Seo et al., 2015). 
 
 
               
Figure 1B. A light microscopy picture of the strain corresponding to OTU3088 that was isolated by a 
targeted approach. The strain shares 99% 16S rRNA gene identity with Sellimonas intestinalis BR72T 
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Discussion 
In this investigation, we studied the cultivability of anaerobic human faecal bacteria 
in order to isolate strains that can serve as reservoirs of antibiotic resistance. 
Therefore, bacterial growth communities on GAM and CP agar media derived from 
faeces of 20 ICU patients receiving SDD therapy were studied. We applied the 
MicroDish PAO Chip to reduce potential toxicity of agar and to facilitate efficient 
parallel processing of a large number of samples. We also applied media 
supplemented with the SDD antibiotics that the patients received upon arrival on the 
ICU. 
 
A first selection of bacteria was made by comparing the cultivated species with the 
strains on the most wanted list that comprises human-associated bacteria of which 
the genome has not yet been sequenced and that are grouped into priority classes 
based on novelty (Fodor et al., 2012). We did not detect high priority taxa at >1% 
relative abundance in the growth communities. Medium priority taxa were detected 
at 1-3% relative abundance but they shared 100% 16S rRNA gene sequence identity 
with strains for which the genome has been already sequenced. Therefore, due to the 
low relative abundance and/or high similarity to previously genome-sequenced 
bacteria, the detected medium and high priority taxa were not further considered 
prime candidates for isolation. However, comparison of the OTU centroid reads with 
the strains in the SILVA type strain database yielded 16 OTUs with <95% nucleotide 
identity and >2% relative abundance. 
 
Based on their novelty, members of these OTUs were considered candidates for 
isolation. Although their prevalence in the gut microbiota is expected to be <20%, 
i.e. they are not on the most wanted list, understanding the biology of such 
populations might be highly relevant in a more personalized approach, where 
individual-specific microbiota signatures are considered key to success (Raes, 2016). 
Our results show that novel human-associated bacteria can still be cultivated using 
conventional methods.  
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The extent to which novel bacteria can still be isolated by conventional methods was 
shown recently by Browne and co-authors in an experiment in which they isolated 
~4,000 pure culture bacterial strains from faeces of six human individuals. The 
authors found that these isolates comprised as much as 96% of the bacterial 
abundance at the genus level and 90% of the bacterial abundance at the species level 
based on average relative abundance across faecal samples of six individuals 
(Browne et al., 2016). 
 
Almost all of the 16 OTUs detected in the growth communities represented novel 
species belonged to the Firmicutes (11 OTUs) and Bacteroidetes (4 OTUs), and these 
phyla were also detected in highest relative abundance in the faecal samples. 
Notably, a single OTU was detected on CP agar at a maximum relative abundance of 
13.2% that shared 85.9% nucleotide identity with the best hit in the SILVA type strain 
database, namely the chloroplast of Thalassiosira pseudonana.  
 
Chloroplasts are thought to have originated from cyanobacteria (Falcon et al., 2010), 
and this finding might suggest the growth of a eukaryote capable of photosynthesis. 
OTU3088, which is a novel OTU belonging to the Firmicutes, was detected in 
samples of nine different patients. Furthermore, on one PAO Chip OTU3088 was 
detected in the presence of the SDD antibiotics at a relative abundance of 49.8%. 
Therefore, it was selected for isolation, which was achieved on GAM-SDD media 
(Figure 1B). After isolation, the 16S rRNA gene of the isolate turned out to share 
99% nucleotide identity with the recently published Sellimonas intestinalis (Seo et 
al., 2015), and high identity (98-99%) with three other strains recently isolated from 
human gut microbiota (accessions KT156811, LN828944 and AY960564).  
 
Therefore, even though a close relative of our isolate has been recently described, 
these results demonstrate that high-throughput cultivation-based screening can be 
used to isolate novel antibiotic resistant bacteria by a targeted approach. The strain 
in question is a candidate to be further analysed as resistance reservoir (e.g. by 
genome sequencing).  
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Besides OTU3088, five other novel OTUs were found to grow in the presence of the 
SDD antibiotic cocktail, and as such are additional candidates for isolation and 
characterization (Table 2). However, it should be noted that antibiotics may be 
broken down by adjacent bacteria, and that therefore these bacteria may themselves 
be not resistant. For example, cefotaxime may be degraded through the secretion of 
a β-lactamase (Deak et al., 1998; Buchschmidt et al., 1992). Bacterial isolation in 
general can also be hampered by the dependence on microbe-microbe interactions 
or host-microbe interactions (Pham et al., 2012). Out of the 16 novel OTUs detected 
on agar media, only OTU (OTU3088) was detected on both GAM and CP media at 
>2% relative abundance. This indicates that the number of target species for 
isolation might be increased by including different media.  
 
We also investigated bacterial growth not pertinent to the isolation of novel species. 
We showed that the composition of bacterial growth communities was significantly 
impacted by medium and by supplementation of media with antibiotics (Figure 3). 
The cocktail used in SDD therapy contains antibiotics that are predominantly active 
against Gram-negative bacteria and fungi (Al Naiemi et al., 2006), and was designed 
in order to eradicate potentially pathogenic bacteria from the gut without harming 
the anaerobic microbiota (de Smet et al., 2012; Buelow, 2015). Indeed, we found that 
six OTUs belonging to the genus Escherichia, one of the SDD-target taxa, grew in 
significantly lower relative abundance on media containing the SDD cocktail. 
However, we also found that five OTUs belonging to the families Ruminococcaceae 
and Lachnospiraceae grew to a significantly lower relative abundance in the 
presence of the SDD antibiotics.  
 
Members from these families are Gram-positive and lack aerobic respiration (Wolf 
et al., 2004), and are therefore collaterally affected by the application of the SDD 
antibiotics that aim to lower the risk of infection with Gram-negative aerobic 
opportunistic pathogens (17).  
 
 
Chapter 8 
 
238 
 
Remarkably, we found that the correlation of bacterial composition of the faecal 
communities and the growth communities varied extensively between patients. We 
cannot exclude that this may have resulted from differences in viability of cryo-
preserved faecal samples, but it might also be related with the individual-specific 
composition of the gut microbiota. 
 
In conclusion, we have shown that high-throughput screening of growth 
communities for bacterial resistance can guide targeted isolation of potential 
reservoir species. The fact that a member of one novel antibiotic-resistant OTU 
(OTU3088) was successfully isolated demonstrates the viability of the approach. 
Follow-up isolation and characterization will be required to analyse the role of 
previously uncultivated species in the dissemination of resistance genes in the gut 
microbiota, including the transfer to potential pathogens. 
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Supplementary data 
 
Supplementary Table S5. Linear mixed-effect models of OTU-level composition data of bacterial 
growth were applied to investigate which OTUs varied in abundance as a results of cultivation conditions. 
This table lists the taxonomic affiliations of OTUs that were found to be enriched at FDR-corrected p-
values of >0.05. Bacterial communities were cultivated on GAM agar and CP agar, both in the presence 
and absence of the SDD cocktail of antibiotics. 
 
Supplementary table S6. Faecal samples of 20 patients were inoculated on PAO chips in duplo. The 
bacterial growth communities were analysed by 16S rRNA gene amplicon. 
 
Data available: http://fungen.wur.nl/supplementary-information_bello-gonzalez/ 
 
 
Supplementary Table S1. Primers that were used for 16S rRNA gene amplicon sequencing. 
 
Primers 
PCR  
step 1  
(5' → 3') 
Primer Name Barcode Unitag Degenerated primer 
Unitag1-27F-DegS   GAGCCGTAGCCAGTCTGC GTTYGATYMTGGCTCAG 
Unitag2-338R-I   GCCGTGACCGTGACATCG GCWGCCTCCCGTAGGAGT 
Unitag2-338R-II   GCCGTGACCGTGACATCG GCWGCCACCCGTAGGTGT 
Primers 
PCR  
step 2 
 (5' → 
3') 
Miseq-
46_TGCCTCTC_Unitag1 TGCCTCTC GAGCCGTAGCCAGTCTGC   
Miseq-
46_TGCCTCTC_Unitag2 TGCCTCTC GCCGTGACCGTGACATCG   
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Supplementary Table S2. A mock community was included in every library that was sent for 16S 
rRNAgene amplicon sequencing. This table shows the OTU-level phyla that were presentin the mock 
community. 
  
#OTU taxonomic affiliation 
Relative 
abundance 
k__Bacteria;p__Actinobacteria;c__Actinobacteria;o__Bifidobacteriales;f__Bifidobacteriaceae;g__Bifidobacterium 0.025913966 
k__Bacteria;p__Actinobacteria;c__Actinobacteria;o__Corynebacteriales;f__Nocardiaceae;g__Rhodococcus 0.996691 
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Bacteroidaceae;g__Bacteroides 0.149503648 
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Bacteroidaceae;g__g 0 
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Porphyromonadaceae;g__Parabacteroides 0 
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Porphyromonadaceae;g__g 0 
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Prevotellaceae;g__Prevotella 0.000996691 
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Rikenellaceae;g__Alistipes 9.96691 
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Rikenellaceae;g__g 0 
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__f;g__g 0 
k__Bacteria;p__Firmicutes;c__Bacilli;o__Bacillales;f__Bacillaceae;g__Bacillus 0.049834549 
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Carnobacteriaceae;g__Granulicatella 0.024917275 
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Enterococcaceae;g__Enterococcus 0.024917275 
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Lactobacillaceae;g__Lactobacillus 0.074751824 
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Streptococcaceae;g__Lactococcus 0.024917275 
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Streptococcaceae;g__Streptococcus 0.049834549 
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Clostridiaceae;g__Clostridium 0.024917275 
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Lachnospiraceae;g__Anaerostipes 0.024917275 
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Lachnospiraceae;g__Blautia 0.996691 
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Lachnospiraceae;g__Incertae_Sedis 0.074851493 
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Lachnospiraceae;g__Pseudobutyrivibrio 0.024917275 
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Peptostreptococcaceae;g__Incertae_Sedis 0.024917275 
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Ruminococcaceae;g__Faecalibacterium 0.000996691 
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Ruminococcaceae;g__Incertae_Sedis 0.024917275 
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Veillonellaceae;g__Veillonella 0.024917275 
k__Bacteria;p__Fusobacteria;c__Fusobacteria;o__Fusobacteriales;f__Fusobacteriaceae;g__Fusobacterium 0.024917275 
k__Bacteria;p__Fusobacteria;c__Fusobacteria;o__Fusobacteriales;f__f;g__g 0 
k__Bacteria;p__Lentisphaerae;c__Lentisphaeria;o__Victivallales;f__Victivallaceae;g__Victivallis 0.024917275 
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Enterobacteriales;f__Enterobacteriaceae;g__Citrobacter 0 
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Enterobacteriales;f__Enterobacteriaceae;g__Enterobacter 0.049834549 
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Enterobacteriales;f__Enterobacteriaceae;g__Escherichia-
Shigella 0.049834549 
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Enterobacteriales;f__Enterobacteriaceae;g__Serratia 0.024917275 
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Enterobacteriales;f__Enterobacteriaceae;g__g 0.049834549 
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Enterobacteriales;f__f;g__g 0 
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Pseudomonadales;f__Pseudomonadaceae;g__Pseudomonas 0.049834549 
k__Bacteria;p__Verrucomicrobia;c__Verrucomicrobiae;o__Verrucomicrobiales;f__Verrucomicrobiaceae;g__Akkermansia 0.024917275 
k__Bacteria;p__Actinobacteria;c__Actinobacteria;o__Micrococcales;f__Micrococcaceae;g__Micrococcus 9.96691 
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Lachnospiraceae;g__Dorea 0.024917275 
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Enterobacteriales;f__Enterobacteriaceae;g__Klebsiella 0.024917275 
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Supplementary Table S3. Faecal samples of 20 patients were inoculated on PAO chips in duplo. This 
table gives information about the growth observed on each chip at the time that the growth communities 
were harvested. Communities on GAM agar were harvested after 48 h and those on CP agar after 72 h. C 
stands for confluent growth. 
 
 
GAM GAM + SDD
Sample ID 10-0 10-1 10-2 Sample ID 10-0 10-1 10-2
241 (1) c c c 241 (1) c c c
241 (2) c c c 241 (2) c c c
188 (1) c c c 188 (1) c c 16
188 (2) c c c 188 (2) c c 12
202 (1) c c 17 202 (1) 33 3 -
202 (2) c c 10 202 (2) 8 3 -
145 (1) c c c 145 (1) c c 34
145 (2) c c c 145 (2) c c 40
256 (1) c c c 256 (1) c 1 -
256 (2) c c c 256 (2) c - -
238 (1) c c c 238 (1) c c c
238 (2) c c c 238 (2) c c c
239 (1) c c c 239 (1) c c c
239 (2) c c c 239 (2) c c c
142 (1) c c c 142 (1) c c 6
142 (2) c c c 142 (2) c 35 3
201 (1) c c c 201 (1) c c c
201 (2) c c c 201 (2) c c c
288 (1) c c c 288 (1) c c c
288 (2) c c c 288 (2) c c c
213 (1) c c c 213 (1) c c c
213 (2) c c c 213 (2) c c c
160 (1) c c c 160 (1) 42 1 -
160 (2) c c c 160 (2) 55 - -
210 (1) c c c 210 (1) c c c
210 (2) c c c 210 (2) c c c
131 (1) c c c 131 (1) c c c
131 (2) c c c 131 (2) c c c
148 (1) c c c 148 (1) c c c
148 (2) c c c 148 (2) c c c
172 (1) c c c 172 (1) c c c
172 (2) c c c 172 (2) c c c
209 (1) c c c 209 (1) - - -
209 (2) c c c 209 (2) - - -
198 (1) c ~110 20 198 (1) 5 1 -
198 (2) c ~120 27 198 (2) 12 - -
236 (1) c c c 236 (1) c c c
236 (2) c c c 236 (2) c c c
266 (1) c c c 266 (1) c ~140 41
266 (2) c c c 266 (2) c ~110 52
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CP CP + SDD
Sample ID 10-0 10-1 10-2 Sample ID 10-0 10-1 10-2
241 (1) c c c 241 (1) c c c
241 (2) c c c 241 (2) c c c
188 (1) c c 50 188 (1) c c 10
188 (2) c c 50 188 (2) c c 10
202 (1) - 30 2 202 (1) - 8 -
202 (2) - 30 2 202 (2) - 8 -
145 (1) c c 58 145 (1) c c 40
145 (2) c c 58 145 (2) c c 40
256 (1) - - - 256 (1) - - -
256 (2) - - - 256 (2) - - -
238 (1) c c c 238 (1) c c c
238 (2) c c c 238 (2) c c c
239 (1) c c c 239 (1) c c c
239 (2) c c c 239 (2) c c c
142 (1) c c c 142 (1) c c c
142 (2) c c c 142 (2) c c c
201 (1) c c c 201 (1) c c c
201 (2) c c c 201 (2) c c c
288 (1) c c c 288 (1) c c c
288 (2) c c c 288 (2) c c c
213 (1) - - - 213 (1) - - -
213 (2) - - - 213 (2) - - -
160 (1) c c c 160 (1) c 4 -
160 (2) c c c 160 (2) c 4 -
210 (1) c c c 210 (1) c c c
210 (2) c c c 210 (2) c c c
131 (1) c c c 131 (1) c c c
131 (2) c c c 131 (2) c c c
148 (1) c c c 148 (1) c c c
148 (2) c c c 148 (2) c c c
172 (1) c c c 172 (1) c c c
172 (2) c c c 172 (2) c c c
209 (1) c 4 - 209 (1) c 2 -
209 (2) c 4 - 209 (2) c 2 -
198 (1) c c 58 198 (1) c c 2
198 (2) c c 58 198 (2) c c 2
236 (1) c c c 236 (1) c c c
236 (2) c c c 236 (2) c c c
266 (1) c c c 266 (1) c 2 -
266 (2) c c c 266 (2) c 2 -
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Supplementary Table S4. Faecal samples of 20 patients were inoculated on PAO chips on top of agar 
media in duplo. This table gives information about the number of reads that were obtained for each 
sample by 16S rRNA gene amplicon sequencing (MiSEQ).  Communities on GAM agar were harvested 
after 48 h and those on CP agar after 72 h. 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Faecal samples Sample ID 10-0 10-1 10-2 10-0 10-1 10-2 10-0 10-1 10-2 10-0 10-1 10-2
2 241 (1) 12075 34574 14019 51838 8920 2012 22929
(54813, 14032) 241 (2) 222887 63202 114244 41963 15668 15377 2617
2 188 (1) 16486 3819 9616 3905 27528 980 159914 17067 4412 24330
(95917, 237616) 188 (2) 19136 6996 2831 9355 14529 7742 60259 14121 9225 11636
2 202 (1) 1387 8723 15794 30244
(1272, 56304) 202 (2) 13225 4195 1821 11016
1 145 (1) 47949 12446 32533 29082 77004 55035 6088 14799 2697
(2678) 145 (2) 132419 56373 45249 25892 25948 6464 1079 2314 7897
256 (1) 25098 46535 205207
256 (2) 10994 48081 12837
2 238 (1) 21396 62244 19894 90769 310326 86633 36188
(87486, 43467) 238 (2) 68745 149739 104929 19713 96942 62351
2 239 (1) 2538 6648 18311 15827 86178 12585 5507 12258
(42032, 52258) 239 (2) 15092 32535 16853 17431 4121 2747 3538 35720
2 142 (1) 30912 40247 28811 136283 8223 61010 206341 89583 9045
(100391, 74306) 142 (2) 50838 78848 131025 131544 12246 121780 371078 4088 14184
2 201 (1) 87727 61353 49327 10454 44113 0 121045
(16813, 21971) 201 (2) 39260 34525 41148 4162 210211 5673 10168
2 288 (1) 43265 42504 44114 8780 7381 5458
(18841, 40696) 288 (2) 3356 48352 30409 3281 16008 40471
213 (1) 86702 2 6432 67109
213 (2) 16757 21710 135068 17415
2 160 (1) 19197 63636 74931 84155
67824, 87621) 160 (2) 75250 154135 93536 43297
2 210 (1) 22409 20505 4503 57428 991 66212 49021 8852 7281 37091 4311 211
(36981, 6641) 210 (2) 12019 697 11316 35206 13100 6099 4139 9539 0 1291 8427 18301
2 131 (1) 5848 4289 4471 15 164 1849 3854 10348 11217 12467 10094 2729
(25992, 102860) 131 (2) 36390 1 6623 14130 1222 440 474 25538 5263 86479 2449 72669
2 148 (1) 22169 47133 129203 682 2120 8040 37399 6279 28368 4253 45832
(9397,33138) 148 (2) 36925 117595 9585 71259 29283 45741 2949 67716 143264 1191 1415
2 172 (1) 15894 10167 15425 68358 153978 46485 60002 6502 45755
(68479, 2765) 172 (2) 171442 157845 49916 72298 37319 58173 1166 45113
2 209 (1) 60367 13846 29706
(73128, 60618) 209 (2) 50252 17047 48309
2 198 (1) 49604 24055 8720 50169 49310
(50210, 40964) 198 (2) 33006 50400 43972 45197 30126
2 236 (1) 83989 23360 170058 0 33954 32425 7147 6775
(0, 31850) 236 (2) 22966 88299 24917 14299 21234 58080 8512 7889
2 266 (1) 62787 34698 11696 0 1284 98639 80814 11777
(15506, 6309) 266 (2) 32979 10456 6008 2107 6814 155180 105253 10872
148
172
209
198
236
266
201
288
213
160
210
131
202
145
256
238
239
142
GAM GAM + SDD CP CP + SDD
241
188
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Figure S1. Boxplots depicting the distribution of no. of OTUs (panel A) and phylogenetic 
diversity values (Panel B) of bacterial communities in different experimental groups. The experimental 
groups are the faecal inocula and their corresponding growth communities on GAM and CP agar media. 
Growth on these media was further subdivided based on the addition of the SDD antibiotics. Asterisks 
indicate that these richness and diversity values of bacterial communities in experimental groups were 
significantly different (p = <0.05) based on the two-tailed t-test 
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Figure S2. The bacterial communities in the faecal samples of 18 intensive care patients were compared 
to the corresponding growth communities on GAM agar and CP agar by calculating the Pearson 
correlation coefficients of OTU-level taxa. Growth on these media was further distinguished based on the 
addition of the SDD antibiotics. Per patient the Pearson coefficients are sorted from lower to higher 
values. 
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DISCUSSION 
Antibiotics represent one of the most powerful tools for the treatment of human 
infectious diseases caused by bacteria. They are also used in agriculture, where the 
influence of antibiotics in the environment and association to human health is still 
unclear (Schmieder and Edwards, 2012). Unfortunately, the extensive use of 
antibiotics is frequently associated with a negative consequence: the development of 
antibiotic resistance in microbes, which generates an enormous problem in the 
health care system (Hancock, 2007; Roca et al., 2015; Barlam et al., 2016). This 
situation affects especially critically ill patients, and is associated with an increase of 
morbidity, mortality and health care cost; in addition to its contribution to the failure 
of antibiotic therapies (Vincent et al., 2011). 
The dissemination of antibiotic resistant bacteria and resistance genes is influenced 
by different factors including, among others, the selective pressure of antibiotics 
(Jernberg et al., 2010). The majority of the currently known resistance genes have 
been identified from clinical and veterinary bacterial isolates by using culture 
dependent techniques. This focus has led to an underestimation of the vast number 
of uncultured bacteria and the importance of other environments that can serve as a 
potential reservoir of antibiotic resistance genes (Seveno et al., 2002). It has been 
established that commensal bacteria serve as a reservoir of antibiotic resistance 
genes, which in turn are frequently located on mobile elements and can be 
transferred from commensal to pathogenic bacteria (Marshall et al., 2009). In fact, 
many antibiotic resistance genes present in human commensal bacteria are highly 
homologous and share similar genetic features with resistance genes found in 
pathogens (Shoemaker et al., 2001). In contrast, in soil, bacterial communities were 
shown to harbour a distinct resistome compared to that associated with pathogens, 
suggesting that antibiotic resistance genes present in soil bacteria do not transfer 
between species (Forsberg et al., 2014).   
 
 
Discussion 
 
255 
 
The increasing number of publications using culture independent approaches on 
putative environmental reservoirs of resistance genes, including soil, water, food and 
gut microbiota is improving our knowledge of the ecological context in which these 
resistance genes are present. Also, it adds to our understanding about the 
mechanisms underlying their spread and distribution in different environments 
(Schmieder and Edwards, 2012).  
In the gut a complex microbial community exists, which is adapted to its particular 
niche, and associated with several nutritional, metabolic, immunological and 
physiological functions (Backhed et al., 2005). Because of its role in the host, 
diversity and dynamics of the gut microbiota have been intensely studied in the last 
decades (Sekirov et al., 2010).  
Antibiotic therapy has since been shown to disturb the ecological balance of the gut 
microbiota, providing a perfect scenario to exchange resistance traits with other 
members of the gut, including potential pathogens (Perez-Cobas et al., 2013). The 
common consequence is the emergence of antibiotic resistance in close proximity to 
the human host, resulting in actual health impact. 
The work presented in this thesis aimed to enhance our understanding of the 
ecological context of antibiotic resistance and subsistence. Moreover, the diversity 
and colonization dynamics of the gut microbiota and associated resistome was 
studied by using a variety of high throughput techniques and metagenomics 
sequencing approaches in combination with traditional and high throughput 
cultivation techniques (Porous aluminium oxide – PAO Chips) to identify and 
characterize the potential reservoir of antibiotic resistance.  
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Subsistence phenotype: an ecological context 
The majority of the antibiotics used in clinical settings is derived from antibiotic 
producing bacteria present in the environment such as Actinomycetes. Several 
members of the bacterial community present in the environment have been 
identified as reservoirs of antibiotic resistance genes (Riesenfeld et al., 2004; 
D’Costa et al., 2006). In addition to resistance, recent studies showed that few 
bacterial species present in soil, seawater and gut microbiota of humans, farm and 
zoo animals are able to use antibiotics as a sole carbon source, known as the 
subsistence phenotype (Barnhill et al., 2011, Dantas et al., 2008; Dopazo et al., 1988; 
Xin et al., 2012, chapter 2 of this thesis). In chapter 2, different approaches were 
implemented to study the genetic determinants involved in this phenotype. The 
results provided insights into the mechanisms, and we concluded that a) the 
presence of a common aminoglycoside resistance gene (aminoglycoside 3’ 
phosphotransferase II (APH (3’) II) is needed for the bacteria to display the 
phenotype, b) by using both higher and lower concentrations of the aminoglycoside 
to mimic the concentrations used for the control of infectious and those present in 
the environment, the subsistence phenotype was still displayed, and c) glycosyl 
hydrolases appeared to play a key role in the subsistence phenotype, since the 
presence of a specific inhibitor (Deoxynohirimycin – DNJ) hampered the bacteria to 
grow on antibiotics as compared with growth obtained by using glucose as a growth 
substrate. However, a discrepancy between the subsistence phenotype and 
measurable antibiotic degradation was observed since no antibiotic degradation 
could be detected.  
Previously, Walsh et al (2013) tried to reproduce and verify the hypothesis that soil 
bacteria are capable to subsist on antibiotics that was brought forwards by Dantas et 
al (2008). Similar to our results, Walsh and coworkers found that soil bacteria were 
not able to degrade antibiotics and as a consequence, it is unlikely to be used as a 
carbon source.  
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Alternatively, Walsh et al (2013) proposed that bacteria possibly use a well 
characterized resistance mechanism that has not been previously linked to antibiotic 
subsistence.  
Nevertheless, future studies on antibiotic degradation should allow researchers to 
elucidate the mechanisms and genes associated with the subsistence phenotype. 
These studies could include the metabolic pathways and role of enzymes involved in 
antibiotic degradation, and could in addition address genetic elements involved in 
the regulation of carbon utilization. Laboratory evolution experiments will be 
required in order to assess the genomic adaptation of bacteria towards the 
subsistence phenotype. Moreover, a deep analysis on the ecological context in which 
the subsistence phenotype occurs would provide insight into the microorganisms 
capable to catabolize antibiotics and their environmental niche, including the genetic 
elements that could participate through enzyme inactivation and their capacity to 
transfer to other members of the microbial community. Until now, the group of 
bacteria that have been described to display the subsistence phenotype are 
phylogenetically diverse and closely related to pathogens associated to human 
infectious diseases. Therefore, it will be important to define the relationship between 
antibiotic resistance and antibiotic subsistence phenotype. 
 
Diversity and dynamics of the gut microbiota in non-human primates 
Several studies using high resolution 16S rRNA gene targeted phylogenetic analyses 
and high-throughput sequencing efforts indicated that great apes, including 
humans, have a particular gut microbiota composition, similar to the most closely 
related species (Ochman et al; 2010). Such evolutionary conservation could hint at 
functional relevance of the microbiota, and perhaps adaptive alterations of the hosts, 
for example regarding diet. In chapter 3, the applicability of the Human Intestinal 
Tract Chip (HITChip) for non-human primates was assessed by studying the gut 
microbiota composition of chimpanzee, gorilla and marmoset, and comparing them 
with faecal samples obtained from healthy humans.  
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The results indicate that the HITChip provides a robust alternative to study the 
microbiota composition of chimpanzees and gorillas. For marmoset samples, 
however, only low signal intensities were observed, suggestive of limited 
applicability. In addition, two human enterotypes were detected in the chimpanzee 
and gorilla samples, reinforcing previous observations that enterotypes are not 
exclusive to humans but can also be encountered in non-human primates (Moeller 
et al., 2012). A strong correlation was obtained when the results were compared with 
a dataset obtained by 454 pyrosequencing from the same animal species. Previous 
studies showed that phylogenetic microarray and pyrosequencing analysis methods 
are strongly correlated, both methods allowing to determine in-depth the 
phylogenetic profile of gut microbial communities (Claesson et al., 2009). Future 
applications of this technique could include the study of microbiota composition of 
wild and captive non-human primates and the effects of external factors such as diet 
and antibiotic administration. 
 
Antibiotic therapy and the human gut microbiota 
Hospital acquired-infections are a common complication in hospitalized patients, 
especially those associated with prolonged stay and caused by antibiotic resistant 
bacteria (Vincent et al., 2011). In the ICU, the application of antibiotic prophylactic 
therapies aims to prevent secondary infections by potential pathogens that could be 
already present in the body or acquired during ICU stay (Houben et al., 2014). 
Previous studies have shown that antibiotic prophylactic therapies reduce the 
incidence of ventilator-associated pneumonia, decrease the morbidity and mortality 
and improve the patient outcomes (Pileggi et al., 2011). However, the diversity and 
colonization dynamics of gut microbiota in ICU hospitalized patients has been poorly 
characterized, and the rate of colonization with antibiotic resistant bacteria during 
and after the application of prophylactic antibiotic therapies in critically ill patients 
is still controversial.  
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In order to assess the diversity and dynamics of the gut microbiome and resistome 
in ICU hospitalized patients, a high throughput phylogenetic microarray platform 
(HITChip) and functional metagenomics approaches were implemented to 
determine the dynamics of the gut microbiota composition during hospital stay in a 
single patient (Chapter 4). The results indicated that the gut microbiota 
composition was highly dynamic, with fluctuations in the relative abundance of 
Bacteroidetes, Clostridium cluster XIVa and IV during SDD therapy, increases of 
Bacilli after therapy discontinuation, and notorious changes after hospital discharge 
(high relative abundance of Firmicutes dominated by Clostridium cluster XIVa). 
Functional metagenomics analysis indicated that the aminoglycoside resistance 
genes (aph (2′′)-Ib and an aadE-like gene) were the two most dominant genes that 
increased in abundance during ICU stay. The aph (2′′)-Ib gene was associated with 
mobile elements and was harboured by a strain from the genus Subdoligranulum 
that includes members of the group of anaerobic commensal microbiota. Our results 
suggested that these genetic mobile elements can be mobilized and/or have been 
acquired through horizontal gene transfer, as reported previously for members of the 
Firmicutes (Jones et al., 2010), which could contribute to the risk of transfer of 
antibiotic resistance genes from commensals to potential pathogens. It cannot be 
excluded that the increase of aminoglycoside resistance genes may also be an effect 
of the SDD therapy since tobramycin is used as part as the cocktail administrated to 
the patients.  
Recently, Oostdjik et al., reported in a randomized clinical trial an increase of 
aminoglycoside resistant Gram-negative bacteria during SDD therapy (Oostdjik et 
al., 2014). Based on these observations, a control of the use of aminoglycoside should 
be considered during therapy, especially for the group of aerobic Gram-negative 
bacteria. 
In clinical settings, metagenomics is not implemented as a routine procedure for the 
analysis, identification and quantification of antibiotic resistance genes due to high 
cost and time constraints.  
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To this end, the recent technological advances in high throughput quantitative PCR 
approaches allow for the identification and quantification of multiple antibiotic 
resistance genes and has been used as an alternative to metagenomics sequencing 
due to lower costs and faster turn-around times. In chapter 5, an extended study of 
the gut microbiota and resistome was performed by using HITChip and nanolitre 
scale high throughput PCR.                 
The study included faecal samples from eleven ICU-hospitalized patients receiving 
SDD therapy and a control group comprising healthy individuals. The results of this 
study reinforced that SDD therapy disturbs the ecological balance of the gut 
microbiota as an uncontrollable secondary effect and decreases the diversity of the 
gut microbiota as compared to healthy individuals. In healthy adult individuals, 
Clostridium cluster IV represents the predominant group of gut bacteria, and is 
considered to play a beneficial role in gut homeostasis (Louis et al., 2009; Machiels 
et al., 2014). In ICU patients we firstly observed a decrease in the abundance of 
Enterobacteriaceae as well as undetectable levels of associated resistance genes, 
most probably as a consequence of colistin administration during the therapy. This 
can be seen as a beneficial effect of the therapy, however, it remains unclear if a 
recolonization post SDD occurs. Secondly, the relative abundance of enterococci was 
increased, and it is tempting to speculate that this might be related to the decrease 
in the population of enterobacteria as described previously (Brandl et al., 2008) and 
a decrease in the relative abundance of Clostridium cluster IV and XIVa as reported 
previously (Benus et al., 2010; Daneman et al., 2013), which could have a sustained 
effect on the homeostasis of the gut microbiota. Thirdly, the presence of genes 
conferring resistance to beta-lactams, tetracycline and aminoglycosides associated 
with commensal bacteria has been described as a protective effect against 
colonization with antibiotic resistant Gram-positive bacteria (Stiefel et al., 2014), 
whereas an increase of antibiotic resistance genes associated with Gram-positive 
bacteria during ICU stay highlight the importance to carefully examine the 
applicability of SDD therapy in countries with high prevalence of antibiotic resistant 
bacteria.  
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Likewise, future studies using e.g. prebiotics and probiotics as a strategy to restore 
the gut microbiota are needed, especially because the reduction of the microbial 
diversity could facilitate the overgrowth by antibiotic resistant-potential pathogens. 
So far, all these methods allow to only identify the resistance genes without being 
able to identify the bacterial host. In fact, only culture dependent techniques are 
commonly used to determine the prevalence of colonization with antibiotic resistant 
bacteria in ICU hospitalized patients as a part of the surveillance control, focusing 
mainly on aerobic bacteria (Daneman et al., 2013). As a consequence, the ecological 
perturbation induced by SDD therapy is underestimated or even neglected since the 
anaerobic commensal bacterial community, an important reservoir of antibiotic 
resistance genes, is not taken into consideration. 
Previous studies have shown that different antibiotic treatments affect the gut 
microbiota (Robinson and Young, 2010). Observed effects are related not only to the 
antibiotic class and structure, but also to the pool of resistance genes present in the 
microbial community, since the dynamics of the resistome is affected by the 
antibiotic target resistance and by the surviving community (Perez-Cobas et al., 
2013). In addition to the antibiotic class and structure, Zhang et al., showed that oral 
administration of antibiotics led to increases of antibiotic resistance genes in the gut, 
while the effect of intravenous antibiotic administration was less pronounced. 
Nevertheless, both effects can be more or less pronounced depending on the 
administered antibiotic dose and the route of excretion (Zhang et al., 2013). It has 
been reported that selection for resistance in bacteria could occur at lethal or non-
lethal antibiotic concentrations, which in the latter case could increase the rates of 
mutations and enrich the pool of antibiotic resistant bacteria (Anderson and Hugues, 
2012). During SDD therapy, a cocktail of antibiotics is administered through the oral 
cavity as well as intravenously, and under such conditions it has been demonstrated 
for instance that the microbial diversity is altered and resistance genes can be 
selected for in the surviving populations (Zaborin et al., 2014). 
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The remaining microbiota could include potential pathogens with the capacity to 
overgrow and survive, in addition to commensal anaerobic bacteria that could serve 
as a reservoir of antibiotic resistance genes.  
Despite efforts to control infections in ICU patients, a better understanding of the 
antibiotic resistant bacteria colonizing the gut microbiota is needed.  
In order to expand our knowledge on the ecological perturbation induced by SDD 
therapy, an extended study of the diversity and colonization dynamics of the gut 
microbiota was performed in eleven ICU patients receiving SDD therapy (same 
patients as chapter 5) by using traditional microbial cultivation approaches 
combined with HITChip analysis (Chapter 6). A range of culture media and 
selective culture conditions allowed to detected a variety of taxonomic groups, 
including the three most common potential aerobic pathogens associated with 
hospital-acquired infections, namely enterobacteria, staphylococci and enterococci, 
with enterococci being the most predominant genus identified, and several members 
of the commensal anaerobic microbiota including butyrate producing bacteria. The 
diversity and colonization dynamics of the gut microbiota in these patients was 
supported by the phylogenetic analysis, which indicated that SDD therapy could 
have a replacement effect on the bacterial community since a suppression of 
Enterobacteriaceae and a concomitant increase of the Enterococcus population was 
observed. In addition, the relative abundance of Clostridium clusters XIVa and IV 
was reduced during therapy. Similar results were obtained by Benus et al. (2010) by 
using 16S rRNA-targeted Fluorescent In Situ Hybridization (FISH), suggesting that 
the Enterococcus population needs to be considered during the application of this 
therapy in countries with high prevalence of enterococcal acquired-infections. 
Using traditional cultivation techniques helps not only to isolate a variety of 
taxonomic groups but also provides an opportunity to map the antibiotic phenotypes 
of these isolates and determine the colonization dynamics with antibiotic resistant 
bacteria during ICU-hospitalization. However, since the majority of the patients 
received additional systemic antibiotic treatment for the control of infections, the 
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exact effect of SDD therapy on the gut microbiota composition in ICU patients 
remains unclear.  
However, based on the antibiotic phenotypes of the majority of the isolates, the 
antibiotic classes of macrolides and tetracyclines may be the main contributors to 
the antibiotic resistance profile observed. Previous studied showed that 
erythromycin and tetracycline antibiotic resistance genes can be acquired by 
conjugative plasmids and conjugative transposons and transfer between Gram-
positive and Gram-negative bacteria (Salyers et al., 2004; Gupta el al., 2003; Wang 
et al., 2003). Therefore, future studies that focus on the genetic elements present in 
the isolates could help to understand the dynamics of the resistance genes present 
during antibiotic treatment. However, it should be noted that merely mapping the 
presence of mobile elements will not disclose the extent or directionality of gene 
transfer.  
It has been indicated that an emergence of polymyxin resistance in Gram-negative 
bacteria could occur after the introduction of SDD therapy, especially in patients that 
carry Gram-negative bacteria that are resistant to tobramycin (Halaby et al., 2013; 
Oostidjk et al., 2013). In the study presented in this thesis, a low rate of antibiotic 
resistance to tobramycin and polymyxin seems to persist in Dutch ICUs as was 
previously reported (Wittekamp et al., 2015). Moreover, during SDD therapy an 
association with the emergence of ESBLs has been described as a result of the use of 
cephalosporins as part of the antibiotic cocktail (Al Naiemi et al., 2006). However, 
the results obtained in that study indicated that SDD therapy is still a useful therapy 
in the control of Gram-negative ESBL bacilli. 
It is still unknown whether the antibiotic concentration present in the gut during 
SDD therapy in patients with constipations make a pre-selection of antibiotic 
resistant bacteria or increase the lateral transfer of resistance genes from one 
bacteria to another. Moreover, considering that the endogenous anaerobic 
microbiota is altered, contributing to an altered (reduced) colonization resistance, 
these results suggest that a re-definition of the concept of selective decontamination, 
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i.e. “SDD therapy does not affect the anaerobic gut microbiota” (van der Waaij et al., 
1990), needs to be considered. 
The work presented here has several limitations that need to be taken into 
consideration for the full interpretation of the results obtained. These include, for 
example, the small number of patients and the inherent limited statistical power. 
Furthermore, the classification of the samples by groups based on ICU stay days was 
established arbitrarily, mainly, because the absence of equal distribution of the 
samples obtained, clinical conditions, administration of opioids and altered gut 
motility that did not allow to obtain faecal samples in the first 24-48 hours of 
hospitalization for all the patients. In addition, it is often unavoidable that patients 
in ICUs are exposed to invasive procedures or receive additional antibiotic 
treatment, which likely affect the results especially because of the antibiotic selective 
pressure present in the gut and use of broad spectrum antibiotics to control 
infectious diseases. Moreover, it was not possible to include a clinical control group 
as the majority of the ICUs in Netherlands nowadays use SDD therapy. Finally, the 
long-term perturbation induced by antibiotic treatment could not be established and 
future studies need to be performed in order to answer this and many other 
questions regarding to the ecological perturbation induced by the administration of 
antibiotics cocktails which leads to collateral damage of the commensal microbiota 
and therefore potentially human health.  
So far, the data obtained in chapters 4, 5 and 6 suggest that the diversity of the 
microbial community is reduced during SDD therapy and resistance genes can be 
selected for in the remaining community members as a strategy to survive the 
environmental conditions, limitation of nutrients and antibiotic pressure. In 
chapter 7, a characterization of Enterococcus colonization dynamics in ICU 
hospitalized patients receiving SOD and SDD therapy was investigated. Overall, the 
results showed a pool of diverse enterococcal species colonizing individual ICU 
patients during prophylactic therapies, being E. faecalis and E. faecium as the most 
dominant species identified.  
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It has been previously suggested that SDD therapy could increase Enterococcus 
colonization in ICU patients (Humphreys et al., 1992).  
In the study presented in this thesis, an increase in the clonal diversity and clonal 
replacement was observed for E. faecium isolates, whereas a narrow clonal diversity 
was observed in E. faecalis isolates, including a new sequence type. Furthermore, we 
detected the simultaneous presence of more than two virulence factors and/or 
virulence factor and antibiotic resistance genes. Recently, Muruzábal-Lecumberri et 
al. (2015) showed a high prevalence of E. faecalis isolated from ICU patients 
receiving SDD therapy and that those isolates were associated with multidrug 
resistance and virulence genes.  
The ability of enterococci to adapt to different environmental conditions facilitates 
their colonization and subsequent infection in hospitalized patients (Guzman Prieto 
et al., 2016). Further studies are needed to investigate the cellular and molecular 
interaction that promotes colonization and the resulting enterococcal infections. 
Even if the percentage of enterococcal infections and antibiotic resistance is low in 
the Netherlands, more research could be focusing on determining the prevalence of 
Enterococcus especially in critically ill patients receiving SDD or SOD therapy and 
in future strategies to prevent and control the spread of antibiotic resistant strains.  
 
Microbial culture chip targeting members of the most wanted list 
The recently reported “most wanted” taxa list from the Human Microbiome Project 
(HMP) suggested that several members have been poorly studied due to the 
difficulties to cultivate them. Moreover, the National Institute of Health (NIH) 
started to actively support the development of novel cultivation techniques in order 
to isolate and characterize these microorganisms and study their role in human 
health and disease (Fodor et al., 2012). In the last years, few studies have been 
performed in order to cultivate the currently uncultivable fraction of the human gut 
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microbiota by using a combination of culturomics and high-throughput sequencing 
techniques (Goodman et al., 2011; Lagier et al., 2012; Rettedal et al., 2014).  
More recently, Lau et al. (2016) showed that by using culture-enriched molecular 
profiling, the majority of the bacteria present in faecal samples can be cultivable. The 
combination of culture dependent and independent techniques has been used to 
determine the effects on antibiotic treatment in the gut microbiota, focusing in the 
anaerobic microbiota as a potential reservoir for antibiotic resistance genes (Rashid 
et al., 2015). In chapter 8, we aimed to isolate previously uncultured resistant 
anaerobic bacteria from faecal samples of 20 patients receiving SDD therapy by 
using a high throughput cultivation approach (PAO-Chips) and 16S rRNA gene 
amplicon sequencing. The results of this study indicated that the PAO Chip is a 
promising tool that allows to isolate several members of the most wanted taxa.  
Moreover, the use of rich and poor media and the addition of antibiotics to the media 
provide useful information regarding the conditions in which specific bacteria are 
able to grow as demonstrated by the relative abundance of Cyanobacteria obtained 
by using CP media. Nevertheless, the implementation of the PAO chip to obtain pure 
cultures using targeted isolation remains challenging, and future studies in these 
directions could help to optimize such techniques. Furthermore, the use of 
antibiotics in the media and the implementation of PAO Chips as a support for the 
bacterial growth will allow to study the syntrophic interaction between bacterial 
species. This study showed that high-throughput screening of growth communities 
for bacterial resistance can guide targeted isolation of potential reservoir species, 
providing useful information on the diversity of the gut microbiota and its antibiotic 
resistance phenotype that cannot be derived by using culture independent 
techniques solely. Future studies including antibiotic resistance phenotyping and 
further genetic and physiological characterization of the isolates could contribute to 
understand the spread of antibiotic resistance genes and the possible transfer to 
other members of the gut microbiota. 
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Outlook and future perspectives 
Subsistence phenotype 
The antibiotic resistance phenotype and antibiotic resistance genes have evolved 
before the use of antibiotics as therapeutics. Moreover, antibiotics and antibiotic 
resistance genes seem to play multiples roles in the environment (Sengupta et al., 
2013). In chapter 2, the subsistence phenotype of bacteria present in the gut 
microbiota of healthy humans and zoo animals was investigated. Although antibiotic 
degradation was not detected, the results obtained provide an insight into the genetic 
background involved in the antibiotic subsistence phenotype. Future studies could 
focus on the metabolic pathways of antibiotic degradation. The information 
generated could fill the gap of knowledge regarding the relationship between 
antibiotic resistance and antibiotic subsistence and the ecological context in which 
the phenotype is displayed naturally. Of particular interest is to study if bacteria 
display the antibiotic subsistence phenotype at low concentration and whether these 
concentrations could contribute to the selection for subsistence. 
 
Antibiotic therapy and the gut microbiota  
The administration of antibiotic therapy in ICU patients has been associated with a 
reduction in the morbidity, mortality and decrease in the prevalence of ventilator-
associated pneumonia. However, the impact of antibiotic therapy on the emergence 
of antibiotic resistance and infections associated with antibiotic resistant bacteria is 
still unclear (Plantinga et al., 2015). The studies presented in this thesis (chapters 
4-7) show that the application of antibiotic therapy has a dramatic impact on the 
diversity and colonization dynamics of the gut microbiota. From an ecological point 
of view, the selective pressure of antibiotics induced during the therapy decreases 
the relative abundance of enterobacteria and increases the relative abundance of 
Enterococcus species.  
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Moreover, a decrease of several members of the commensal anaerobic bacteria, 
which can play important roles in metabolic, nutritional and protective process in 
the host, was observed. Individual-specific variation in colonization dynamics with 
antibiotic resistant bacteria including Gram-positive and Gram-negative bacteria 
was detected. This information certainly expands our understanding of the dynamics 
of the gut microbiota under antibiotic selective pressure and could provide novel 
targets for therapeutic development.  
So far, the level of antibiotic resistance in ICUs in the Netherlands seems to be low, 
and antibiotic therapy appears to be a useful tool for the control of hospital-acquired 
infections, which is supported by a microbiological monitor of antibiotic resistance 
development (Plantinga et al., 2015). However, the results obtained in this thesis 
indicated that a careful control and monitoring of the development of antibiotic 
resistance in Gram-positive bacteria, especially Enterococcus species that harbour 
antibiotic resistance and virulence genes, should be monitored since the rate of 
colonization apears to increase during SSD therapy. The implementation of 
antimicrobial practices, use of broad spectrum antibiotics only under strict 
conditions, selection of narrow spectrum antibiotics whereever possible, 
administration of laxatives or promotors of gut motility and prevention of horizontal 
transmission through hand-washing, glove use and improving the workflow in the 
health care units, could reduce the emergence and dissemination of antibiotic 
resistant bacteria.  
 
Novel cultivation approaches to study the commensal reservoir of 
antibiotic resistance 
Currently, there is an increased interest to isolate, identify and characterize members 
of the commensal anaerobic gut microbiota that have not yet been cultivated. Such 
uncultured species could be important as a reservoir of antibiotic resistance genes.  
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Traditional and novel cultivation approaches such as minibioreactor arrays 
(MBRAs), culture enriched molecular profiling, culturomics methods, microcapsules 
and Bio-chips (Auchtung et al., 2015; Lau et al., 2016; Dubourg et al., 2014; 
Rettendal et al., 2014; Zengler et al., 2005; Ingham et al., 2007) combined with high 
throughput sequencing techniques are increasingly being used to study a relatively 
poorly explored ecosystem present in the human gut microbiota: the anaerobic 
microbiota. The ability and capacity to cultivate and isolate pure cultures of these 
microorganisms can contribute to understanding their role in human health and 
disease. This also includes the possibility to use available isolates for the generation 
and study of synthetic microbial communities that allow addressing ecological 
questions regarding microbiota composition and functioning, as well as the 
application of synthetic consortia for microbial theraphies building on the success of 
fecal microbial transplantation (de Vos, 2013). Also, phenotypic insights into these 
poorly characterized species, especially regarding their resistance profiles, could 
provide useful information in response to antibiotic treatment of the gut microbiota 
and will contribute to improve infection control measures, by making them more 
targeted to the detrimental species, while leaving the beneficial microbiota intact.  
Although the development of novel culture techniques is still required to increase the 
ability to explore the microbial gut ecosystem, the initial strategies already 
implemented should incorporate the study of the resistome as a key component to 
understand the interplay between the gut microbiota and antibiotics. 
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